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Abstract
Surface Acoustic Waves (SAWs) devices for droplets manipulation have become widespread
in the last twenty years for their ability to work at the microscale, focusing their energy on
small targets. SAWs, combined with vesicles-based drug carrier systems such as liposomes,
offer the opportunity of efficient drug delivery to the lungs. Liposomes are important drug
delivery systems due to their structure, able to retain either a hydrophilic drug within
their aqueous core, behind a phospholipid barrier, or a hydrophobic drug associated with
the membrane's hydrophobic core. They are capable of releasing the drugs in a controlled
manner in conjunction with pH or temperature changes, which is a fundamental feature
for the treatment of many diseases such as cancer. SAW devices are ideal platforms for
liquid manipulation at the micro-scale, due to their low fabrication cost and low power
consumption. The main advantage as a nebuliser, for pulmonary drug delivery, lies with
their ability to provide control of the aerosolized droplet size. Another advantage, com-
pared to a commercially available nebuliser, is given by the high frequencies (>1MHz)
employed during the nebulisation, which avoids denaturation of the delivered molecules
by cavitation. The aim of this PhD is the development of a SAW nebulisation device,
capable of delivering drug-loaded liposomes in a targeted manner to the deep lung tissues.
The creation of a novel SAW nebulisation platform, where liposomes can be formed in-situ
and drugs (or complex molecules) can be loaded in one single step, will avoid drugs side
effects and wastage of expensive drugs.
The project can be divided into three main objectives. The first objective was the
design of the SAW platform, studying the SAW interaction with pre-formed liposomes,
the effects of the SAW on temperature sensitive-enzyme and the stability of liposomes after
the SAW nebulisation. Once the feasibility of using SAW as a method to deliver drugs
encapsulated in liposomes, the second objective was focused toward the control of the
aerosols size and the liposomes’ formation in-situ on the same platform. The aerosols size
is a key parameter to deliver efficiently drugs and biologics into the lungs and the liposomes
are also key to protect the compound from early degradation and guide it in a specific
target. After the optimised parameter were controlled, the final objective was to test the
platform in-vitro on lungs cancer cells, delivering nucleic acids as DNA luciferase plasmid
and GAPDH siRNA and showing high transfection performance. I have demonstrated
i
ABSTRACT ii
that this platform has the potential to be an efficient drug delivery system in terms of
drug stability, delivering biologics and optimum absorption of the drug in the lungs.
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1.1 Image representing the respiratory tract. Air enters through the mouth
or the nose and then arrives in the pharynx and trachea, which divides
into two bronchi. In this part of the respiratory tract, inertial impaction is
the main deposition mechanism. The two bronchi then divide into several
branches, starting the bronchial tree, where different deposition mechanism
can be found: impaction, sedimentation, interception and electrostatic pre-
cipitation. The final end of the respiratory tract is made of alveolar ducts
and sacs, where small particles are characterised by the Brownian diffusion,
which is the random motion of small particles suspended in a fluid/gas
caused by the collision with fast-speed molecules in the fluid/gas [27]. Fig-
ure from [28]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2 Liposome structure, which entraps an aqueous core behind a clearly demar-
cated phospholipid bilayer structure. Due to the phospholipid structure
made of a hydrophilic polar head and a hydrophobic tail, different com-
pounds can be encapsulated. Figure adapted from [34] . . . . . . . . . . . 6
1.3 Classification of liposomes based on the number of lamellae. Multilamellar
vesicles (MLV) have multiple lamellae and the diameter is higher than 0.5
µm, unilamellar vesicles are made of one lamella and multivesicular vesicles
are made of a vesicle larger than 1 µm in diameter, which contains several
smaller vesicles. Unilamellar vesicles can be of different size ranges and
they are divided based on their size into small unilamellar vesicle (SUV,
d = 20/100 nm), large unilamellar vesicle (LUV, d > 100 nm) and giant
unilamellar vesicle (GUV, d > 1 µm). . . . . . . . . . . . . . . . . . . . . . 8
1.4 Packing parameter of three different phospholipids.(a) Lysophosphatidyl-
choline has an inverted cone topography. (b) 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) has a cone shape. (c) 1,2-dioleoyl-sn-glycero-
3-phosphocholine (DOPC) has a cylinder shape. Fig. adapted from [51] . . 9
vii
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1.5 MLVs Formation. Polar head of dried phospholipids start to swell in contact
of water. The fatty acid rearrange their structure to minimise the contact
with water, closing themselves and forming MLVs with sizes between 1-15
µm of diameter. Figure adapted from [54] . . . . . . . . . . . . . . . . . . 10
1.6 Large unilamellar vesicles formation, adding energy to the system, multil-
amellar vesicles are breaking down into bilayer phospholipid fragment and
then due to the hydrophobic effect of the phospholipid fatty chain, the
bilayer close themselves. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.7 Different vesicles preparation methods, according to the mechanism of vesi-
cles formation proposed by Lasic, [54]. Phospholipid solution describes the
phospholipid in organic solvent while phospholipid dispersion is a multil-
amellar vesicles solution. Changing the solubility of the solution and with
the disruption of the bilayers in the phospholipid dispersion case, the forma-
tion of bilayered phospholipid flakes or fragments (BPFs) will occur. One
BPFs are formed, they will fuse and bend in vesicles, due to the hydrophobic
effect of the hydrocarbon chains. Figure arranged from [53] . . . . . . . . . 12
1.8 Solution of MLVs pushed through a polycarbonate membrane with 100 nm
pore diameter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
1.9 Different scattering effects: Rayleigh scattering for small particles which re-
radiates the signal with the same phase. Mie scattering is used for particles
with a diameter similar to or larger than the wavelength of the incident
light and they re-radiated the scattered signal with different phases. . . . . 18
1.10 Confocal microscope components. A laser, which acts as an excitation
source, passes through the first pinhole. The dichromatic mirror reflects
the light which is then focused on the specimen by an objective. The dye in
the sample fluoresces and emits light which passes through the dichromatic
mirror and hits the second pinhole. The second pinhole prevents light from
coming from out-of-focus focal planes from reaching the photomultiplier
detector [93]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.11 Transmission electron microscopy. Differences between negative and pos-
itive staining. In negative staining approach, the background is stained
while the specimen is not affected [96]. When the electron beam passes
through the sample, it will be deflected by its interactions with the sample
and the stain. Since the protein sample excludes stain, the deflection of
the electron beam through the sample is less than through the stain region.
Regarding positive staining, the stain is attached to the surface of the spec-
imen, resulting in a dark image of the sample against a light background
[96]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
LIST OF FIGURES ix
1.12 A schematic of the evolution of pulmonary drug delivery devices. First de-
veloped nebulisers were composed of a liquid reservoir and a pump that was
used to spray out a pressurised liquid by hand force. In 1938 a hand-bulb
nebuliser was developed, which replace the pump of the previous version
[111]. In the early 40s and 50s, metered-dose and dry powder inhalers were
manufactured. In 1964, first jet nebuliser and then ultrasonic one was pro-
duced and finally, in 1993 the first mesh nebuliser was marketed by Omron
[9]. Figure arranged from [33]. . . . . . . . . . . . . . . . . . . . . . . . . . 25
1.13 (a, b) Representation of a crystal structure with the centre of symmetry. (a)
A cubic unit cell with a centre of symmetry is represented and in absence of
applied force, the net polarisation is equal to zero. Without applying stress
the centre of mass (c.m.) of the positive charges coincides with the c.m.
of the negative charges. (b) A force is applied and the total polarisation
is still null. Any motion from an ion is reflected by symmetry to an equal
and opposite motion that cancels out the dipole moment. (c, d, e) Repre-
sentation of a crystal structure without the centre of symmetry. (c) The
hexagonal unit cell does not have a centre of symmetry, when unstressed
the c.m. of the negative charges coincides with the c.m. of the positive
charges, thus the net polarisation is null. (d) A force is applied along y,
the charged in A and B position move in A’ and B’ position and their c.m.
become shifted. (e) A force is applied in a different direction (x) and gives
rise to a polarisation in other crystal directions. Figure adapted from [122]. 29
1.14 Propagation along the y-axis of a Rayleigh wave. Rayleigh waves are a
type of surface waves made of longitudinal and vertical shear components,
which make the particles in the solid moving in an elliptical motion. Figure
adapted from [123], [16]. In the red rectangle a close up of the elliptical
motion and the propagation of the surface wave. . . . . . . . . . . . . . . . 30
1.15 SAW propagation into a droplet of liquid. SAW diffracts into the droplet
of liquid, following a specific angle, called Rayleigh angle [131] . . . . . . . 32
1.16 RNA synthesis. The process consists of three steps: initiation, elongation
and termination. During the initiation process, RNA polymerase binds with
the promoter sequence and unwinds the double-stranded DNA. In the fol-
lowing elongation phase, an RNA molecule of a sequence complementary to
that of the single-stranded DNA template is formed, the mRNA. Elongation
continues until the RNA polymerase detects the termination sequence. . . 35
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1.17 Double stranded RNA is processed into an siRNA by the RNase II enzyme
Dicer. The siRNA is loaded into the RISC. The endonuclease AGO2 cleaves
the sense strand of the siRNA, while the antisense strand remains associ-
ated with the RISC. The antisense strand then binds with complementary
mRNA, then AGO2 cleaves the bound complementary mRNA. . . . . . . . 37
2.1 (a) Zoom in of the fingers structure of an IDT. The main parameters are
shown in the image: IDT aperture, IDT finger width (d) and the wavelength
(λ) of the surface wave. (b) Mask designed on L-Edit for IDTs. After
cleaning the substrate and spinning of the photoresist, the mask is placed
on the substrate. The mask alignment and then UV hard exposure (nitrogen
pressure under the substrate) for 4 s, were carried out to lithographically
define the electrode pattern. . . . . . . . . . . . . . . . . . . . . . . . . . . 44
2.2 IDT Microfabrication processes: 1. LiNbO 3 cleaning, 2. Photoresist spin-
ning on LiNbO 3, 3. Mask alignment and UV exposure to remove the pho-
toresist exposed to light, 4. Photoresist development, 5. Metal evaporation
and deposition, 6. Metal lift-off. . . . . . . . . . . . . . . . . . . . . . . . . 44
2.3 (a) Block diagram of a 2-port network analyser, showing the main compo-
nents. The 2 ports of the DUT are denoted as P1 and P2. The switch
SW1 indicates the direction where the signal will pass, in this case, will go
through the port 1 of the DUT, and the parameters S11 and S21 can be
measured. (b) The IDT results as a one-port network, where a network
analyser was used to send a signal to the one-port network and evaluating
the reflected signal, the S11 parameter can be evaluated. . . . . . . . . . . 46
2.4 From the network analyser (a), (b), the evaluation of S11 was made, finding
out that for the specific IDT design, the resonance frequency was of 9.7
MHz. Where the amplitude is zero, the test signal sent from the network
analyser to the IDT is completely reflected. Oscillations are due to the
noise of the environment. (a) Frequency range from 8 to 12 MHz. (b)
Zoom in, frequency range from 9.4 to 10 MHz, the maximum amplitude is
found around 9.7 MHz. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
2.5 Dry etching process. The first step involves cleaning and spinning of the
positive photoresist AZ4562 on the silicon wafer. In the second step, the
mask alignment is employed to expose the wafer for 24 s to UV light. The
third step was carried out by a JWNC technician, using the PlasmaPro
100 Estrelas Deep Silicon Etch System for 60 minutes. Finally, the samples
were treated with piranha solution for 60 s and then plasma-ashed for 120
s at 100 W to create a hydrophilic surface. . . . . . . . . . . . . . . . . . . 49
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2.6 SEM SU8240 images of the dry-etched silicon chip, after photolithography
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2.7 Thin film hydration technique was used to form unilamellar vesicles. (1).
Phospholipids, which were chosen based on the experiment, are firstly dis-
solved in an organic solvent as chloroform. (2). A lipid film was produced
by spreading the lipid/chloroform solution with a dry nitrogen gun for a
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2.8 (a-b) Cryo-TEM image of unilamellar vesicles on the left and multilamellar
vesicles on the right. Scale bar: 200 nm. (c) Classification of liposomes
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size are visible. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
2.10 Main components of the Zetasizer Nano ZS90. A He-Ne laser 633 nm,
passes first through an attenuator, which ensures that the detector will not
be saturated. The light then hits the cell with the nanoparticles in the
solution and a detector at 90◦measure the intensity of the scattered light.
From the detector, the signal is processed by a correlator. . . . . . . . . . . 56
2.11 Instrumentation for aerosol size distribution measurement using laser diffrac-
tion (Spraytec). The image shows that the aerosol has to be at 15 cm from
the detector array. The laser hits the aerosol and the light is scattered at
different angles based on their sizes. The scattered light is then collected
by the detectors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
2.12 Andersen cascade impactor structure. A cross section of the Andersen cas-
cade impactor with a separation in 7 stages, where nozzles of different sizes
are present. The particles deposit onto the collection plate or continue to
follow the air stream based on their inertia. Larger particles will be cut-off
at the upper stages of the cascade. After the nebulisation ended, the col-
lection plates were washed to analyse the quantity deposits on each stage.
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2.13 (a) Side view of the SAW nebulisation setup. From the bottom, the heat
sink is in contact with the Peltier to remove the heat from the hot side. The
cold side of the Peltier is in contact with the IDT to keep the temperature
constant and avoid thermal stresses within the lithium niobate. On top of
the IDT, a thin layer of ultrasound transmission gel was added to fix the
silicon chip on top of it. (b) Schematic of the SAW nebulisation setup,
where the different layers are shown. From the bottom, the heat sink is
connected with a power supply to activate the fan, which removes the heat
from the Peltier. A thermal paste, which is thermally conductive, is applied
between the heat sink and the hot side of the Peltier. The cold side of the
Peltier is in contact with the IDT, which is connected through a metal
conductive paste (ELectrodag) and two wires to an amplifier. The latter is
amplifying a sinusoidal signal at a resonant frequency. . . . . . . . . . . . . 62
2.14 SAW Nebulisation equipment. The SAW nebuliser, placed on top of a
Peltier module and a heat sink, to keep a uniform temperature. 100 µl of
MLV mixture was nebulised and 100 µl of collection buffer was placed on
top of the nebulised flow to allow collection of sufficient volume for particle
sizing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
2.15 Three stage model of lipid bilayer solubilisation by Helenius and Simons. (I)
Detergent monomers (blue) insert into the outer bilayer (red), (II)Formation
of lipid-detergent mixed micelles and (III) mixed micelles become further
enriched in detergent. Picture taken from [208]. . . . . . . . . . . . . . . . 64
2.16 Andersen cascade impactor instrumentation. (a) A silicon chip with cavities
size of 100 µm was placed on top of the IDT. A syringe pump was loading
the LUVs dispersion at 200 µl/min flow. (b) At the bottom of the cascade
impactor, a pump was connected in order to create an air flow of 28.3 L/min.
The air flow was measured using a flow meter (Platon NGX, Roxspur, UK). 65
2.17 Mouthpiece design. SolidWorks draft of the mouthpiece, which collects the
aerosolised particles from the SAW nebuliser into the cascade impactor. The
simple geometry has an internal diameter, set by the size of the impactor
and the length was chosen in order to have enough space to form a 90◦angle. 66
2.18 HRP-TMB reaction. (a) TMB acts as an electron donor for the reduction
of H2O2 to H2O, and the reaction is catalysed by HRP. After H2O2 and
TMB react with HRP, (b) the Tetramethylbenzidine (TMB) is oxidised to
form Tetramethylbenzidine diimine, resulting in a blue colour . . . . . . . 67
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2.19 A calibration curve for the Bradford assay was obtained using bovine serum
albumin, starting from a stock solution of 1 mg/mL. Absorbance measure-
ments at λ = 595nm were made for BSA concentrations of: 1, 0.8, 0.6, 0.4,
0.2, 0.1 and 0 mg/mL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
2.20 Cell division over 3 days. (a) after 2 hours, (b) after 1 day and 5 hours,
(c) after 2 days and (d) after 3 days, reaching 70-80% confluence. Images
taken using the CytoSMART System, Lonza . . . . . . . . . . . . . . . . . 73
2.21 Trend of cell coverage over 3 days. (a) after 2 hours, (b) after 1 day and 5
hours, (c) after 2 days and (d) after 3 days, reaching 70-80% confluence . . 74
2.22 SAW transfection upright nebulisation setup. (A.) A549 cells were seeded
in a single well and after 24 h the medium was removed. Scale bar 50
µm. Two sets of experiments were carried out: one nebulising a solution
of DOTAP: cholesterol with DNA plasmid luciferase and the other with
GAPDH siRNA. The solution was nebulised for 2 min, placing the well
containing the cells upside-down on top of the nebulised flow. (B.) Image
of a lipoplex complex; picture adapted from [34]. . . . . . . . . . . . . . . . 75
2.23 Design of the collection box for transfection of A549 cells, using the SAW
nebulisation. PMMA sheets were laser-cut and glued together with a solu-
tion made of acetone and PMMA. The nebuliser was placed upside-down
to leave the cells culture in their medium. . . . . . . . . . . . . . . . . . . 76
2.24 Upside-down nebulisation setup for SAW transfection. A549 cells were
seeded in a single well. Two sets of experiments were conducted. Solu-
tions of DOTAP:cholesterol with DNA luciferase plasmid and with GAPDH
siRNA were nebulised. In order to be able to leave the cells in the medium,
the setup was placed upside-down, with the nebulised flow beginning at the
top of the well. Nebulised droplets were collected in the well containing the
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3.1 Size distribution of extruded liposomes after different incubation times.(a)
Solution of 0.01 %v/v of Triton X-100, incubation time of: 1 min (black),
5 min (red), 10 min (blue) and 20 min (green).(b) Solution of 0.50 %v/v of
Triton X-100, incubation time of: 1 min (black), 5 min (red) and 10 min
(blue). Higher concentrations of Triton X-100 reduced the time taken for
the complete solubilisation of the phospholipid bilayer. . . . . . . . . . . . 80
3.2 Size distribution of extruded liposomes after an incubation time of 1 min
with a 1.00 %v/v Triton X-100 solution. With a concentration of 1.00 %v/v
of detergent, solubilisation of the membrane was achieved by 1 min. . . . . 81
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3.3 Size distribution of extruded liposomes with HRP encapsulated (in black).
The same sample was then subjected to SAW nebulisation (in red) and
finally, the blue graph shows the size distribution after adding Triton X-
100. The results show that Triton X-100 solubilised the liposome bilayer. . 81
3.4 A negative control was run to prove that the optical depth signal was due
to the sole interaction between the HRP and TMB. (a) Two samples of
liposomes (a) without HRP (10 nM) encapsulated and (b) with HRP en-
capsulated in the liposomes were solubilised to test the optical depth of
both samples. As expected, OD from the sample (a) was null. . . . . . . . 82
3.5 Negative control with Triton X-100. 10 nM HRP was used for each sample
and different concentrations of Triton X-100 were tested, in order to assess
if the detergent was affecting the HRP-TMB reaction. Triton X-100 con-
centrations of 0.00 %, 0.01%, 0.10%, 0.50% and 1.00% v/v were compared.
The P value obtained was higher than 0.05, meaning that no statistically
significant differences were found between the samples. Thus, Triton X-100
is suitable for solubilising HRP-containing liposomes, since it does not seem
to interfere with the HRP-TMB reaction. . . . . . . . . . . . . . . . . . . . 83
3.6 A HRP-TMB reaction calibration curve was obtained in a 96-well plate.
100 µl volumes of HRP at different concentrations were prepared (n=5).
(a) Concentrations of 0.002, 0.4, 0.8, 2, 5, 10, 15, 20 and 30 nM were used,
as were three different incubation times of 90 s (black), 60 s (red) and 30 s
(blue). (b) The following concentrations were also tested: 5, 7.5, 10. 12.5,
15, 17.5 and 20 nM, at the same incubation time. PBS was used as a
negative control. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.7 Size distribution of liposomes after extrusion through polycarbonate pores
of 200 nm diameter. The peak width indicates a narrow, monodisperse
distribution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
3.8 Size distribution of extruded liposomes containing HRP (in black). The
same sample was then dialysed (results in red) and finally, the blue graph
shows the size distribution after SAW nebulisation. The results show that
SAW nebulisation is a suitable method for delivering liposomes that are 200
nm in diameter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
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3.9 (a) A calibration curve was made using different concentrations: 1, 2.5, 5,
10, 15, 20, 25, 50 µM of RhB. (b) Comparison between Pre-SAW, which
is made of 100 µM of RhB without nebulisation, and Post-SAW, which
represent the same solution after SAW nebulisation. The reduction in sig-
nal indicates loss during nebulisation, which was calculated to be around
51%. The graphs show the mean of three measurements and the error bars
represent the SD. ***p<0.001 . . . . . . . . . . . . . . . . . . . . . . . . . 88
3.10 Optical depth measurements of HRP and TMB reaction products pre-
dialysis, post-dialysis, post-dialysis with the addition of DI water and post-
dialysis with the addition of Triton X-100 in the solution. The mean of
three measurements is represented and error bars show standard deviation.
For comparison between different groups, an ANOVA followed by a Tukey
test was carried out with *p<0.05, **p<0.01, ***p<0.001. . . . . . . . . . 89
3.11 Optical depth measurements of HRP and TMB reaction pre-dialysis, post-
dialysis, post-SAW nebulisation with the addition of DI water, post-SAW
nebulisation with the addition of Triton X-100 in the solution and the Post-
SAW with the addition of Triton X-100 normalised, taking into account
the 51% loss of the original solution during nebulisation. The mean of
three measurements is represented and error bars show standard deviation.
For comparison between different groups, an ANOVA followed by a Tukey
test was carried out with ***p<0.001. A higher signal was obtained for
the nebulised sample following the addition of the detergent, showing the
release of HRP from the liposome cores. In the drawing showing the level of
OD, the blue circle represents an LUVs, the H is for HRP and the red cross
indicates the action of the Triton X-100 during the bilayer solubilisation to
release the encapsulated HRP. . . . . . . . . . . . . . . . . . . . . . . . . . 90
3.12 Schematic of Fig. 3.11. In the pre-dialysis sample, the HRP is both inside
and outside the liposomes, after dialysis the concentration of the HRP in the
outer solution decreased, but also the number of liposomes, due to the loss
during pipetting and dialysis. After the SAW nebulisation, the number of
liposomes decreased more due to the sub-optimal collection of the nebulised
sample, the last sample shows the addition of Triton X-100 to the solution
which causes the solubilisation of the liposomes and an increase of optical
depth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
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3.13 Optical depth measurements of HRP and TMB reaction, after SAW neb-
ulisation with the addition of DI water and after SAW nebulisation with
the addition of Triton X-100 in the solution. The mean of three measure-
ments is represented and error bars show standard deviation. T-tests have
been performed with **p<0.01 The higher optical depth after adding Tri-
ton X-100 shows the release of HRP encapsulated in the liposomes and
the suitability of SAW to nebulise active compounds encapsulated in the
liposomes without breaking them. An unpaired t-test was run, showing a
statistically significant difference between the two samples with p ≤ 0.05 . 92
3.14 Optical depth measurements of HRP and TMB reactions after heating the
nebulisation platform (IDT) at 20◦C, 65◦C and 95◦C. The same OD value
was observed following exposure to higher temperatures, showing that en-
zyme activity was not destroyed. . . . . . . . . . . . . . . . . . . . . . . . 93
3.15 Optical depth measurements of HRP and TMB reaction, post-dialysis, post-
SAW nebulisation with the addition of water and post-SAW nebulisation
with the addition of Triton X-100. The graph shows that during the nebu-
lisation process around 49% of the solution is lost. Then, after the addition
of Triton X-100, the O.D increased again by 50%. Each point represents
the mean values of three measurements. Error bars represent the standard
deviation of three measurements. . . . . . . . . . . . . . . . . . . . . . . . 94
4.1 SAW Confined Nebulisation. (a) The graph shows volume intensity plotted
against aerosol size distribution. From laser diffraction measurements a size
distribution in the optimal size range for pulmonary drug delivery (1 µm <
d < 5 µm)was obtained using a silicon chip with pore size of 100 µm. (b)
The relationship between the characteristic length scale of the pores and
the aerosol median droplet size. The graph shows that with the decrease of
the pore sizes, from which the SAW nebulisation occurs, a decrease of the
aerosol droplet size was obtained [235]. The mean of three measurements
is represented and error bars show the standard deviation. . . . . . . . . . 97
4.2 SAW nebulisation from silicon chip. (a) Nebulisation from 800 µm cavities
in diameter. (b) Close-up of the SAW nebulisation within 800 µm cavities.
(c) SAW nebulisation from 200 µm cavities. . . . . . . . . . . . . . . . . . 98
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4.3 Size distribution from DLS of MLV mixture. (a) Measurements at an in-
put power of -4 dBm. The black line shows the size distribution of MLV
mixture, the red line represents the size of vesicles after SAW nebulisation
without silicon structure and the blue line represents vesicle size after SAW
nebulisation with silicon structure of 300 µm pores. A reduction in vesi-
cle size occurred when the nebulisation was carried out through the silicon
chip. (b) Measurements were repeated at -2 dBm input power. The black
line shows the size distribution of MLV mixture, red (-4 dBm) and pink (-2
dBm) lines represent the size of liposomes after SAW nebulisation without
silicon structure. Blue (-4 dBm) and green (-2 dBm) lines represent lipo-
somes size after SAW nebulisation with silicon structure of 300 µm pores.
When the nebulisation occurs through the chip, the power increase does
not seem to change the size of the liposomes. . . . . . . . . . . . . . . . . . 100
4.4 SAW-formed liposome size distribution from DLS. In red, spinning lipid
approach, in black nebulisation of MLV solution, a small bump is present
around 30-40 nm, which indicates that probably during the nebulisation
some of the lipids collapsed into aggregates. Sample preparation: spin
uniform layer on IDT, add silicon chip, incubate with DI water, application
of SAWs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
4.5 Size distribution of the liposomes obtained by SAW nebulising an MLV
mixture through cavities of different size (100, 300, 400, 600 and 800 µm),
as measured by DLS. The solution was made of 2.00 mg/ml DOPC in DI
water. Three replicas were made for each cavity size. IDT parameters:
9.552 MHz with an input power of -4 dBm. . . . . . . . . . . . . . . . . . . 102
4.6 Two students T-test of liposome’s size against cavity size. SAW nebulisation
of a solution of 2.00 mg/ml DOPC in DI water was evaluated for cavity
sizes of 100, 300, 400, 600 and 800 µm. This graph is showing that a clear
relationship between the cavity size and the size of the liposomes produced
cannot be made. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
4.7 (a) Size distribution of nebulised droplets by laser diffraction. SAW nebu-
lisation of DI water through cavities of black line 180 µm, red line 200 µm,
blue line 400 µm and green line 600 µm. IDT parameters: 9.675 MHz with
an amplitude of -6 dBm. (b) Vesicles size against cavity size, measured by
laser diffraction. SAW nebulisation of a solution of 2.00 mg/ml DOPC in DI
water was evaluated through cavities of 180 µm, 200 µm, 400 µm, and 600
µm. The graph shows a positive correlation between the cavities size and
the size of the aerolised droplets. The mean value of three measurements is
reported. Error bars show the standard deviation of three measurements. . 104
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4.8 SAW nebulisation of different concentrations of MLV mixtures. Size dis-
tribution from (a) DLS and (b) laser diffraction of different concentrations
of phospholipid dispersions, nebulised through 300 µm cavities. Black line
is the size distribution of SAW nebulisation of a solution of 1.00 mg/ml
DOPC in DI water, red line is the one of a solution of 5.00 mg/ml and blue
line of a solution of 10.00 mg/ml. . . . . . . . . . . . . . . . . . . . . . . . 106
4.9 Size distribution of (a) SAW-formed vesicles and (b) Aerosol droplets at
different input power. (a) Size distribution from DLS of different input
power applied through SAW. Using input power range from -6 dBm to -
1 dBm and amplified by 40 dB, the total power used is changing from 1
W to 5 W, not showing a significant change in size. The same result was
obtained by laser diffraction measurements (b), a bi-modal distribution was
established for the nebulisation using power from -6 dBm to -1 dBm. . . . 107
4.10 Probe sonication of MLV mixture. Sonication with 200 W power was con-
ducted in 1 ml of MLV mixture (represented by pink line), for 10 s (blue
line), 20 s (red line) and 30 s (black line). From the result, 30 s of sonication
are necessary to be able to obtain a monomodal-like size distribution. . . . 108
4.11 Confocal microscope image, 100x. (a) Picture of the MLV dispersion before
the SAW nebulisation. (c) Sample during the SAW nebulisation, which was
stopped to be able to retrieve the sample. The picture shows a decrease
in vesicle size and higher monodispersity compared to picture (a). (b), (d)
represent pictures (a) and (c) with enhanced edges to help to visualise the
vesicle population. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
4.12 Size distribution of liposomes during SAW nebulisation of confocal images
in Fig. 4.11. The black line is the size distribution of Fig. (4.11,(b)), which
represents the pre-nebulisation sample. The red line is the size distribution
of Fig. (4.11,(d)), which represents the size distribution after interrupting
the nebulisation. A decrease in liposome’s population size is showed. . . . . 110
4.13 (a), (b) Confocal microscope image, 100x. (a) Vesicles extruded through
100 nm membrane (b) Liposomes formed using SAW and 300 µm cavities.
In both cases, the vesicles were produced from a solution of 2.00 mg/ml
DOPC in DI water. The graphs are showing the DLS size distribution of
extruded liposomes through 100 nm membrane (black) and SAW-formed
liposomes, nebulisation of MLVs through 300 µm cavities size (red). The
results from the two methods are comparable in terms of size and volume
intensity. Presence of a small peak around 3 µm indicates the presence of
impurities or bigger vesicles. . . . . . . . . . . . . . . . . . . . . . . . . . . 111
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4.14 TEM negative staining. Liposomes made by extrusion through a membrane
of 100 nm (left), and SAW-formed liposomes from the nebulisation of MLVs
through 300 µm cavities. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
4.15 Cryo-TEM. Liposomes extruded through 100 nm membrane. Images are
showing different size of vesicles with a range from 50 nm to 250 nm. Most
of the vesicles have more than one bilayer, highlighted by the red arrows. . 113
4.16 SAW-formed liposomes, produced via nebulisation of MLV mixture through
cavities of 300 µm pore size. The size distribution is lower, with a lower
concentration of vesicles. The sample is highly monodisperse (PDI < 0.1).
As indicated by the red arrows, the vesicles produced are mainly unilamellar.113
5.1 OMRON NE-U22 nebuliser. (a) Front view, (b1) Top view with the cap
containing the mesh opened and the view of the piezoelectric material. (b2)
Top view with the cap closed, the top view of the mesh and the reservoir at
the back. (c) Drawing of the mesh nebuliser: the solution in the reservoir
goes on top of the piezoelectric material, which pushes the solution through
the mesh and creates the aerosol. Viscous solutions can clog the mesh pores.117
5.2 (a) Rhodamine B calibration curve was made, using the fluorescence in-
tensity, measured at wavelength λ = 590 nm, of different concentrations of
RhB: 1, 5, 10, 20, 37.5, 40, 50, 75, 100 µM. The curve shows a plateau value
at 100 µM. (b) Starting from a solution of 100 µM different concentrations
were obtained using a different fraction of volume of the starting solution.
A volume/concentration curve was obtained, from which the particle size
distribution was evaluated. Error bars are smaller than the size of the point
and measurements were done in triplicate. . . . . . . . . . . . . . . . . . . 118
5.3 Aerosols deposition from the nebulisation of a 100 µM solution of rhodamine
B. From the fluorescence measurements after SAW nebulisation without
cavities (blue), with cavities (red) and OMRON NE-U22 (black), higher
deposition in the optimum size range (stages 3-7) was observed for the
SAW nebuliser with cavities. . . . . . . . . . . . . . . . . . . . . . . . . . . 119
5.4 A sodium chloride calibration curve was made in order to check particles size
distribution from the SAW nebulisation of a 1% w/v solution. Calibration
was made with concentrations of 1%, 0.75%, 0.5%, 0.25%, 0.1% and 0.0%
w/v of sodium chloride (black line). A volume/concentration curve of NaCl
was also made in order to retrieve the particles size distribution after the
SAW nebulisation with the silicon chip (blue line). Error bars are smaller
than the size of the point and measurements were done in triplicate. . . . . 121
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5.5 Aerosols deposition of a 1% w/v solution of NaCl from the SAW nebulisation
with cavities (100-200 µm). Each collection plate of the cascade was washed
with 1 mL and the conductivity associated with each plate was measured. . 122
5.6 Percentage of the delivered volume by three different nebulisers, the data
showed that higher volume fraction in the clinical validated range (stage 5)
were produced by the SAW nebuliser with cavities. . . . . . . . . . . . . . 123
5.7 Dynamic light scattering measurements of the extruded liposomes after col-
lection with the cascade impactor. The graph shows the SAW nebuliser
ability to deliver 100-200 nm in different stages of the impactor, displaying
the same liposomes size distribution over all stages. . . . . . . . . . . . . . 125
6.1 Gel retardation assay of HS-DNA before and after SAW nebulisation. The
similar intensities of the two bands (A. HS-DNA solution before SAW and
B. Solution with DI water and C. same solution of A. but after SAW neb-
ulisation) indicate the suitability of SAW for the nebulisation of nucleic
acids. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
6.2 Gel retardation assay of DOTAP:cholesterol (4:1) and lipid-siRNA com-
plexes prepared at 2:1, 10:1, 20:1 and 30:1 ratios (w/w). Lipid vesicle and
siRNA complexes were incubated for 30 min. . . . . . . . . . . . . . . . . . 128
6.3 A549 cells were seeded in a 96-well plate. 24 h post-transfection, lipid
vesicles complex bound with GAPDH siRNA were added to cells in order
to test their toxicity. After 4 h, MTT solution (0.8 mg/ml) was added
to the cells. After 2 h, the formazan precipitate was dissolved in 100 µl
isopropanol and the absorbance was measured at λ = 595 nm. The graph
shows the mean of three measurements and the error bars represent the SD. 129
6.4 DNA luciferase luminescence measurements. Naked DNA and DNA bound
with Lipofectamine 2000 were used as controls. Two different DOTAP:cholesterol
lipid ratios - 4:1 and 2:1 - were tested. For each of them, different ratios of
lipid to DNA were made in order to check the efficiency of the carrier. The
graph shows the mean of three measurements and the error bars represent
the SD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
6.5 Luminescence measurements were made following the standard transfection
of different concentrations of DNA luciferase plasmid. 0, 0.25, 0.5, 0.75,
1.00, 1.50, 2.00, 2.50 µg/mL of DNA were delivered in triplicate. A dose-
response curve was obtained. . . . . . . . . . . . . . . . . . . . . . . . . . . 131
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6.6 Western blot of lipid - siRNA complexes prepared with: A. DOTAP-Cholesterol
ratio of 4:1, 2.4 mg/mL and a lipid-siRNA ratio of 6:1 or 10:1. B. DOTAP-
Cholesterol ratio of 2:1, 2.4 mg/mL and ratio of lipid-siRNA of 6:1, 10:1, or
20:1. RE samples were prepared by the hydration of the lipids. (+) indi-
cates transfection with the positive GAPDH siRNA, and (-) with negative
control siRNA. In each sample, the density of the band for (+) samples
is lower than in those transfected with negative control siRNA (-). This
demonstrates the successful knockdown of GAPDH expression in A549 cells. 132
6.7 Comparison between the untreated sample, standard transfection of ex-
truded liposomes and SAW transfection with the upright nebulisation setup
(Section 2.9.2 of MLV mixture. The luminescence value of the SAW-
transfected sample is very low compared to that of the standard transfected
one, although higher than that of the untreated sample. The main reason
for this is loss during SAW nebulisation. The graph shows the mean of
three measurements and the error bars represent the SD. **p<0.01 . . . . 133
6.8 DNA luciferase transfection was carried out using both STD, the standard
transfection method, and the SAW nebulisation-based method with the
optimised upside-down setup. Both extruded cationic liposomes and mul-
tilamellar lipid solution were used as carriers. SAW-based and standard
transfection were compared in order to test the feasibility of using the SAW
platform to nebulise nucleic acids for drug delivery in the lungs. For the
standard transfection of naked DNA and the SAW transfection of naked
DNA, the delivered DNA resulted almost null. The standard transfection
of extruded liposomes and the SAW transfection of MLV mixture obtained
comparable signals, indicating the formation during the SAW nebulisation
of the nucleic acid carriers. When using the same lipid solution MLVs but
through the standard transfection method, a lower transfection efficiency,
30% reduction of the signal, was reported, which can be explained by the
fact that unilamellar vesicles were forming during the SAW nebulisation.
The graph shows the mean of three measurements and the error bars rep-
resent the SD. *p<0.05, **p<0.01 . . . . . . . . . . . . . . . . . . . . . . . 134
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6.9 SAW transfection was employed to transfect the same MLVmixtures, bound
with DNA at a concentration of 3.33 µg/mL and 6.66 µg/mL, but using
standard transfection method and SAW nebulisation. SAW transfection of
MLVs resulted in 50% higher signal compared to the standard transfection
method of MLVs. It is shown that: (1) increasing the DNA concentration
and amount of lipids (so as to maintain the 6:1 lipid:DNA ratio), increased
the amount of DNA delivered, (2) during SAW nebulisation compared to
standard transfection the formation of LUVs occurred, which increased the
quantity of DNA that entered into the cell. *p<0.05, **p<0.01, ***p<0.001 135
6.10 siRNA GAPDH transfection was carried out using extruded cationic lipo-
somes as a carrier. SAW-based and standard transfection methods were
compared. (A) Untreated sample, (B) Standard transfection of extruded
LUVs and (C) SAW transfection of MLVs. Results show the comparable
performance of the SAW-based and standard transfection methods. . . . . 136
6.11 Confocal Images of A549 cells at 4 h post-transfection. The cell was trans-
fected by standard transfection. A lipid-siRNA mixture was used, made
of DOTAP-cholesterol (4:1) in 5% glucose, with a lipid-siRNA ratio of 6:1.
Cell nuclei (blue) were stained with Hoechst. No cellular uptake resulted
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Thesis Outline
This thesis is divided into seven chapters and a brief description is given.
Chapter 1 is an overview of different drug delivery system, with main attention to
the pulmonary route, exploring the use of liposome in drug delivery in the lungs. A
literature review on existing inhalers and nebulisers, including SAW-based previous work,
highlighting advantages and disadvantages will also be presented in Chapter 1.
Chapter 2 will describe the general material and methods common to each chapter.
In particular, Interdigitated Transducer (IDT) microfabrication process is also described.
A description of particle size distribution methods is given with particular interest to
dynamic light scattering and laser diffraction, which are the most used in this work.
Chapter 3 will be based on testing liposomes to be nebulised with SAW, using en-
zymatic colorimetric assay (e.g. horseradish peroxide), as an indirect method to test
liposomes'stability, and dynamic light scattering for the vesicles size distribution.
Chapter 4 will present a study on unilamellar vesicles formation and on the control of
the aerosols size. Using a microfabricated silicon structure, the formation of LUVs was
obtained using the SAW. SAW-formed liposomes were characterised using dynamic light
scattering, laser diffraction and transmission electron microscopy. A mechanism for the
formation of liposomes in-situ is proposed.
Chapter 5 will discuss the analysis the lung deposition of SAW nebulised particle,
measuring fluorescence intensity and conductivity of the nebulised solution using the An-
dersen Cascade Impactor to evaluate size distribution. Comparison with the commercial
nebuliser Omron MicroAIR U22 was made to check the SAW nebuliser efficiency.
The final experimental chapter, Chapter 6 (carried out at the University of Hong Kong)
will be focused on the in-vitro study of nucleic acids transfection to lungs cancer cells. DNA
luciferase plasmid and GAPDH siRNA were delivered using the SAW platform and SAW
formed liposomes complex. Cell transfection was carried out on A549 lung epithelium cell
line, comparing SAW transfection method to the standard one.
Finally, Chapter 7 will show future works, including a design of mouse inhalation
chamber towards the in-vivo testing of SAW nebulisation platform, in a small animal
model.
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Chapter 1
Introduction
1.1 Motivation of Study
The most common respiratory diseases are asthma, chronic obstructive pulmonary dis-
ease (COPD), cystic fibrosis and pulmonary hypertension [1]. According to the World
Health Organisation (WHO), 235 million people suffer from asthma and more than 3 mil-
lion people die per year from COPDs, which is an estimated 6% of all deaths worldwide
[1]. Pulmonary diseases are typically treated by the inhalation of aerosols [2]. Aerosol
delivery introduces drug directly into the lungs, reducing off-target (e.g. toxicity) effects
associated with systemic delivery of drugs in the blood [3]. Effective respiratory drug
delivery requires a droplet size distribution between 1 and 5 µm, due to the characteristic
lung structure made of multiple diameters’ airways [4]. Most of the available nebulisers
produce aerosols with a wide range of droplet size distribution, limiting their efficiency for
high-value drugs [5]. An effective nebuliser delivers the drug in a targeted way, with mini-
mum wastage and at a low-cost [6]. Reported studies from the usage of current nebulisers
on the market resulted in a large amount of drug wastage (50% loss) and only 10% of the
dose placed in the nebuliser was deposited in lungs [6]. It was shown that 2/3 of the dose
placed in the nebulised chamber remain there at the end of nebulisation. This quantity is
acceptable for the delivery of bronchodilators, for which only a small dose is necessary to
achieve adequate results. However, for the delivery of expensive drugs, it is important that
the quantity delivered reaches the target [7]. Jet and ultrasonic nebulisers, for instance,
are bulky, relatively expensive with poor delivery efficiency and non-portable [8]. Mesh
nebulisers showed improvements compared to the jet and ultrasonic nebulisers [9], such
as higher production of particles in the respirable range and portability, but showed also
difficulties in the nebulisation of viscous solutions, resulting in a clogged mesh requiring
a long cleaning procedure. This is caused mainly to the size of the pores on the mesh,
which are around 1-5 µm. Over the last two decades, several groups worked on surface
acoustic waves (SAW) nebulisation [10], [11], [12], creating a novel nebuliser, with high
1
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potential. Using SAWs different compounds were successfully delivered, but none of those
studies showed a specific control of the nebulised particle size.
1.2 Aim and Objectives
Surface acoustic waves are increasingly used in biomedical engineering applications, such
as cell sorting [13], real-time PCR [14], biosensing [15] and nebulisers [10], [16], [17].
The main advantage of using SAW is their portability, as we can create a miniaturised
device, which can facilitate for example the analysis of compounds and have a lab-on-a-chip
concept [18]. SAWs are also able to manipulate small volumes, which is a great advantage
especially when working with blood samples, they required small amount of power, 1-5 W
are enough to nebulise and deliver drugs [19]. In particular, regarding SAW nebulisation,
specific control of the size of the aerosol has not been shown yet, previous studies reported
only the final particle size distribution [16], [11], [20]. The aim of this research is to create
a low cost, portable and user-friendly pulmonary drug delivery platform using SAW [21],
[10], [22], which can deliver the drug in an efficient way, avoiding wastage and side effects.
Firstly, the aim of this research is to test the feasibility of SAW to deliver intact
liposomes and retain the size and structure of the vesicles. The liposomes can help the
delivery of a biological compound to cross the cell membrane and at the same time protect
it from degradation.
The second objective was to create a functional drug delivery system and integrate into
the same platform, both the control of the aerosols size and the formation of liposomes
in-situ, two fundamental characteristics for an efficient pulmonary drug delivery system.
A novel approach was used, which has the advantage of combining time-consuming steps.
The third objective was to give a proof of concept of the SAW platform’s capability to
deliver nucleic acids in-vitro in lung cancer cells. Cell transfection using directly the SAW
platform was performed.
1.3 Drug Delivery Systems
For millennia, drugs have been used to improve health and extend life expectancy [23].
Drug delivery systems are engineered technologies capable of targeted delivery and con-
trolled release of therapeutic agents. The drug has to be precisely released in a specific
area, improving the effectiveness of the active agent and reducing the toxicity of a therapy
[24]. Many drugs possess negative aspects, termed side effects, which mainly occur when
non-targeted cells are exposed to a given drug. There are different anatomical routes by
which medical drugs can be delivered into the human body. The choice of the path de-
pends on various factors, such as the desired effect and/or the kind of disease. The most
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common routes of drug administration are [25]:
• Oral route. This is the most commonly employed route, used for conventional drug
delivery, due to the simplicity and the lowest cost of administration. However,
the main drawback associated with it is the reduction of the drugs’ bioavailability,
during the exposure of the given drug to the digestion enzymes in the gastrointestinal
system.
• Parenteral route. This route includes intramuscular, intravenous, intra-arterial and
subcutaneous injection. It can be used for drugs that are poorly absorbed or inef-
fective when given orally. Associated drawbacks are potential pain or discomfort of
the patient.
• Transdermal route. The medical treatment is applied to the skin. This route of
administration transferred directly a given drug to the systematic circulation by-
passing the gastrointestinal and the liver metabolism. However, the transdermal
route could be unsuitable for drugs that irritate the skin and the drug entry is
limited by the skin’s permeability.
• Inhalation route. In this type of medical treatment application route, the drug will
directly reach the lungs. This route is considered the first choice in respiratory disease
treatment because it avoids the systemic effect and it increases the bioavailability of
the drug. The lungs have also a large epithelial surface area of 70 m2 and they are
highly permeable to gas. However, the size of the inhaled droplet must be controlled.
1.4 Pulmonary Drug Delivery and Lungs Structure
Among all the drug administration routes, the inhalation one can be employed, not only
for respiratory diseases but also as an alternative route for the systemic administration of
the drug. As a matter of fact, lungs offer large absorption area which is around 70 m2 and
low enzymatic activities. Studies have shown the advantage of this route over others, for
the delivery of biological products, such as insulin [26].
As previously mentioned, there are many advantages associated with the inhalation
route. Furthermore, the direct delivery of drugs to the lungs requires lower overall quanti-
ties of the therapeutic agent and consequently brings fewer side effects [29]. It is considered
to be a less invasive delivery system, compared to the parenteral route. Moreover, many
macromolecules cannot be administered orally, as oral delivery exposes drugs to the diges-
tion system: extreme pH conditions (pH 3) and potential enzymes degradation [30]. The
pulmonary route bypasses the gastrointestinal tract and the patient metabolic differences
that affect gastrointestinal absorption, showing higher suitability in delivering therapeutic
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Figure 1.1: Image representing the respiratory tract. Air enters through the mouth or the nose
and then arrives in the pharynx and trachea, which divides into two bronchi. In this
part of the respiratory tract, inertial impaction is the main deposition mechanism.
The two bronchi then divide into several branches, starting the bronchial tree, where
different deposition mechanism can be found: impaction, sedimentation, interception
and electrostatic precipitation. The final end of the respiratory tract is made of
alveolar ducts and sacs, where small particles are characterised by the Brownian
diffusion, which is the random motion of small particles suspended in a fluid/gas
caused by the collision with fast-speed molecules in the fluid/gas [27]. Figure from
[28].
macromolecules [8], [31]. In order to understand the importance of the size of the aerosol
in pulmonary drug delivery, the lung structure has to be described. The respiratory tract
can be divided anatomically into upper airways, which include the nose, paranasal sinuses,
pharynx and lower airways, which include bronchi, bronchioles, alveolar ducts and sacs,
and alveoli. It is also divided into conducting and respiratory zone, based on the function
of transporting or exchanging gas. As shown in Fig. 1.1, the conducting zone starts with
the air enters the respiratory tract through the nose or the mouth. When air passes across
the nose, it is humidified and warmed before getting to the pharynx, which is part of both
the digestive and respiratory tract. Here, food is channelled to the stomach by the oesoph-
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agus, while air goes to the lungs from the trachea [32]. The trachea is divided into two
branches called bronchi, starting the bronchial tree. Each time the bronchial tree divides,
it forms a new generation. There are 23 generations of airways and the gas exchange is
carried out only in the last eight generations [32], which are part of the respiratory zone.
Gas exchange is a physical phenomenon, where gases move by diffusion across a surface.
In particular, the oxygen in the alveoli passes quickly into the blood in the pulmonary
capillaries, similarly, the carbon dioxide moves from the blood into the alveoli and then
exhaled. Due to the lung structure, at each division the number of generations and the
total cross-sectional area increase, while the diameter of the generations decreases (Fig.
1.1). Therefore, the absorption of the particles within the different respiratory zones de-
pends on the droplet size [3]. The aerosol size affects also the way particles are deposited
within the lungs. They can be deposited by inertial impaction, gravitational sedimenta-
tion, Brownian diffusion and in some cases, electrostatic precipitation and interception
[27].
In the first ten generations of the lungs, from the trachea to the terminal bronchioles,
the air velocity is high and the airflow is turbulent. Therefore, it is the area where inertial
impaction occurs. [33]. The impaction on airways wall is a consequence of the changing
airflow direction and the particle momentum. Gravitational sedimentation predominates
in smaller bronchi and bronchioles, in the last five to six airways generation, where the air
velocity is low. It occurs when gravitational force equals the opposing resistive force of
the air and the particle reaches the settling velocity [27]. Diffusion is predominant in the
alveolar region, where the air velocity is negligible, so the movement of a substance will
follow its gradient concentration [33]. It results from the random particle motions caused
by the collision with gas molecules. Electrostatic precipitation refers to the attraction of
charged particles to the airway walls. It contributes to less than 10% of the overall depo-
sition. An interception occurs when elongated particles have one of their ends touching
the airway. It is common when the particle size is comparable to the size of the airway
[27].
1.5 Carrier Mediated Drug Delivery System
1.5.1 Liposomes: Classification and Formation
Once the delivery route is chosen, it is important to have a drug carrier to guide the
compound to a specific target. In order to successfully deliver the drug into the lungs, have
better control on the release and protect it from degradation before reaching the target,
biological carriers, such as liposomes are often used in drug delivery system. A liposome
is a small structure (nm - µm) made up of an aqueous core confined by a lipid bilayer
membrane. It can be formed naturally for example during the cellular secretion process
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Figure 1.2: Liposome structure, which entraps an aqueous core behind a clearly demarcated
phospholipid bilayer structure. Due to the phospholipid structure made of a hy-
drophilic polar head and a hydrophobic tail, different compounds can be encapsu-
lated. Figure adapted from [34]
(exocytosis) or artificially, creating liposomes. Liposomes consist of an aqueous solution of
vesicles, which entrap an aqueous core behind a clearly demarcated phospholipid bilayer
structure (Fig. 1.2). They can contain one or more phospholipids bilayers, which are
known as lamellae [35]. Liposomes with one bilayer are called unilamellar, while liposomes
with multiple layers are called multilamellar [36]. They are largely exploited in drug
delivery since they can reach a small size (nanometer scale) and can be used to deliver a
different type of drugs. As shown in Fig. 1.2, hydrophilic compounds (green) can be loaded
in the aqueous core and hydrophobic drugs (red) are associated with the membrane. In
1961, liposomes were first described and studied by Bangham [37], [38], [39], who noticed
that they form spontaneously when phospholipids are dispersed in an aqueous medium.
Bilayer Properties of Liposomes
The bilayer properties of a liposome are due to phospholipids. Phospholipids are am-
phipathic molecules, containing both a polar head group and a non-polar portion made
of two fatty acid chains [40], [41]. In aqueous medium, they align themselves closely to
minimise the interaction between the bulk aqueous phase and the long hydrocarbon fatty
acid chains, giving rise to characteristic supramolecular arrangements [42]. The tightness
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of the phospholipids packing can be modified based on different factors [36], such as in-
creasing the hydrocarbon chain length of the phospholipids or adding cholesterol, results
in a tighter film packing. Looser film packing is obtained by increasing the degree of
unsaturation of the hydrocarbon chain or increasing the temperature of the system.
Effect of Temperature on Phospholipid Bilayer
Different parameters can modify the structure of the bilayer. A specific temperature, the
transition temperature (Tm), has a key role in the fluidity of the phospholipid bilayer [43].
The membrane is subjected to a phase transition around (Tm). Once the phospholipids are
assembled together to form a membrane and then a vesicle, the membrane displays different
behaviours depending on the temperature of the solution. The Tm is determined by the
length and degree of saturation of the hydrocarbon chain, forming the phospholipid tail,
and the charge of the phospholipid head. As the length of the hydrocarbon chain increases,
the Van der Waals interactions become stronger, requiring more energy to disrupt the
ordered packing, and thus the phase transition temperature increases [44]. Above Tm,
the membrane is fluid and the phospholipids can diffuse freely inside the bilayer, but
the bilayer configuration is conserved thanks to the hydrophobicity of the tail group [45].
Below Tm, the membrane is in a gel phase-the phospholipids are tightly packed and they
remain relatively immobile. Around Tm, the two phases can coexist [45] and it can also be
modified by higher salt concentration in the solution [45]. Due to their different structure
above or below Tm, it is important during the liposome formation to work at a temperature
above Tm.
Classification and Lamellarity
As explained, during the liposome’s formation it is important to check the Tm, but more
important for a drug delivery application is the size of the liposome. To produce smaller
liposomes and/or with fewer lamellae, additional energy has to be dispersed in the system,
through mechanical (sonication or extrusion) or electrochemical energy (change of pH,
ionic strength) [36]. Smaller liposomes and with fewer lamellae may be stable for longer
periods [36]. The preparation method influences their physical structure and size; they
can be prepared from different kind of phospholipids. Liposomes are also classified based
on their lamellarity, as shown in Fig. 1.3. Lamellarity refers to the number of the lipid
bilayers that form the liposomes [46]. Based on their size and lipid structural arrangements,
different classes of liposomes are produced. In particular, multilamellar vesicles (MLV)
with a diameter above 0.5 µm are made of numerous lamellae, unilamellar vesicles (LUV)
have a single lamella and can be of different size ranges, based on their diameter they can
be classified in a small, large and giant unilamellar vesicle. Finally, multivesicular vesicles
are made of several compartments or smaller vesicles encapsulated in a larger one.
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Figure 1.3: Classification of liposomes based on the number of lamellae. Multilamellar vesicles
(MLV) have multiple lamellae and the diameter is higher than 0.5 µm, unilamellar
vesicles are made of one lamella and multivesicular vesicles are made of a vesicle
larger than 1 µm in diameter, which contains several smaller vesicles. Unilamellar
vesicles can be of different size ranges and they are divided based on their size into
small unilamellar vesicle (SUV, d = 20/100 nm), large unilamellar vesicle (LUV,
d > 100 nm) and giant unilamellar vesicle (GUV, d > 1 µm).
This classification is key in defining which type of liposomes is the most suitable to use
in a drug delivery system. LUVs and SUVs are the most common type of vesicles used in
drug delivery, due to their small size and because it is easier to control a single layer instead
of multiple. The use of MLVs is restricted by many factors: large diameter, low entrapped
volume (due to numerous lamellae), wide size distribution and lack of uniformity during
preparation [47]. Furthermore, fast degradation (or removal from the bloodstream) in the
presence of the mononuclear phagocyte system (MPS) [48] and, most importantly, the lack
of control over content release have limited the use of MLVs as a drug carrier [49]. SUVs
and LUVs are produced from MLVs, which are formed using the film hydration method.
In this work, unilamellar and multilamellar liposomes are mainly used.
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Phospholipids Topology and Critical Packing Parameter
In order to form a bilayer, the molecular shape of phospholipids has to be chosen accurately
to model the membrane shape that they will form. Depending on their head group and tail
group components, they can be in a conical, inverse-conical or cylindrical shape (Fig.1.4).
A parameter called the packing parameter was developed, which is useful in determining
the size and shape of lipid aggregates [50]. It is described by:
S = v/a0l (1.1)
where v is the hydrocarbon chain volume, a0 is the area of the head group, and l is the
critical length of the hydrophobic chain. The value of S determines the aggregate formed
by lipids or any amphiphiles upon hydration. It has been shown that lipids aggregate
forms spherical micelles where S < 1/2, as in Lysophosphatidylcholine case (LSPC);
nonspherical (cylindrical) micelles, where 1/3 < S < 1/2; bilayers where 1/2 < S < 1
(DOPC); and reverse micelles or hexagonal phases where S > 1, such as 1,2-dioleoyl-sn-
glycerol-3-phosphoethanolamine (DOPE).
Figure 1.4: Packing parameter of three different phospholipids.(a) Lysophosphatidylcholine has
an inverted cone topography. (b) 1,2-dioleoyl-sn-glycero-3- phosphoethanolamine
(DOPE) has a cone shape. (c) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)
has a cylinder shape. Fig. adapted from [51]
A stable solution of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) in PBS, formed
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a characteristic cylindrical shape of a bilayer (SDOPC < 1), as shown in Appendix A,
Fig. A1. Moreover, in heterogeneous phospholipid systems, the packing parameter is
additive and the average bulk structure is based on the average packing parameter of the
lipid mixture. Phospholipids with an average of S < 1/2 forms structure with positive
curvature, those with S around 1 form flat non-curved structures, and those with S > 1
adopt negatively-curved structures [52].
1.6 Liposomes: Formation and Production
1.6.1 Spontaneous Formation of Multilamellar Vesicles
Multilamellar vesicles are formed spontaneously and can be disrupted to form unilamellar
vesicles. Once a dry lipid film comes in contact with water, based on the packing pa-
rameter of the phospholipids, MLVs are formed spontaneously upon agitation to help the
detachment [38]. Due to the amphipathic nature of phospholipids, the fatty acids tails
rearrange their structure to minimise the contact with water, forming bilayers and after
shaking, MLVs of 1-15 µm in diameter are generated [53] (Fig. 1.5).
Figure 1.5: MLVs Formation. Polar head of dried phospholipids start to swell in contact of
water. The fatty acid rearrange their structure to minimise the contact with water,
closing themselves and forming MLVs with sizes between 1-15 µm of diameter. Figure
adapted from [54]
In a laboratory setting, this principle is used to generate MLVs via a multistep process.
Firstly, a suitable lipid in powder is dissolved in a solvent, once the solvent evaporates
and a thin lipid film is created, as shown in Fig. 1.5, the hydration and agitation in an
aqueous solution will occur to favour the vesicle self-assembly into MLVs [53]. Despite
a large number of studies regarding lipid vesicle formation, the theory behind it is still
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Figure 1.6: Large unilamellar vesicles formation, adding energy to the system, multilamellar
vesicles are breaking down into bilayer phospholipid fragment and then due to the
hydrophobic effect of the phospholipid fatty chain, the bilayer close themselves.
not completely understood. To form LUVs and SUVs from MLVs, different techniques are
followed [36].
One of the main theories on liposomes formation was proposed by Lasic [54]. Accord-
ing to his study, once an MLV dispersion is formed, different methods can be used in
order to decrease the size and the lamellarity of the vesicles, by applying energy to the
system, usually performed under cavitation, adding pressure or rapidly changing the tem-
perature (e.g. freeze-thaw cycles) [47]. Bilayer phospholipid fragments (BPFs) are formed
by adding energy to the MLV mixture [47]. Once BPFs are formed, due to the exposure of
hydrophobic chains to water, and depending on the thermodynamic conditions, LUVs can
form from BPFs fusion. The liposomes formation process is described in Fig. 1.6. Besides
Lasic et al., Talsma [55] proposed the bubble method, where nitrogen gas bubbles are in-
troduced in a solution of water with dried lipids, to promote the formation of phospholipid
monolayer at the nitrogen gas/water interface. This theory was subsequently utilised by
Feng et al., who demonstrated the formation of a nanoemulsion through bubble bursting
at a compound interface [56].
Most common methods for producing SUVs and LUVs from an MLV dispersion, which
is obtained using the thin film hydration method, use a mechanical approach, such as
extrusion, sonication and freeze-thawing liposomes. Chemical approaches, which can be
used to form heterogeneous vesicle sizes, are solvent dispersion method, are detergent
depletion and reverse phase evaporation techniques [35]. The vesicles’ formation process
was described by Lasic et al., [53], [54], [47] and summarised in Fig. 1.7.
1.6.2 Methods of Producing Liposomes
The production of lipid vesicles involves three steps [35]: (1) drying lipids in an evaporated
organic solvent to form a lipid film, (2) dispersion of lipids in an appropriate aqueous
solution and (3) size reduction and characterisation of liposomes. To dry lipids a rotary
evaporator can be used. If the sample volume is lower than 1 mL then a stream of nitrogen
can be utilised instead of [57].
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Figure 1.7: Different vesicles preparation methods, according to the mechanism of vesicles for-
mation proposed by Lasic, [54]. Phospholipid solution describes the phospholipid
in organic solvent while phospholipid dispersion is a multilamellar vesicles solution.
Changing the solubility of the solution and with the disruption of the bilayers in
the phospholipid dispersion case, the formation of bilayered phospholipid flakes or
fragments (BPFs) will occur. One BPFs are formed, they will fuse and bend in
vesicles, due to the hydrophobic effect of the hydrocarbon chains. Figure arranged
from [53]
The second step, which involves the hydration of lipids in an aqueous solution, can be
achieved using the thin film hydration method (described in Chapter 2) or organic solvent
dispersion and detergent dispersion [58].
Mechanical Dispersion: Production of LUVs and SUVs
A thin layer of dried lipids is hydrated in an aqueous solution (thin film hydration method)
[59], the head group of the lipids starts to swell and absorb water until the lipid is peeled
off to form multilamellar vesicles, while the hydrophobic effect holds the bilayer together.
A gentle agitation could help in detaching the MLVs.
Sonication
Sonication uses ultrasonic frequencies (>20 kHz) to disrupt phospholipid membranes and
produce unilamellar vesicles from multilamellar vesicles, usually applied using an ultra-
sonic bath or probe. High energy ultrasound is introduced into a liquid medium, forming
alternating cycles of high pressure (compression) and low pressure (rarefaction) [60]. Dur-
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Figure 1.8: Solution of MLVs pushed through a polycarbonate membrane with 100 nm pore
diameter.
ing the low-pressure cycle, small vacuum bubbles are created. When the bubbles attain
a volume at which they can no longer absorb energy, they collapse violently during a
high-pressure cycle. This phenomenon is termed cavitation. During the implosion, high
temperatures (approx. 5,000 K) and pressures (approx. 2,000 atm) are reached locally, re-
sulting in liquid jets of up to 280 m/s velocity [60]. The main disadvantages of this method
are low volume entrapment, metal pollution from the probe tip, high temperature, which
might have a detrimental effect on the structure and stability of encapsulated proteins and
multimodal distribution of the produced vesicles. Disruption of MLV suspension using tip
ultrasonication typically produces small, unilamellar vesicles with a diameter in the range
of 15-50 nm.
Extrusion
The extrusion mechanism involves passing a solution of MLVs through a polycarbonate
membrane filter with defined pore size, Fig. 1.8. The solution is sequentially extruded to
decrease the size of the vesicles [61]. One of the main advantages of this method is the
homogeneous size of the vesicles. However, the resulting produced liposomes are larger
than vesicles generated via sonication and the process is time-consuming and labour-
intensive.
Freeze-Thawed Liposomes
MLVs are rapidly frozen at -80◦C and thawed in a water bath at 37◦C. This process is
repeated at least 3 cycles. During freeze-thawing, rapidly-forming ice crystal disrupts the
structure of MLVs, leading to the formation of liposomes (see Appendix, Fig. C1). How-
ever, obtaining a specific size range of vesicles is difficult and using this process biological
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material can be damaged due to the exposure to low temperatures.
Organic Solvent Dispersion
Lipids dissolved in ethanol are injected into a huge excess of the buffer. MLVs are rapidly
formed, but the techniques produce a heterogeneous population of liposomes and the
ethanol removal is challenging [58].
Reverse Phase Evaporation
Reverse phase evaporation is a method based on the formation of inverted micelles. They
are formed by sonicating a mixture of the aqueous phase, which contains the molecules to
be encapsulated into liposomes, and an organic phase in which the amphiphilic molecules
are solubilized [62]. The organic solvents are removed under reduced pressure during
continued rotary evaporation and liposomes are formed. The main disadvantage is the
exposure of the encapsulated material to an organic solvent and the sonication [58], which
can cause DNA damage or protein denaturation.
Detergent Dispersion and Solubilisation
Lipids are solubilised in an aqueous solution through the addition of detergents, which are
then removed slowly to help the formation of liposomes [63].
Detergent Depletion
Lipid solubilisation can be obtained using detergents at their critical micelle concentrations
(CMC). As the detergent is removed from detergent/lipid-mixed micelles, they increase in
numbers and combine to form liposomes [64]. As the detergent needs to be removed via
dialysis, the whole process is relatively time-consuming. Additionally, this method results
in non-homogeneous populations of liposomes.
1.6.3 Stability of Liposomes
After the description of the main liposomes’ formation methods, a explanation of lipo-
somes’ stability is made. To deliver a functional compound the liposome has to be stable
and intact during the nebulisation. Stability testing is the primary tool used to assess the
expiration date of pharmaceutical products under typical storage conditions (shelf-life).
Liposome stability is affected by physical, chemical and biological processes. One physical
process, such as fusion, affects liposome size, shelf life, and the release of encapsulated
material [66]. Chemical degradation, such as hydrolysis of the ester bond linking the
fatty acids to the glycerol backbone, also affects liposome stability. Biological stability is
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Liposomes production method Advantages Disadvantages
Sonication FastSmall liposomes
High temperature (>80◦C)
Denaturation of biologics
Metal pollution
Need MLVs solution
[60]
Extrusion Monodispersity
Time consuming
Liposomes diameter ≥100 nm
Need MLVs solution
[65]
Freeze-Thaw Easy to operate
Extreme temperatures (-200 ◦C)
Denaturation of biologics
Size control
Need MLVs solution
[36]
Reverse phase evaporation Fast
Polydispersity
Time consuming
Exposure to organic solvent
Size control
[41]
Detergent depletion Stability
Polydispersity
Presence of detergent
Size control
[40]
SAW nebulisation
Fast
Stability
Monodispersity
Aerosols formation
Delivery of biologics
Need MLVs solution
(Chapter 4)
Table 1.1: Comparison of different methods to produce liposomes. The advantages of using the
SAW nebuliser to produce liposomal aerosols are analysed and studied in Chapter 4.
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affected by liposome degradation in the bloodstream. The use of proteins prolongs the
circulation time of liposomes by increasing their stability [67].
The stability of liposomal aerosols was previously tested when using jet and ultrasonic
nebulisers [68]. Jet nebulisers (Airlife, Respirgard II Filtered Medication Nebuliser) use
compressed gas to produce aerosols from an aqueous solution but induce fragmentation
of the vesicles during nebulisation due to high shear stress, and design of the nebuliser
that allows the recycling of liposome-containing liquid within [5], [69], [70]. Ultrasonic
nebulisers are less widely used, both because of the heating that occurs during nebulisation,
which denatures proteins, and because of their inability to nebulise liquids of viscosity
higher than 6 centipoise [71]. In Taylor's study [70], sodium cromoglycate (SCG), widely
used in the prophylactic treatment of asthma, was encapsulated in liposomes, and drug
loss was measured using a multi-stage liquid impinger (MLI), which was also employed to
evaluate the particle size distribution. Analysis of the solution on the stages of the MLI
indicated over 50% loss of the entrapped drug during nebulisation. A decrease in vesicle
diameter was also apparent, suggesting that the liposomes were fragmented upon their
passage through the nebuliser [72]. To increase the stability of liposomes, they are usually
frozen before storage, adding into the freezing solution cryo-protectants, at a concentration
below 10% v/v [73], [74]. Whilst this does indeed improve the stability of the liposomes, it
is time-consuming. Moreover, it causes the liposomes to shrink and swell, which can cause
the encapsulated compound to leak out due to an imbalance in osmotic pressure [75]. The
vesicles initially shrink due to the higher concentration of cryoprotectants outside of them
and then swell due to the osmotic movement of the cryoprotectant into them [73].
Liposome leakage can be affected by changes in temperature, cholesterol levels and pH
[44]. According to experimental results, higher temperatures (compared to room temper-
ature), and pH 1.9 to 5, increase the fluidity of the double bilayer, thereby destabilising
the vesicle and increasing leakage. The insertion of cholesterol into a DPPC phospholipid
membrane at a molar ratio higher than 0.5:4, in terms of cholesterol: DPPC, decreases
leakage [44].
1.6.4 Liposomes in Pulmonary Drug Delivery System
Liposomes were previously used as a pulmonary drug delivery carrier [4], [Price], [76].
Many studies have shown the safety of liposomes inhalation [77], [78], [79]. The successful
development of an anticancer liposomal formulation for inhalation depends on the inhala-
tion device, which produces the aerosols and the size of the liposomes [80]. Therefore, it
is critical to find a suitable device, which can retain the liposomes functionality. Intratra-
cheally instilled liposomes in mice were reported to be uptaken by pulmonary cells [81].
Mainelis outlined the advantages of local intratracheal delivery of Liposomal Doxorubicin
(DOX) for the treatment of lung cancer when compared with systemic administration
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of the same drug [82]. With the intratracheal delivery of the DOX, a higher peak of
the DOX concentration and much longer retention of liposomes was noticed in the lungs
of a nude mouse with an orthotopic model of the human lung (A549 non-small cell lung
carcinoma). Using a five ports nose-only exposure system for small animal, a greater reduc-
tion of the tumour volume after inhalation delivery of liposomal DOX was observed [82].
Therefore, the advantages of administrating intratracheally a combination of liposomes
and anticancer drug, such as DOX, were previously demonstrated [83]. Different devices
can affect the delivery of liposomal formulation. Pressurised metered-dose inhalers were
employed to deliver liposomes by dissolving the phospholipids in CFC propellant, which
have been reported to be depleting the ozone layer [84]. Thus, safe alternative propellants
are used, but in which phospholipids have low solubility. Main issues encountered are low
deposition and stability. The delivery of liposomes using dry powder inhalers resulted in
additional freeze-drying step in the liposomes formation procedure and in the insertion of
cryo-protectants.
1.7 Liposomes Characterisation
Size measurements are one of the main characterisation methods of dispersion. Direct
measurements of particle size are based on microscopy which cannot be used for nano-size
dispersion and hard to achieve for aerosols. Confocal microscopy and transmission electron
microscopy (TEM) are briefly described, but they were not used to measure the size of the
liposomes. Confocal was used to track changes in the liposomes population size and TEM
was used to test the structure of the liposomes, but resulted in an expensive and time-
consuming method. Therefore, indirect methods, based on light scattering and diffraction
are used instead. In this section, a background of light scattering is presented, followed by
the dynamic light scattering (DLS) and laser diffraction, which are the principal methods
used for characterisation of nano-particles and aerosols in this study.
1.7.1 Light Scattering
Potential interactions of light, when passes through a material are absorption, trans-
mission, fluorescence and scattering. The scattering signal may be analysed by several
methods:
• Static: average signal strength
• Dynamic: fluctuations of signal
• Electrophoretic: shift of the signal
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Figure 1.9: Different scattering effects: Rayleigh scattering for small particles which re-radiates
the signal with the same phase. Mie scattering is used for particles with a diameter
similar to or larger than the wavelength of the incident light and they re-radiated
the scattered signal with different phases.
The scattering process can be: (1) elastic, where the wavelength of the scattered light
is the same as the incident light (the kinetic energy of the particle is conserved), (2)
inelastic, where the emitted radiation has a different wavelength from the incident one
(loss of the kinetic energy) and (3) quasi-elastic scattering, where the wavelength of the
scattered light has been shifted (small loss of kinetic energy) [85].
Two types of elastic scattering are [86] (Fig.1.9):
• Rayleigh scattering, which is the elastic scattering of light of molecules and particles
much smaller than the wavelength of the incident light (d < 110λ).
• Mie scattering is a broad class of scattering of light by spherical particles with a
diameter similar to or larger than the wavelength of the incident light.
The intensity I of light scattered by any one of the small spheres is [87]:
I = I0(
1 + cos2θ
2R2 )(
2pi
λ
)4(n
2 − 1
n2 + 2)(
d
2)
6 (1.2)
where I0 is the laser intensity, θ is the angle from where the scattering is observed, n is
the refractive index of the solvent, R is the laser radius and d is the particles diameter.
1.7.2 Dynamic Light Scattering
Dynamic Light Scattering (DLS) is a technique that measures the fluctuations of the
light scattered by nano-particles in dispersion, which are moving under Brownian motion.
Stokes-Einstein equation describes the diffusion coefficient of a particle under Brownian
motion in a quiescent fluid at uniform temperature [88]:
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D = kT6piηr (1.3)
where k is the Boltzmann's constant, T is the absolute temperature, η the viscosity of the
fluid in which particles are immersed and r is the hydrodynamic radius of the particle.
The sample, which is made of particles dispersed in a solution, is illuminated by a laser.
As the laser passes through the medium, it interferes with particles and scatters, resulting
in an intensity pattern, which varies as particles move. The intensity fluctuations from the
Brownian motion of the particles is analysed by a digital correlator [87]. The correlator
compares signals, two different ones or one signal with itself at varying time intervals. At
time zero the signal is perfectly correlated with itself, so the correlation is high, over the
time as particles diffuse, the correlation will reduce, until there will be no relationship
with the original signal and the correlation will be zero. The decay of the correlation
is characteristic of the diffusion speed and thus the particles size. The autocorrelation
function of the scattered light g(2) for a given delay time τ is described by [89]
g(2)(τ) = 〈I(t)I(t+ τ)〉〈I(t)〉2 (1.4)
where I(t) and I(t+τ) are the intensities of the scattered light at t and t+τ times, and
the angled brackets indicate an averaging over t. The intensity-intensity time autocorre-
lation function can be also expressed in terms of field-field time autocorrelation function
g(1)(τ) by Siegert relation:
g(2)(τ) = B + β[g(1)(τ)]2 (1.5)
where B (usually B = 1), referred as baseline, is the long-time value of g(2)(τ), β is
the geometrical factor and with g(1) individuated by:
g(1)(τ) = 〈E(t)E
*(t+ τ)〉
〈E(t)E*(t)〉2 (1.6)
where E(t) and E(t + τ) are the scattered electric fields at t and t + τ times. For
monodisperse particles in solution the field-correlation function decays exponentially,
g(1)(τ) = exp(−Γτ) (1.7)
with a decay rate of γ = Dq2, where D is the diffusion coefficient of the particles and
q is the magnitude of the scattering wave vector. The scattering wave vector q is the
difference between the incident and the scattered wave vectors and its magnitude is given
by:
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q = 4pin
λ0
sin(θ2) (1.8)
where n is the refractive index of the solvent, λ0 is the wavelength of the laser in
the vacuum, and θ is the scattering angle. For a polydisperse sample, g(1)(τ) cannot be
represented by a single exponential, but as a sum or an integral over a distribution of
decay rates G(Γ) by:
g(1)(τ) =
∫ ∞
0
G(Γ)exp(−Γτ)dΓ (1.9)
where G(Γ) is normalised so that
∫ ∞
0
G(Γ)dΓ (1.10)
G(Γ) using Laplace transform techniques, as g(1)(τ) is the Laplace transform of G(Γ).
Polydispersity Index
The polydispersity index (PDI) is used to characterise the width of the particle size dis-
tribution from the DLS measurements [86]. A DLS measurement generates an autocorre-
lation function, which is evaluated using the cumulant analysis [90], which is a moment
expansion that produces different values, such as the polydispersity index [87]. In the
cumulants analysis, a single particle size mode is assumed and a single exponential fit is
applied to the autocorrelation function [91]. The polydispersity index can be an indicator
of the quality of the sample. Values greater than PDI = 0.7 indicate that the sample has
a very broad size distribution and is probably not suitable for the dynamic light scatter-
ing (DLS) technique [90]. PDIs values around 0.1-0.2 indicate high quality, monodisperse
sample.
1.7.3 Confocal Microscopy
A laser scanning confocal microscope (Zeiss LSM 5 Live, Jena) was used to check the
different population of vesicles, both before and after SAW nebulisation. The main ad-
vantages of confocal microscopy are the point-by-point illumination of the sample and the
presence of a pinhole which rejects the out-of-focus light, leading to high contrast images
[92]. The excitation light is provided by a laser, which encounters a pinhole and becomes
the point source of light. The laser light (in this case green, LSM 5 LIVE) reflects off a
dichromatic mirror [93], Fig. 1.10. The light is then focused by an objective lens on a
desired focal plane in the specimen. The laser excites the DOPE-rhodamine in the lipid
samples (MLV mixture, which fluoresces and emits light (red)(λabs = 560 nm, λem = 583
nm). The light emitted by the sample passes through the dichromatic mirror. The second
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Figure 1.10: Confocal microscope components. A laser, which acts as an excitation source,
passes through the first pinhole. The dichromatic mirror reflects the light which
is then focused on the specimen by an objective. The dye in the sample fluoresces
and emits light which passes through the dichromatic mirror and hits the second
pinhole. The second pinhole prevents light from coming from out-of-focus focal
planes from reaching the photomultiplier detector [93].
pinhole prevents the light which is coming from a different focal plane from reaching the
photomultiplier detector [93].
1.7.4 Trasmission Electron Microscopy: Negative Staining and
Cryo-TEM
Resolution in microscopy is limited to about half a wavelength of the illumination source
used to image the sample [94], [95]. To overcome this limitation, an illumination source
with a shorter wavelength than visible light is needed. LUVs (nanometer order) are below
the resolution of a light microscope. Therefore, transmission electron microscopy (TEM)
was used in order to visualise SAW-formed vesicles of 100 nm in diameter. Using an
accelerated electron beam as a light source, a higher resolution compared to the light
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Figure 1.11: Transmission electron microscopy. Differences between negative and positive stain-
ing. In negative staining approach, the background is stained while the specimen
is not affected [96]. When the electron beam passes through the sample, it will be
deflected by its interactions with the sample and the stain. Since the protein sam-
ple excludes stain, the deflection of the electron beam through the sample is less
than through the stain region. Regarding positive staining, the stain is attached
to the surface of the specimen, resulting in a dark image of the sample against a
light background [96].
microscope can be obtained and thus, an object of nanometer order can be revealed.
Moreover, it is extremely useful for examining different layers of specimens and their
structures. When an electron passes through an atom, it encounters three effects, it is
so fast that it could pass through the atom and does not interact; it could bounce into
the nucleus of the atom, without changing neither the energy or the speed, but only the
direction. It is called elastic scattering and it generates the contrast in the image. Finally,
the electron could be inelastically scattered and the interaction with electrons in the
sample will cause an energy loss of the electrons that will damage the sample. It is called
inelastic scattering and it is responsible for the noise in the image. Three problems were
highlighted when electron microscopy is used with biological materials [97]. First of all,
most biological samples are suspended in aqueous solution thus, if, in contact with a high
vacuum, which is needed for the electron beam, their structures will collapse; liposomes,
for instance, will burst. Second, elements that are most common to biological (H, N,
O, C) have low intrinsic contrast in water and finally, biological samples are radiation
sensitive. To solve these problems, two approaches can be applied: negative/positive
staining and cryo-TEM [98]. In the negative staining process, heavy metal salts derived
from molybdenum, uranium or tungsten can be used to generate high contrast [94]. These
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materials readily interact with the electron beam and produce phase contrast, i.e. the
light encounters a greater phase shift as it interacts with the stained sample. As shown in
Fig. 1.11 stains can be employed for negative and positive staining. In negative staining
the stain surrounds the specimen, as it is being excluded from the volume occupied by
the sample, producing a clear and detailed image of the sample. In positive staining the
stain is attached to the surface of the specimen, resulting in a dark image of the specimen
against a light background.
Cryo-TEM has some advantages over negative staining namely, the sample is always
in solution and no stain is required. In cryo-TEM, the sample is frozen so fast that water
molecules do not have the time to re-organise into ice crystals, thus, it is called vitrified
water. Advantages include good preservation of the sample and high resolution, but it is
technically demanding and the contrast is limited [99].
1.8 Aerosols Characterisation
1.8.1 Particle Size Distribution and Aerodynamic Diameter
In drug delivery systems, the size of the carrier compound is a key parameter. In order
to deliver molecules within the human body is important to have particles of a specific
size range, depending on the application [100]. For instance, to pass through the blood-
brain barrier, the particle has to be in the range of 15-50 nm, whereas to pass through
the endothelium, it has to be smaller than 150 nm [101]. To be able to reach the lungs,
the aerosols have to be in the size range of 1-5 µm [102]. The particle size distribution is
also crucial to assess the sample quality; if the sample is monodisperse, characterised by
particles of uniform size [103], the sample quality is improved and a higher concentration
of the drug will reach the desired target. Particles are three-dimensional objects, therefore,
to describe them using a single number, a spherical approximation must be used, which is
the approach taken by most techniques. For instance, the aerodynamic diameter is used in
the inertial impaction method to measure the particle size. It is defined as the equivalent
diameter of a spherical particle with a density of 1000 kg/m 3 with the same terminal
velocity of the particle of interest [104].
1.8.2 Cascade Impactors
Cascade impactors are instruments employed for the characterisation of aerosols, produced
by inhalers and nebulisers. The most commonly used cascade impactors are the ACI
and the Next Generation Impactor (NGI), both recommended by the US and European
Pharmacopeia. The multi-stage liquid impinger (MSLI) was also widespread but was
recently substituted by ACI and NGI for the higher resolution in particles diameter. The
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Method Parameter Size order
Dynamic light scattering (liposomes) Liposomes size nm
TEM negative staining (liposomes) pre-CryoTEM visualisation nm
Cryo-TEM (liposomes) Lamellarity of liposomes nm
Laser diffraction (aerosols) Aerosols size µm
Cascade Impactors (aerosols) Aerosols size µm
Table 1.2: Summary of liposomes and aerosols’ characterisation method, measured parameter
and size order.
MSLI has the only advantage compared to the ACI and the NGI that the collection stages
are kept moist, avoiding the bouncing effect [105]. The NGI is the improved and more
recent version of the ACI. The ACI has a stage size overlap and its use is more time-
consuming for the operator, which has to disassemble the impactor at each measurement
to recover the deposition on the collection plates [106]. Nevertheless, results from the
ACI and the NGI measurements showed comparable values [107], in terms of particle size
distribution.
1.8.3 Laser Diffraction
Laser diffraction is an established method to measure the size of the nebulised particles
[90]; In this manuscript, a laser diffraction system was used to measure the aerosol pro-
duced by the SAW nebuliser. The main advantages of using laser diffraction for aerosol
size measurements are: it covers a wide size ranges from submicron to millimetres, repro-
ducibility, easy and rapid measurements [108]. This technique uses the angular variation
in the intensity of the light after passing through a particle, to evaluate the particle size
distribution. The software analyses the collected angular scattering intensity data, using
Mie theory, and provides the measurement based on the given refractive index of particles
and medium, assuming a volume-equivalent sphere model. An approximation of the Mie
scattering theory, which was used in older laser diffraction instrument is the Fraunhofer
diffraction theory can be used when the following conditions are fulfilled: (1) when the
particle is 10 times the wavelength and (2) the scattering angle is less than 30◦. The two
theories are used together in order to ensure that a wide range of particles diameter is
covered [109].
1.9 Overview of Inhalers and Nebulisers
In this work, the inhalation route is chosen as the most direct drug delivery route to the
lungs. Carrier-mediated drug delivery system were described introducing liposomes and
their main characteristics, but an overview of the current available devices is needed to
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understand what is the need and what are the problems in order to develop a more efficient
nebuliser. Inhalers and nebulisers are largely used to treat pulmonary diseases, by directly
delivering drugs to the lungs. They have been employed since the 19th century (Fig. 1.12).
There are two primary parameters used to evaluate their performances: the aerosols size
distribution and the drug output rate, which depends on several factors, such as, the device
type and its design as well as the particular drug delivered [4]. The main difference between
inhalers and nebulisers are that first ones need patient’s breath-coordination, while second
ones operate continuously. Two principal inhalers are currently on the market: metered-
dose inhalers (MDI) and dry powder inhalers (DPI). During the activation of a metered-
dose inhaler, a pre-measured dose of drug solution is released at high velocity (100 km/h).
In order to obtain a clinical efficacy of the treatment, patients need to simultaneously
inhale during the drug release. This breath-coordination dependency resulted in difficulties
for children and elderly patient [110]. In a dry powder inhaler, the drug is provided in
powdered form. Most of the resulting particles are too large to penetrate the lungs, but
the turbulent stream created in inhalers during inhalation causes the aggregates to break
up into smaller particles [6].
Figure 1.12: A schematic of the evolution of pulmonary drug delivery devices. First developed
nebulisers were composed of a liquid reservoir and a pump that was used to spray
out a pressurised liquid by hand force. In 1938 a hand-bulb nebuliser was devel-
oped, which replace the pump of the previous version [111]. In the early 40s and
50s, metered-dose and dry powder inhalers were manufactured. In 1964, first jet
nebuliser and then ultrasonic one was produced and finally, in 1993 the first mesh
nebuliser was marketed by Omron [9]. Figure arranged from [33].
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Device Advantages Disadvantages
Inhalers (MDI, DPI) Stability of the formulation(dry powder)
Breath-coordination
Large aerosols
Small volumes
Low deposition (7-21%)
[113], [110], [107]
Jet nebuliser Large volumes
Damage of biologics
Large aerosols
Bulky and noisy
High power
[5], [113], [6], [114]
Ultrasonic nebuliser Portability
Damage of biologics
Large aerosols
Bulky
Limitations with suspensions
[5], [113], [115], [114]
Mesh nebuliser Optimum aerosols size
Clogged mesh
Small pores (∼1-5 µm)
Difficulties in cleaning
[5], [9], [66], [116]
SAW nebuliser
Versatile
Optimum aerosols size
Delivery of biologics
Disposable
Small volumes
[17], [18], [117], [118]
Table 1.3: Comparison of inhalers and different nebulisers, highlighting advantages and disad-
vantages. The table shows the numerous advantages of the SAW nebuliser, between
them the most important are the size control of the aerosols and the delivery of
biologics, which are discussed in Chapter 4 and 6.
The main drawback of using inhalers is that their efficiency, which can be measured
in terms of therapeutic effect, depends on the amount of energy that the patient uses to
inhale. Nebulisers are capable of delivering a higher drugs quantity compared to inhalers
because they operate over a longer period and they do not require coordination skills from
patients [110]. The most common forms of nebulisers are jet and ultrasonic nebulisers.
Jet nebulisers are based on the Venturi principle, they convert a solution of a drug into a
mist of droplets by passing compressed air through a narrow hole [6], [112]. The presence
of the constricted section (narrow hole) creates a reduction of fluid pressure, which moves
the fluid from the reservoir and breaks it up into droplets by the jet. The main drawback
is represented by the nebulisers cumbersomeness due to the compressor size.
The jet of gas expands when exiting the orifice, creating an area of subatmospheric
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pressure into which the fluid is moved from the reservoir by the Bernoulli effect and is
broken up into droplets by the jet. Droplets are then filtered by baﬄe structures within the
nebuliser. The continuous production of aerosol from the nebuliser during both inspiration
and expiration phases causing the production of a large amount of wasted drug. Only 10%
of the drug is deposited in the lungs [8]. Ultrasonic nebulisers use a piezoelectric crystal
to produce aerosolised particles. Ultrasonic vibrations from the piezoelectric material are
transferred into a drug solution, which produces standing waves on the solution surface.
Droplets are produced from the crest of the standing waves and are released as a mist
[17]. Main advantages of ultrasonic nebulisers are the device portability, which reduces
the number of emergency room visits and hospitalisations required and the ease of use
compared to inhalers. A significant drawback is the damage of biological compounds and
proteins due to the creation of high shear stress from the frequency range used (below
MHz order).
Mesh nebulisers are the first choice for inhalation treatment [9], even though they are
the latest developed nebulisers on the market (1993). In mesh nebulisers, the liquid drug
is forced through multiple apertures [9]. They can be classified into two types: vibrating
(active) and static (passive) mesh nebulisers. The drug solution is loaded in a reservoir and
in the static mesh nebuliser, a force is applied on the liquid to push it through the mesh
[113]. In the vibrating mesh, the mesh vibrates and push the liquid through the pores [5].
Mesh nebulisers, compared to jet and ultrasonic ones, have increased portability and can
provide higher drug doses to the patients [5], other advantages are the low shear stress
produced and the possibility to produce different aerosols size, based on the manufacturing
process of the mesh. Despite all these advantages, different challenges are associated with
mesh nebulisers. For instance, the difficulty to deliver a viscous solution and consequently,
the clogged mesh pores, which are of few microns order and the high cost of the device.
For all these inhalation therapies the main negative aspect is the low deposition ef-
ficiency of the drug in the targeted area [27]. SAW nebulisation technology offers many
advantages that will be discussed at the end of the Chapter. Table 1.3 summarises the
main inhalation devices on the market with their advantages and disadvantages.
1.10 Surface Acoustic Waves (SAW)
1.10.1 IDT and piezoelectricity
For a better understanding of the advantages of the SAW nebuliser compared to com-
mercially available devices, a brief description of the SAW characteristics and ultrasonic
atomisation is made. SAW devices are a relatively new technologies (90s) and still in
development. There are many advantages of using SAW for medical purposes, especially
in the gene therapy field, which are going to be illustrated in the following Section 1.11.1.
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Interdigitated Transducer (IDT) represents the main part of the SAW nebulisation plat-
form, it consists of pairs of gold fingers deposited onto a piezoelectric crystal. In this work
Lithium Niobate (LiNbO 3) is used as the substrate. Piezoelectricity is the generation
of an electrical charge as a result of applied mechanical stress. It is a linear effect and
reversible. In the SAW nebuliser the inverse piezoelectric effect is used, where the for-
mation of mechanical stress was caused by the application of an electric field [119]. The
effect is caused by the relative motion of ions in the crystal structure, as a consequence
of the changed dipole moment [120]. As shown in Fig. 1.13, only crystal without a centre
of symmetry can exhibit piezoelectricity [119] because in centre-symmetric materials any
motion from an ion is reflected by symmetry to an equal and opposite motion that cancels
out the dipole moment [121].
SAWs are mechanical waves that travel along the surface of a piezoelectric material,
which can be generated by an interdigitated transducer (IDT) [10], with an amplitude
that decays exponentially inside the material [117].
SAWs propagate as Rayleigh waves, first described as a combination of a longitudinal and
vertical shear components, Fig.1.14.
When a Rayleigh wave propagates on the surface of the piezoelectric material the par-
ticles in the solid move in elliptical paths, with the major axis of the ellipse perpendicular
to the surface of the solid. As the wave propagates in depth of the material, the width of
the elliptical path decreases [124]. The wave motion attenuates rapidly as the wave moves
into the substrate up to 4-5 wavelengths [125]. SAW devices are commonly used as filters,
oscillators and transformers that are based on the transduction of acoustic waves. Over the
past years, SAW devices have been adopted for micro-scale fluid manipulation, capable of
generating range of complex fluid transport phenomena, including mixing, centrifugation,
pumping and nebulization [19] through the use of 1-100 MHz acoustic waves. Various
microfluidic applications use SAW as a microscale fluid actuation mechanism [126]. The
most attractive aspects of SAW employment is the efficient fluid-structural coupling, due
to the confinement of the energy adjacent to the surface. The choice of using high fre-
quencies (MHz) compares to lower frequencies (KHz)is due to the advantage of using high
accelerations. Friend and Yeo in their review highlighted that for 10MHz frequency vibra-
tions the acceleration of the fluid is over 107m/s2, which allows the ejection of droplets
from a SAW device [127]. Moreover, a MHz frequency device allows miniaturisation of the
device.
1.10.2 Ultrasonic Atomisation and SAW nebuliser
Previous studies on ultrasonic atomisation have shown a correlation between the median
diameter of the aerosol droplets, the surface tension of the liquid, the acoustic excitation
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Figure 1.13: (a, b) Representation of a crystal structure with the centre of symmetry. (a) A
cubic unit cell with a centre of symmetry is represented and in absence of applied
force, the net polarisation is equal to zero. Without applying stress the centre of
mass (c.m.) of the positive charges coincides with the c.m. of the negative charges.
(b) A force is applied and the total polarisation is still null. Any motion from an
ion is reflected by symmetry to an equal and opposite motion that cancels out the
dipole moment. (c, d, e) Representation of a crystal structure without the centre of
symmetry. (c) The hexagonal unit cell does not have a centre of symmetry, when
unstressed the c.m. of the negative charges coincides with the c.m. of the positive
charges, thus the net polarisation is null. (d) A force is applied along y, the charged
in A and B position move in A’ and B’ position and their c.m. become shifted.
(e) A force is applied in a different direction (x) and gives rise to a polarisation in
other crystal directions. Figure adapted from [122].
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Figure 1.14: Propagation along the y-axis of a Rayleigh wave. Rayleigh waves are a type of
surface waves made of longitudinal and vertical shear components, which make the
particles in the solid moving in an elliptical motion. Figure adapted from [123],
[16]. In the red rectangle a close up of the elliptical motion and the propagation of
the surface wave.
frequency and wavelength of the surface waves formed on the liquid surface [128]. These
studies used bulk acoustic waves with low ultrasonic frequency (< 1 MHz).
In 1831, Faraday reported the formation of standing waves on the surface of a fluid,
when it is placed on a vertically vibrating plate. These small waves on the surface of the
fluid are known as capillary waves. Capillary wavelength is described by [129]:
λ = (2piσ
ρfc
2 )
1/3 (1.11)
where λ is the wavelength, σ is the surface tension, ρ is the liquid density and fc
is the frequency of the surface waves on the surface of the liquid (i.e., capillary waves).
Throughout this thesis, a small volume of liquid was used and waves on the surface of
fluid are considered as capillary waves.
Based on the assumption that capillary waves are subharmonic Faraday waves [18], it
was proposed that the frequency waves on the surface of the liquid are half of the excitation
frequency and Lang proposed that equation (1.2) can be rewritten as:
D = Cλ = C(8piσ
ρF 2
)1/3 (1.12)
where F is the excitation frequency, the relation fc = F/2 was proved by Eisenmenger
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[130], indicating that capillary waves oscillate at half of the excitation frequency.
The drop formation is based on the instability mechanism of the capillary waves [16],
as their amplitude is growing [130], droplets are ejected into the air [128].
Recent studies suggested that the assumption on the capillary wave frequency (i.e.,
fc = F/2) is not valid for high frequency excitation (> 1 MHz) [117]. This is explained
with the fact that in early studied low frequencies in kHz range were used, which are
comparable to the natural oscillation frequency of the liquid [117]. However, the relation
between aerosol droplet size and capillary wavelength is well establish in the literature
[117], [131], [118], [132].
In 1995, Kurosawa produced for the first time a mist of droplets using a surface acoustic
wave transducer, where a mean diameter of the nebulised particles of 19 µm was obtained
[16]. As described by Kurosawa, during the nebulisation the fluid was first spreading out
into a thin layer and then the nebulisation occurred from the crest of the capillary wave.
It was noticed that increasing power, the atomising rate increased. Also, an increase in
frequency would induce a smaller device size and a decrease in the atomising rate [16].
Using a 10 MHz transducer, the overall generated droplet size distribution had two peaks,
one at 40 µm and the other at 3 µm [16]. A transducer of 48 MHz was also employed,
showing the same droplet size distribution with two peaks, but one at 11 µm and the other
at 3 µm. A reduction of the largest peak from 40 µm to 11 µm was obtained, where the
smallest group of droplets (3 µm) retained their size [133]. Therefore by using a higher
frequency transducer, (i.e. 48 MHz instead of 10 MHz), did not bring advantages in terms
of droplet size. A reduction of size from 40 µm to 11µm was noticed, but not enough for
the particle to be within the clinically validated size range for pulmonary drug delivery.
Moreover, the nebulisation rate was lower, reducing the delivered amount of liquid. If the
liquid is loaded on the SAW propagating path, the SAW radiates its energy into the liquid
[117]. From Giovannini et al., the energy (W) required to disperse a volume of liquid into
smaller droplets is [134]:
W = (σN)(4pir2) = σ( V4/3pir3 )(4pir
2) (1.13)
where, V is the volume of the atomised liquid, r is the radius of the droplets, N is the
number of droplets and σ is the liquid surface tension.
Chono et al. in 2004, used a filter paper to obtain a stable nebulisation, in order to
keep a thin liquid film. Experimental results showed that the angle and the height of
the mist depend on the SAW input power. As shown in Fig. 1.15, due to the different
propagation speed of the SAW in the two medium, water and lithium niobate, once the
wave reached the liquid, it refracts into the droplet of liquid, following a specific angle,
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Figure 1.15: SAW propagation into a droplet of liquid. SAW diffracts into the droplet of liquid,
following a specific angle, called Rayleigh angle [131]
called Rayleigh angle:
θR = sin−1(cw/cs) (1.14)
where cw = 1485 m/s is the speed of sound in water and cs = 3965 m/s is the speed of
sound in lithium niobate.
Further studies were made by Qi et al., where experimental results values showed a
weak dependency between droplet size and frequency, especially for frequency above 10
MHz [135]. The droplet size appeared to be related to a balance between the capillary
stress, which tends to pull the droplets out from the liquid bulk and the viscous force [135],
which represents the fluid resistance to the flow. The explanation of the independence of
the droplet size and the driving frequency as previously claimed [16], [133], [20], relies
on the fact that SAW nebulisation uses much higher frequency (F > 10 MHz) compared
to the ultrasonic nebuliser (F < 1 MHz), for which the Kelvin’s and Lang’s equations
were formulated. The capillary destabilisation and breaking up process depends on the
capillary-viscous resonance [135]:
fc ∼ σµR (1.15)
where fc is the resonant frequency of the capillary waves, µ the viscosity of the liquid and
R is the radius of the droplets. As a consequence of the capillary-viscous resonance, the
capillary wavelength, which determines the size of the aerosols, depends on the proper-
ties of the liquid. Different liquid with various surface tensions and viscosities produced
different size distributions [117]. The efficacy of SAW nebuliser has been demonstrated
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for proteins [136], nucleic acids [137] and pulmonary stem cell delivery [138]. Cortez-Jugo
at al. [139] delivered monoclonal antibody to A549 cells, by incubating the cell suspen-
sion with a nebulised solution of the antibody. Rajapaksa et al. [137], nebulised a 75 µg
of DNA plasmid tagged with a fluorescence label solution and added it to lungs tissue.
Results showed a low intensity of the fluorescent plasmid after the incubation and the
demonstration of the DNA entry in the cell’s nucleus was not proven [137]. Alhasan et
al. [138], used SAW to nebulise stem cells, they demonstrated that SAW does not have
a deleterious effect on the cells, the effective delivery was not shown, having also the size
of the cells larger than the optimal size range for lungs absorption, between 1-5 µm in
diameter [102].
To summarise, the main advantages of using a SAW platform, as a nebuliser for pul-
monary drug delivery system, are the low-cost fabrication, made it possible with the use of
silicon superstrates over piezoelectric materials [22], the relatively low power consumption
(1-2 W), the reduced quantity of the sample (µl) and the control over the aerosol droplet
size [132].
1.11 SAW Nebuliser in Gene Therapy
1.11.1 Nucleic Acids and Gene Therapy
Nucleic acids are important macromolecules for the storage, transmission and expression
of genetic information [140]. Over the past two decades, nucleic acids have been used
in biomedical research for the development of gene-targeted therapies, for their ability
to modulate gene expression both at the transcriptional and post-transcriptional levels,
in the form of DNA sequences or small interference RNAs respectively [141], [142]. The
introduction of nucleic acids into cells can target defective genes responsible for numerous
diseases [143], [144]. Individual genes code for specific proteins that perform functions as
widespread as the regulation of body's muscle and organ tissue, receptors and enzymes
[145]. Gene therapy represents a promising potential treatment for numerous diseases
including immuno-deficiencies, haemophilia, Parkinson’s disease, cancer and even some
viral infections such as those with HIV [146]. There are more than 1800 monogenic hered-
itary disorders that could be addressed by the replacement of a missing or defective gene
[147]. The first attempt to correct a hereditary disorder (in this case, adenosine deam-
inase deficiency) was undertaken in 1990 by Blaese and Anderson using a gene transfer
method [143], [148]. Since then, there have been 95 approved trials of gene transfer ther-
apy. Currently, gene therapy is mainly considered for diseases for which alternative modes
of treatment are unknown [149]. Although it is still considered experimental [150], fur-
ther research will develop gene therapy into a new effective tool for modern medicine. The
main advantages of using nucleic acids as therapeutics are their high specificity, versatility,
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low toxicity, and low molecular weight, which facilitates their cellular uptake [151], [152].
Nucleic acid therapy includes the use of antisense nucleotides, aptamers and small inter-
fering RNAs (siRNAs), [153]. Antisense nucleotides are either DNA or RNA sequences.
An antisense oligonucleotide-based therapeutic agent for the treatment of cytomegalovirus
retinitis (CMV) has been approved by the FDA and is the first of its kind. CMV causes an
inflammatory viral infection of the eye and belongs to the same family as the herpesvirus
[154]. It often infects immunocompromised patients, causing serious diseases like retinitis,
hepatitis, colitis and pneumonia [155]. The oligonucleotide, Fomivirsen (Vitravene), has a
specific sequence that is complementary to that of the viral mRNA, which is transcribed
from the main transcriptional unit of CMV. Thereby, it blocks the expression of the virus
in CMV-infected cells [141], [156]. Aptamers are short sequences of nucleic acid that are
15-80 nucleotides in length. Their ability to target molecules with high specificity and
affinity is attributable to their unique 3D structures. Recently, they have been studied for
targeted delivery into various types of cell, in combination with siRNAs [157]. An siRNA
is a double-stranded RNA molecule consisting of 20-25 base pairs, that functions via the
RNA interference pathway.
1.11.2 Mechanism of Small Interfering siRNA Activity
RNA has a similar structure to DNA, except for the presence of a ribose sugar residue
instead of deoxyribose. It also differs from DNA in that it is typically single-stranded and
does not contain thymine, which is replaced by the base uracil [152]. In order to explain the
mechanism by which siRNAs exert their activity, the process of gene expression consisting
of transcription and translation is now described. A gene encodes for a specific protein,
which has a specific function in cells. Firstly, RNA is synthesised from the DNA sequence
(transcription) [158]. This process catalysed by RNA polymerase and consists of three
steps: initiation, elongation and termination. [159].
RNA polymerase binds with the promoter sites on the DNA sequences, which are
generally towards the 5' end, and then separates the double-stranded DNA to produce a
single-stranded template for gene transcription. An RNA strand of a sequence comple-
mentary to that of the DNA template is formed (elongation); this is the messenger RNA
(mRNA) [160]. During elongation, the RNA polymerase selects the correct ribonucleo-
side triphosphate and catalyses the formation of a phosphodiester bond, building an RNA
molecule from bases complementary to those of the DNA template. The RNA polymerase
keeps building the RNA transcript until the termination sequence in the gene is detected,
as showed in Fig. 1.16. The mRNA strand is then detached from the DNA template.
Once the mRNA is detached from the DNA, translation can begin. The sequence
of an mRNA code for a specific protein. The mRNA is translated at ribosomes into
a sequence of amino acids (polypeptides), which then folds into an active protein and
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Figure 1.16: RNA synthesis. The process consists of three steps: initiation, elongation and ter-
mination. During the initiation process, RNA polymerase binds with the promoter
sequence and unwinds the double-stranded DNA. In the following elongation phase,
an RNA molecule of a sequence complementary to that of the single-stranded DNA
template is formed, the mRNA. Elongation continues until the RNA polymerase
detects the termination sequence.
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performs its functions in the cell [161]. The mRNA is read based on the genetic code, in
which 3 bases constitutes a codon and each codon codes for a specific amino acid. There
are also non-coding RNAs: functional RNA molecules that are transcribed from DNA,
but not translated into a protein. An example is small interfering RNA (siRNA)[162].
siRNAs are short double-stranded RNAs that are 20-25 base pairs in length, and that
have been extensively researched in recent years [163], [164], [152], due to their high
specificity in inhibiting the expression of specific mRNAs. They do this by inducing the
RNA interference (RNAi) pathway, which prevents protein translation [165]. RNAi is a
natural mechanism of sequence-specific gene silencing, playing an important role in gene
regulation [166]. Cells use short double-stranded RNA (siRNA) to recognise mRNAs
that are then destroyed and unable to be translated into proteins [167]. Specifically, a
double-stranded RNA (dsRNA) is processed into an siRNA by the RNase II enzyme Dicer
[168], as shown in Fig. 1.17. The siRNA is then loaded into an RNA-induced silencing
complex (RISC) [169]. Part of the RISC is the endonuclease AGO2, which cleaves the sense
strand (passenger strand) of the siRNA while the antisense strand (guide strand) remains
associated with the RISC [168]. The guide strand, as part of the RISC, can scan and bind
with complementary mRNA. AGO2 then cleaves the bound complementary mRNA. Since
the cleaved mRNA is no longer recognised by the cells, it is degraded. Thereby, the gene
from which that mRNA was transcribed is silenced [168] [163].
siRNA has huge potential for use as therapeutic agents, but getting them into cells
remains a significant challenge. As mentioned previously, nucleic acids are negatively
charged, and so they cannot easily pass through the cell membrane unless a carrier is used
[168]. Nanoparticles and liposomes are commonly used as carriers since both are able to
efficiently deliver siRNAs whilst protecting them from degradation [170].
siRNA Delivery: Extracellular and Intracellular Barriers
Fifteen years after the discovery of the RNAi pathway, research to determine the best
way to deliver siRNA into cells is still ongoing [171]. An ideal siRNA carrier should
overcome extracellular and intracellular barriers, be biodegradable and biocompatible, and
be neither cytotoxic nor immunogenic [172]. It must also protect the nucleic acid from
degradation by nucleases, evade degradation by macrophages, and be reversibly bound so
that the siRNA can be released at the target area. [151]. It should also facilitate cellular
uptake and promote endosomal escape [168]. To be effective, siRNAs should be delivered
into the cytoplasm. The barriers to the delivery of the nucleic acids depend on the type
of cell targeted, and the route of administration. Systemic administration of an siRNA is
most common, but the siRNA is thereafter degraded by nucleases and excreted through
the kidneys, limiting its bioavailability [173]. Local delivery of siRNA to lung cells can
be non-invasive and avoids interaction with the serum and consequent degradation [171].
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Figure 1.17: Double stranded RNA is processed into an siRNA by the RNase II enzyme Dicer.
The siRNA is loaded into the RISC. The endonuclease AGO2 cleaves the sense
strand of the siRNA, while the antisense strand remains associated with the RISC.
The antisense strand then binds with complementary mRNA, then AGO2 cleaves
the bound complementary mRNA.
Pulmonary epithelial cells are the key target for gene knockdown therapies against diseases
such as cystic fibrosis, COPD, and asthma [174], in which direct access to the lungs and
pulmonary circulation is important [175]. In the lungs, alveolar macrophages represent the
main barrier to siRNA delivery. When siRNA/carrier complexes reach the cell they have
to pass through the cell membrane, overcoming the extracellular barrier primarily through
endocytosis. Once within the cell, they have to escape the endosomal compartment before
being degraded by lysosomes [176]. Different means of facilitating endosome escape can
be adopted, including membrane fusion, proton sponges, and inserting fusogenic peptides.
[176].
Phospholipid and Nucleic Acid Complexes
Lipoplex, which is a complex of nucleic acid and lipids [177], can promote endosomal escape
owing to its ability to fuse with the endosomal membrane [178]. It is also proposed that
the phospholipid DOPE can aid release due to transforming the bilayer into an inverted
hexagonal structure [179]. As discussed previously (Chapter 4), lipids adopt different
topologies based on their head groups, fatty acid chains and saturation [34]. Before they
can enter the cells and promote endosomal escape, the particles or siRNA/carrier com-
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plexes have to first of all actually reach the target cells deep in the lungs and be deposited
around them. Deposition of siRNA complexes in the lungs depends on the aerodynamic
diameter of the particles in which the siRNAs are formulated, as described in Chapter 1.
Only particles between 1 and 5 µm in size can be effectively absorbed in the lungs [102].
The ability to control aerosol size is a major advantage of using surface acoustic waves
for nebulisation. The production in situ of nucleic acids' carriers within the optimal size
range is a promising development in the progress towards making a targeted pulmonary
drug delivery platform capable of delivering nucleic acids to target cells.
1.11.3 Nucleic Acid Carriers
The cell phospholipidic membrane is relatively hydrophobic, and its amphipathic structure
restricts the entry of large and charged molecules [180]. A nucleic acid is hydrophilic and
negatively charged due to the phosphate group backbone. To be able to cross the cell
membrane, they, therefore, need a carrier [178]. These carriers (or vectors) are divided
into two main categories: viral and non-viral vectors.
Viral Vectors
Viral vectors are highly efficient in the delivery of nucleic acids to specific types of cell.
The main challenges they present are avoiding a response by the body's immune system
and eliminating the pathogenicity of the virus [181]. Different type of virus is used for
various applications, such as retroviruses and adenoviruses. However, even if the viruses
are modified to remove their pathogenicity, there remain some risks associated with their
use as vectors. The administration of a modified virus can cause the body to develop an
immune response if it is seen as a foreign invader. An example of the failed employment
of viruses in gene therapy was the clinical trial of Jesse Gelsinger in 1999 [150], which
increased ongoing concerns about the safety and ethical issues surrounding this approach.
Non-Viral Vectors
Non-viral vectors, although less efficient than viral vectors, present several advantages, in-
cluding lower pathogenicity, lower risk of insertional mutagenesis, a DNA mutation caused
by the insertion of base pairs, as well as lower cost and easier production [182]. Non-viral
methods of delivery can be divided into two groups: physical methods, or multicompo-
nent carriers such as positively charged phospholipids and polymers [183]. Among physical
methods, electroporation is the most commonly employed. Its concept relies on the use of
electric pulses to temporarily create pores in the cell membrane [183]. Other methods like
sonoporation (ultrasound) and hydrodynamic (pressure) delivery are less common because
cell targeting needs to be specific [184]. Specific ligands and receptors can be added into
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the formulation in order that the complex may be delivered only to specific cells, but this
increases the difficulty of the process. Liposomes, which can either encapsulate nucleic
acids or bind to them via electrostatic interaction, are one of the oldest nanocarriers used
in gene therapy [185]. In the work detailed in this chapter, cationic liposomes were used as
a carrier to deliver DNA luciferase plasmids and GAPDH siRNA into the A549 cell line.
1.11.4 Cationic Lipid-Nucleic Acid Complexes and Cellular Up-
take
Cationic lipids are one of the most commonly used non-viral nucleic acid carriers, because
of their non-immunogenicity, low toxicity, ease of production and their ability to carry
nucleic acids into cells [186]. They are used for both gene delivery (DNA) and gene
silencing (siRNA), despite their transfection efficiencies remaining low compared to viral
vectors [186]. It is known that charged molecules are not able to cross the membrane, due
to its hydrophobic core. Nucleic acids thus need a carrier to balance the charge, in order
to enter into a cell's nucleus or cytoplasm [180]. Cationic liposomes consist of at least one
positively charged phospholipid, which forms a complex with negatively charged nucleic
acids through electrostatic interactions, forming a lipoplex. Electrostatic interaction is
attractive or repulsive interactions between molecules having different charges. It is a non-
covalent interaction, meaning that it does not involve the sharing of electrons. It is critical
in maintaining the three-dimensional structure of molecules such as proteins and nucleic
acids [187]. The most commonly used cationic phospholipids are N-[1-(2,3-silyloxy)propyl]-
N,N,N-trimethylammonium chloride (DOTMA) and N-[1-(2,3 Dioleoyloxy)propyl]-N,N,N-
trimethylammonium chloride (DOTAP). For a successful delivery, it is also important to
optimise the ratio of lipids to DNA/RNA. It is suggested that an excess of lipids can entrap
the nucleic acids between the liposomes' lamellae [185], while increasing the amount of free
DNA for example, plasmids were found close to the lipids' vesicles. In order to find the
optimal ratio between nucleic acids and carriers, agarose gel electrophoresis was employed.
For cationic liposomes, both endocytosis and fusion were proposed as nucleic acid uptake
mechanisms. Understanding of the mechanism of transfection and the interaction between
the nucleic acid complexes and cell components are still lacking. The endocytic pathway
is known to be a major mechanism by which biological agents such as DNA and siRNA
are taken up by cells. Nucleic acid-lipid complexes are trapped in endosomes and then
degraded by specific enzymes in the lysosome [176]. Part of the cellular membrane starts
to bend inside the cell in order to form an endocytic vesicle, containing the substance to
be internalised such as an siRNA/DNA complex. Once the endosome is formed inside the
cell, the contents have to achieve endosomal escape in order to reach the cytoplasm or
nucleus [188]. The size of the carrier is a key parameter in the endosomal escape. Carriers
of diameter d ≤ 100 µm have been reported to accumulate better in tumours, hepatocytes
CHAPTER 1. INTRODUCTION 40
and inflamed tissues, whereas larger particles are taken up by the reticuloendothelial
system [188].
1.11.5 SAW Nebulisation of Nucleic Acids
Jet and ultrasonic nebulisers do not facilitate efficient nucleic acid delivery. They do not
allow tight control over the size of the aerosolised droplets, and the high shear stress gener-
ated during nebulisation can damage the RNA/DNA material [116]. Yeo’s group has been
working on SAW drug delivery in the lungs, testing the nebulisation of plasmid vaccines
in a large animal model [137]. In their experiments, 300 µg/mL of DNA plasmid bound
with yellow fluorescent protein were delivered through SAW nebulisation. Images from
confocal microscopy showed that the pDNA was successfully delivered, thus proving the
suitability of SAW. However, they found that the efficiency of delivery could be increased
by using a vector. As previously mentioned, a positively charged carrier would be a good
approach to helping the DNA to enter the cell's nucleus. In the results section, Fig. 6.8, it
is shown that naked DNA (without the presence of a carrier) is less efficiently transfected
than that within a lipoplex. Here lies the necessity of creating a unique platform which
will not damage the compound to deliver and at the same time can form the drug carrier
to guide the compound inside the cell.
Chapter 2
Materials and Methods
This Chapter describes the materials, the methods and the different experimental setup
used throughout the entire thesis. Microfabrication processes to produce the SAW neb-
uliser were carried out at the James Watt Nanofabrication Center (JWNC). Gel elec-
trophoresis, western blot and cell culture (methods used in Chapter 6) were carried out
at the University of Hong Kong.
2.1 Materials
General chemicals, phospholipids and kits were obtained from Sigma-Aldrich (Merck
Group) unless otherwise stated. 1, 2−dioleoyl−sn−glycero−3−phosphoethanolamine−
N − lissamine rhodamine B sulfonyl (DOPE-RhB) was purchased from Avanti Polar
Lipids, Inc. (USA) and used without further purification. Herring Sperm DNA and
Luciferase assay system were purchased from Promega For in-vitro gene expression, DNA
luciferase plasmid was purchased from Aldevron (USA). 30% Acrylamide/Bis Solution 29:1
and dye reagent concentration for protein assay were purchased from Bio-Rad (USA) Lipo-
fectamine 2000 was purchased from Invitrogen (USA) and used as a transfection carrier
control. Silencer GAPDH siRNA Human and Silencer select negative control siRNA were
obtained from Ambion. Gel loading capillaries of 25 mm length were obtained from Lab-
con (USA) The A549 cell line was purchased from ATCC (Manassas, VA, USA). Cells were
grown in the cell culture medium DMEM (Dulbecco’s Modified Eagle’s medium, Gibco,
ThermoFisher Scientific), supplemented with 10% (v/v) FBS and 1% (v/v) antibiotic-
antimycotic (ThermoFisher Scientific). A549 cells were seeded in 24 well-plates (Corning
Costar TC-Treated Multiple Well Plates, d = 15.6 mm) at a concentration of 0.5× (10)5
cells/mL in 1 mL medium, and in single well-plates (Nunc Cell Culture/Petri Dishes,
d = 35 mm) at a concentration of 0.8 × (10)5 cells/mL in 2 mL medium. Conductive
paint, Electrodag 1415, was purchased from Agar Scientific (UK). 4-inch wafers of Lithium
Niobate 127.8◦ Y-cut X-propagation to produce the IDT and silicon wafers of 200, 270
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and 500 µm were obtained from University Wafers (USA).
2.1.1 Buffer Solutions
All stock solutions and subsequent buffers can be found in Table 2.1 and were made using
deionised (DI) water and autoclaved before use. A TAE buffer solution made up of Tris
base, acetic acid and EDTA was employed for running gel electrophoresis. It is commonly
used for this purpose due to its low ionic strength and buffering capacity. A solution with
high ionic strength can reduce the current carried by the sample, thus decreasing the rate
of migration. Buffering is important because pH can also affect the migration rate [189].
2.2 Microfabrication of Interdigitated Transducer
2.2.1 L-Edit IDT Design
As mentioned in the Introduction, the IDT is the main part of a SAw nebuliser, which needs
to be designed to work at a specific resonant frequency. The Tanner L-Edit IC Layout
(Mentor Graphics, US) software was used to design IDTs for this study, as represented in
Fig. 2.1. An IDT is made of two interlocking comb-shape arrays of metallic electrodes.
The resonant frequency of the IDT is determined by the distance between fingers and
speed of sound in the substrate. The IDT was designed to have a resonance frequency
at 9.7 MHz with 20 pairs of fingers, composed of 10 nm of titanium and 70 nm of gold
deposited onto the substrate. By using the following equation:
λ = 4d = c
f
(2.1)
where d is the spacing between the metal fingers of the IDT, c is the speed of sound in
the substrate (Lithium Niobate, c = 3980 m/s) and f is the resonant frequency of the IDT.
IDTs with different resonant frequencies were designed by varying the wavelength from 800
µm, 400 µm and 200 µm with resonant frequencies of 4.9, 9.9 and 19.9 MHz, respectively.
Highest nebulisation rate was obtained by the IDT with a resonant frequency of around 9.7
MHz, which was used as a reference in all the experiments in this thesis. Higher frequency
IDT dispersed power through heat (IDT is subjected to high temperature), while lower
frequency IDT needed a higher power to obtain an effective nebulisation rate.
2.2.2 Photolitography
Lithium Niobate 127.8◦ Y-cut X-propagation, a piezoelectric non-symmetric crystal, was
used as a substrate, due to its high electromechanical coupling efficiency [121]. The mi-
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Buffer Name Composition
SDS-Page Lower Buffer
(1.5M Tris/HCl, 0.4% SDS)
18.16 g Tris base
0.4 g SDS
pH to 8.8 with HCl.
Final volume of 100 ml with DIW
The solution was filtered and stored at 4C
SDS-Page Upper Buffer
(1.5M Tris/HCl, 0.4% SDS)
6.06 g Tris base
0.4 g SDS
pH to 6.8 with HCl.
Final volume of 100 ml with DIW
The solution was filtered and stored at 4C
SDS-Page Running Buffer (10x)
30.30 g Tris base
144 g Glycine
10 g SDS
pH should be around 8.3
Final volume of 1000 ml with DIW.
Blotting Buffer (1x)
100 ml 10x blotting buffer
700 ml DIW
200 ml methanol
Tris Buffered Saline, TBS (10x)
24.22 g Tris (0.2 M)
87.83 g NaCl (1.5 M)
pH to 7.4.
Final volume of 1000 ml with DIW.
Lower Gel (10%)
3.4 ml of 30% Acrylamide Bis
2.5 ml of SDS-Page lower buffer
4.1 ml DIW
0.1 ml of 10% APS
0.01 ml of TEMED.
Upper Gel
0.65 ml of 30% Acrylamide Bis
1.25 ml of SDS-Page upper buffer
3 ml DIW
0.03 ml of 10% APS
0.02 ml of TEMED.
Gel loading dye
0.2 g bromophenol blue
6 ml of 50% glycerol
4 ml of DIW
Table 2.1: List and compositions of buffers used mainly to make gel electrophoresis and western
blot. Protocols used were rearranged from Dr. Michael Chow, the University of Hong
Kong.
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Figure 2.1: (a) Zoom in of the fingers structure of an IDT. The main parameters are shown
in the image: IDT aperture, IDT finger width (d) and the wavelength (λ) of the
surface wave. (b) Mask designed on L-Edit for IDTs. After cleaning the substrate
and spinning of the photoresist, the mask is placed on the substrate. The mask
alignment and then UV hard exposure (nitrogen pressure under the substrate) for
4 s, were carried out to lithographically define the electrode pattern.
Figure 2.2: IDT Microfabrication processes: 1. LiNbO 3 cleaning, 2. Photoresist spinning on
LiNbO 3, 3. Mask alignment and UV exposure to remove the photoresist exposed
to light, 4. Photoresist development, 5. Metal evaporation and deposition, 6. Metal
lift-off.
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crofabrication process, carried out in James Watt Nanofabrication Center (JWNC), is
depicted in Fig. 2.2 and a 4-inch wafer of LiNbO 3 was processed as described below:
1. Substrate was cleaned in three steps of 5 minutes inside an ultrasonic bath with
Opticlear, acetone, and methanol. The cleaned substrate was consequently rinsed
with RO water and dried with nitrogen.
2. Positive photoresist S1818 was spun on the cleaned substrate at spinning speed of
4000 rpm for 30 s, forming a 1.8 µm thick photoresist layer. The sample was then
baked at T = 100◦C for 3 minutes.
3. The coated substrate is then patterned using an MA6 Mask Aligner(Karl Suss).
The substrate was exposed to UV light for 4 s using the designed mask (Fig. 2.1)
as shown in Fig. 2.2, stage 3.
4. The exposed substrate is developed with the recommended developer for S1818 (Mi-
croposit MF-319) for 75 s. The sample was then subjected to the plasma asher, to
remove the traces of resist on the substrate.
5. Metal deposition of 10 nm of Titanium and 70 nm of Gold was completed with
Plassys IV (electron beam evaporation).
6. The final stage is the photoresist lift-off (Fig. 2.2, stage 6), that was completed by
leaving the substrate in acetone for 1 hour followed by rinsing with reverse osmosis
(RO) water and drying with a nitrogen gun.
Gold is selected for IDTs as a preferred metal due to its higher conductivity and corrosion
resistance and a thin layer of titanium provides better adhesion between substrate and
gold.
2.2.3 Characterisation of IDTs
To check the IDTs’ reflection and the working frequency, a network analyser was used.
In order to understand the concept of high-frequency network analysis, which involves
incident, reflected and transmitted waves travelling along a transmission line, a comparison
with a light wave, that travels through an optical lens can be made [190].
When the light hits the lens, part of it can be reflected, part continues to travel through
the lens and part can be absorbed, if the lens is made of a lossy material, the same can
occur in a transmission line [191]. The resonant frequency of IDTs was found using a
network analyser (Agilent Technologies E5071C ENA series, USA).
A network analyser measures parameters of electrical networks, which can be seen
as a black box interacting with other circuits through ports. It is usually composed of
CHAPTER 2. MATERIALS AND METHODS 46
Figure 2.3: (a) Block diagram of a 2-port network analyser, showing the main components.
The 2 ports of the DUT are denoted as P1 and P2. The switch SW1 indicates the
direction where the signal will pass, in this case, will go through the port 1 of the
DUT, and the parameters S11 and S21 can be measured. (b) The IDT results as a
one-port network, where a network analyser was used to send a signal to the one-port
network and evaluating the reflected signal, the S11 parameter can be evaluated.
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a test set, which routes the output from the signal generator to the device under test
(DUT), a signal generator, a receiver and a display. The circuit in Fig. 2.3 shows the
main components of a 2-port network analyser. P1 and P2 are the 2 ports of the DUT.
In Fig. 2.3 the switch (SW1) directs the test signal to the port P1. From SW1 the signal
goes to a splitter, which is dividing the signal to a reference channel and to P1through a
directional coupler DC1.
Directional couplers are most frequently constructed from two coupled transmission
lines set close enough together such that energy passing through one is coupled to the
other.
To characterise a device, the network analyser sends a signal with an amplitude and
phase to the DUT and measures the amplitude and phase of the reflected signal and the
output signal. Using the ratio between the incident, the transmitted and the reflected
signal, the scattering parameter can be evaluated.
Scattering parameters (S parameters) describe the electrical behaviour of linear elec-
trical networks when travelling currents and voltages in a transmission line encounter a
discontinuity, caused by the insertion of a network in a transmission line.
The network is then characterised by a signal matrix which can be used to calculate
its response to the signal applied to the ports. For an N-ports network, a matrix of N-
dimensions and N2 elements can be built. In the case of IDTs, only one port is present,
therefore the parameter of interest is only one, S11, which is also called input port voltage
reflection coefficient (Fig. 2.3). As from Fig.2.4, when the amplitude is zero (S11 = 0) then
all the power is reflected and nothing goes through the IDT, and the resonance frequency
can be found for the lowest value of S11.
A parameter that can be also evaluated using the network analyser is the characteristic
impedance of a transmission line (Z0), connecting devices with same impedance reduces the
signal reflection and maximise the power transfer from the device to the IDT. Therefore,
a frequency with an impedance of 50± 0.5 W was chosen as optimal frequency. The Smith
Chart on the network analyser was used to check the impedance at specific frequencies.
2.3 Microfabrication of the Silicon Chip
Cylindrical cavities were produced on a silicon wafer of 270 µm thickness. The choice of
the thickness was made, after trying out a 500 µm thickness wafer, which was dumping
the power and was too thick to be etched, and a 200 µm thickness one. The latter was too
thin and during the etching process, all the material was removed, leaving only some part
of the chip. A dry etch process was carried out to remove the material to form cylindrical
cavities of diameters: 100, 200, 400, 600, 800 and 1500 µm.
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Figure 2.4: From the network analyser (a), (b), the evaluation of S11 was made, finding out
that for the specific IDT design, the resonance frequency was of 9.7 MHz. Where
the amplitude is zero, the test signal sent from the network analyser to the IDT
is completely reflected. Oscillations are due to the noise of the environment. (a)
Frequency range from 8 to 12 MHz. (b) Zoom in, frequency range from 9.4 to 10
MHz, the maximum amplitude is found around 9.7 MHz.
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Figure 2.5: Dry etching process. The first step involves cleaning and spinning of the positive
photoresist AZ4562 on the silicon wafer. In the second step, the mask alignment is
employed to expose the wafer for 24 s to UV light. The third step was carried out
by a JWNC technician, using the PlasmaPro 100 Estrelas Deep Silicon Etch System
for 60 minutes. Finally, the samples were treated with piranha solution for 60 s and
then plasma-ashed for 120 s at 100 W to create a hydrophilic surface.
Cleaning Substrate and Spinning
A 4-inch silicon wafer of 270 µm thickness was subjected to organic solvent cleaning.
Opticlear, acetone and methanol were used for 5 min each in an ultrasonic bath to remove
any dirt. Then, RO water was used to rinse and a nitrogen gun was employed to dry
quickly the wafer. A positive photoresist (AZ4562) was then spun at 200 rpm (thickness
around 3 µm, Photoresists MicroChemical GmbH). The procedure is shown in Fig. 2.5,
step (1). Pre-baking steps were employed at 60◦C for 3 min and at 110 ◦C for 10 minutes.
Photolithography
In order to create a pattern of cylindrical cavities pattern, designed using L-Edit, a pho-
tolithography process was employed with a mask aligner (Karl Suss MA6 Mask Aligner)
through a UV hard exposure for 24 s, Fig. 2.5, step (2).
Development and Dry Etch
Photoresist exposed to UV light becomes soluble to a photoresist developer, while the
parts covered by the mask remained insoluble. AZ 400K developer was diluted 4 times in
deionised (DI) water before the samples were agitated in the developer for 4 minutes. After
the development, the samples were loaded on a carrier wafer and dry-etched for 60 minutes
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Figure 2.6: SEM SU8240 images of the dry-etched silicon chip, after photolithography process
to create the cylindrical cavities pattern.
in order to remove the material inside the cylindrical cavities (Fig. 2.5, step (3) and Fig.
2.6), using Oxford Instruments Estelas 100 ICP RIE Deep Silicon Etch Tool. A squared
design was also fabricated (see Appendix B, Fig. B1) Dry etch consists of the removal of
material from a patterned sample using a plasma of the gases: sulfur hexafluoride (SF6),
octafluorocyclobutane (C4F8), nitrogen (N2), argon (Ar), helium (He) and oxygen (O2).
The samples are subjected to a bombardment of ions which etch the cylindrical cavities
directionally [192].
2.4 Lipid Mixtures
2.4.1 Film Hydration Method
In this work, the phospholipid suspensions were made using the thin film hydration
method, which is one of the simplest methods to prepare a multilamellar vesicles mixture
and to encapsulate various compounds within the vesicles [59]. A lipid film was produced
by depositing the lipids within a clean glass vial, drying under a stream of dry nitrogen,
followed by chloroform evaporation through desiccation of the solution for 90 min. The
dried lipid layer was rehydrated by addition of 1 ml of phosphate-buffered saline (PBS) or
DI water, forming a multilamellar vesicles (MLV) mixture, unless otherwise stated. Gentle
hydration of the lipids followed by swelling in excess water yields an ensemble of vesicles
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Figure 2.7: Thin film hydration technique was used to form unilamellar vesicles. (1). Phos-
pholipids, which were chosen based on the experiment, are firstly dissolved in an
organic solvent as chloroform. (2). A lipid film was produced by spreading the
lipid/chloroform solution with a dry nitrogen gun for a small amount of volume,
for volume higher than 1 mL, the rotary evaporator technique has to be used. The
sample was left in vacuum for 90 min to allow the chloroform to evaporate. (3).
Hydration of the lipid cake and agitation were applied in order to have the forma-
tion of multilamellar vesicles MLVs. (4.) Downsizing that can be applied through
a different method such as extrusion, sonication or chemical methods (See Chapter
1).
with a broad size distribution [35]. A high polydisperse sample (PDI > 1) is obtained
with vesicles larger than 5µm, which are not suitable for drug delivery.
Different techniques were used to downsize the vesicles and to increase the stability of
the vesicles [36]. Freeze-thaw cycles and probe tip ultrasonication (Hielscher Ultrasonic
Technology) were used to rupture and reform MLVs.
Fluorescent Liposomes
Different MLV mixtures were made using 1.00 mg/ml, 5.00 mg/ml and 10.00 mg/ml of
1, 2− dioleoyl − sn− glycero− 3− phosphocholine (DOPC) concentration and 0.1%mol
of 1, 2− dioleoyl− sn− glycero− 3− phosphoethanolamine−N − lissamine rhodamine
B sulfonyl (DOPE-RhB) in DI water, Fig. 2.9. Phospholipids were dried at the bottom of
a clean glass vial. A lipid film was produced by using a stream of nitrogen (phospholipids
were stored in chloroform). The sample was left in vacuum for at least 1 hour to allow
the chloroform to evaporate. To hydrate the lipid layers and create an MLV mixture, 2
ml of DI water were added to each sample. Fig. 2.9 shows a confocal microscopy image of
the MLVs population, the red colour is due to DOPE-RhB, which, together with DOPC,
is forming the lipid membrane.
This type of mixture was used to check the vesicles population prior to the SAW nebuli-
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Figure 2.8: (a-b) Cryo-TEM image of unilamellar vesicles on the left and multilamellar vesi-
cles on the right. Scale bar: 200 nm. (c) Classification of liposomes based on the
lamellarity and size. From the left: small unilamellar vesicle (SUV), large unilamel-
lar vesicle (LUV), giant unilamellar vesicle (GUV) and multilamellar large vesicle
(MLV).
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Figure 2.9: (a-b) Confocal microscopy image of MLV mixture, (100x magnification, λexc = 560
nm, λem = 583 nm). The solution was made using 2.00 mg/ml of DOPC and 0.1%
mol of DOPE-RhB. Multilamellar vesicles of different size are visible.
sation and during the nebulisation step, as described in Chapter 4.
Enzyme-Encapsulated Liposomes
In order to encapsulate a hydrophilic enzyme within the liposomes, DOPC at 1.00 mg/ml
was dried and left under vacuum and Horseradish Peroxidase (HRP) was chosen as an
enzyme model and dissolved in DI water at a concentration of 20 nM using the thin film
hydration method [37]. The concentration of HRP was tested using a calibration curve
(Results Chapter 3).
This method is a quick and easy way of encapsulating the compound in the liposomes
but has the disadvantage that a large amount of drug remains in the external medium.
Cationic Liposomes
Lipid mixtures of DOTAP/cholesterol were made at ratios of 2:1 and 4:1, to a total
concentration of 2.4 mg/mL. Mixing only DOTAP and cholesterol in DI water did not
lead to the formation of a bilayer system. Lipids have many topographies that depend on
their head groups and tail group chemical bonds and can be described as conical, inverse-
conical and cylindrical [34]. Both DOTAP and cholesterol are geometrically conical lipids,
meaning that they cannot form a bilayer by themselves (Chapter 4). Therefore, a solution
of 5% sucrose was used to hydrate the lipid film in order to enable the formation of a
bilayer between DOTAP and cholesterol. Sucrose occupies head group volume, such as to
overcome the negative curvature of DOTAP and cholesterol, which would otherwise result
in the formation of only inverted micelle structures.
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Cationic liposomes were used as a carrier for the transfection of both DNA plasmid
luciferase and GAPDH siRNA (Chapter 6). Comparison of transfection efficiency (in terms
of relative light units (RLU)/mg protein) between extruded liposomes and SAW-formed
liposomes was performed. Two terms will be used in this chapter to refer to different
methods of transfection: standard transfection, where the solution is added directly to the
cell culture dish, and SAW transfection, where the transfection solution is nebulised by
SAW.
2.4.2 Downsizing of Multilamellar Vesicles
Large unilamellar vesicles (LUVs) of defined size and homogeneity were obtained by a
sequential extrusion (Avanti Polar Lipids, Alabaster, U.S) through a polycarbonate mem-
brane with fixed pores of 200 nm in diameter [43] at a temperature above Tm of DOPC
(Tm = −17◦C).
2.4.3 Extrusion
The extrusion process is based on pinching off part of the liposomes, as it is pressed through
a pore of a diameter smaller than its own. The vesicle can deform to a certain extent,
but it reaches a point where the pressure differential on the opposite sides of the pore
causes the bilayers to rupture. The ruptured bilayers would anneal immediately, forming
smaller vesicles, which can eventually all pass through the pore. The extrusion process was
carried out using the Mini-Extruder (Avanti Polar Lipids, USA). The extrusion protocol
from Avanti Polar Lipids [193] is described, which was used to form unilamellar vesicles
of 100 and 200 nm in diameter.
MLVs were initially subjected to 5 cycles of freeze-thaw by immersing an Eppendorf
vial containing 1 ml of MLVs in liquid nitrogen (-210◦C/-195◦C) and then in a water bath
at 37◦C. The reduced size MLVs were then extruded through a membrane with a pore size
of 100 nm. Firstly, a syringe full of the buffer is passed through the extruder in order to
pre-wet the polycarbonate membrane and to reduce the dead volume. After discarding the
buffer, the sample is loaded into the syringes and place in one end of the Mini-Extruder,
making sure the empty syringe plunger is set to zero. The extruder is then inserted into
the heating block, so it will guide the pushing of the lipid dispersion. The lipid mixture
is pushed 11 times between syringes. An odd number of pushes is important, so that the
final extrusion step fills the initial empty syringe, avoiding contamination with remaining
large particles in the first syringe. Finally, the mixture is collected in a clean vial and the
extruder is cleaned.
A change in the turbidity of the vesicles mixture through the extrusion process indicates
the breakdown of larger vesicles into smaller ones. The large size and the several lamellae
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of initial MLVs in the buffer makes the mixture turbid, as it passes through the membrane
[194], the size of vesicles reduces, reducing the turbidity. The vesicles final size is measured
to be in the range of 100 nm (see Chapter 3).
2.4.4 Sonication
A probe sonication (UP200S, Hielscher, Germany) was used to downsize the multilamellar
vesicles suspension. To estimate if the power employed by the SAW nebuliser was high
enough to determined the break up of MLVs in smaller liposomes, a comparison of the
power used in the probe sonication method with the SAW nebuliser was made. During
the sonication process, a power of 200 W was utilised for 30, 20 and 10 seconds, while the
SAW device was using a power of 5 W. Results are shown in Chapter 4. From Giovannini
et al. [134], a power of 3 mW was estimated to disperse a volume of liquid into smaller
droplets, but data regarding the power necessary to break down liposomes are not present
in the literature.
2.5 Liposomes Characterisation
2.5.1 Dynamic Light Scattering
Particle Sizing and Correlation Curve
From the DLS measurements, the software from Zetasizer 90 calculated a correlation curve,
which has to be smooth and a single exponential decay function, for a monodisperse
sample. If an exponential function is used to fit the correlation function, the diffusion
coefficient (D) can be calculated and using the Stokes-Einstein equation the hydrodynamic
diameter can be evaluated [90]. In this work, a representation of the particles size is made
using the intensity distribution, which is the most sensitive representation, compared to the
volume and number distributions, to the presence of larger particles in a sample (I ∝ d6).
It could indicate an early sign of the instability of the sample, which is an important
parameter to test the quality of the sample.
2.5.2 Zetasizer Nano ZS90
For dynamic light scattering measurements, Zetasizer ZS90 (Malvern Panalytical, UK) was
used. It is composed of six main components. A Helium-Neon laser with a wavelength of
λ = 633 nm is used to illuminate the dispersion loaded into the cell, where some light will
pass through the dispersion and some will be scattered by the particles in the solution.
An attenuator is used to reduce the intensity of the laser since the detector is sensitive
and it can saturate if too much light is detected. In this particular model, the detector
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Figure 2.10: Main components of the Zetasizer Nano ZS90. A He-Ne laser 633 nm, passes first
through an attenuator, which ensures that the detector will not be saturated. The
light then hits the cell with the nanoparticles in the solution and a detector at
90◦measure the intensity of the scattered light. From the detector, the signal is
processed by a correlator.
is at 90◦to measure the intensity of the scattered light. From the detector, the scattered
signal goes through a digital signal processor called correlator. The correlator compares
the scattering intensity at consecutive time intervals and then the data is passed to a
computer, which will analyse it and derive size information.
2.5.3 TEM negative staining and Cryo-TEM
TEM negative staining was used with 2% methylcellulose/uranyl acetate (pH 7) as a
negative stain, pictures were taken at the Dept. of Chemistry, the University of Glasgow.
A small drop of the sample was placed on the carbon-coated grid, allowed to settle for 1
minute and blotted dry with a filter paper. Then, the sample was covered with a small
drop of stain and blotted dry after, to wick away the stain. Some of the major drawbacks
of this technique are artefacts, which are frequently observed when the stain is uneven, and
the sample distortion during the sample drying, which can cause a collapse of its structure.
In order to check the size and lamellarity of SAW produced vesicles, Cryo-TEM (JEM-
220FS) pictures were taken at the Centre for Virus Research at the University of Glasgow.
To convert a naturally-hydrophobic carbon-coated layer of the grid into hydrophilic, the
grid was subjected to a glow discharge, which allowed the sample to spread on the grid
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[195]. Then, Vitrobot (the University of Glasgow, Centre for Virus Research) a completely
automatised vitrification process, was used to vitrify the sample. Two blotting papers on
either side of the sample were pressed against the grid, leaving a thin layer of the sample.
The sample was then plunged into liquid ethane, and, finally, the grid containing frozen
vesicles was loaded into the electron microscope.
2.6 Aerosol Characterisation
2.6.1 Laser Diffraction: Spraytec
A standard procedure operation (SOP) was made for different experiments, in order to
obtain a precise measurement. In the case of nebulisation of a lipid dispersion, a refractive
index of n = 1.38 was set for DOPC. During the measurements, a single event of 4s was
considered and the trigger signal was set for a signal transmission below 99%. The data
collection was set for 400 ms before the trigger. The volume intensity (%) was evaluated
and obtain through an average of the scattered data. The software provides different
average size measurements (e.g. D23, D34); in this work, the median droplet size (D50) is
reported as the standard value in pulmonary drug delivery literature.
Figure 2.11: Instrumentation for aerosol size distribution measurement using laser diffraction
(Spraytec). The image shows that the aerosol has to be at 15 cm from the detector
array. The laser hits the aerosol and the light is scattered at different angles based
on their sizes. The scattered light is then collected by the detectors.
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2.6.2 Andersen Cascade Impactor and Inertial Impaction
The ACI is composed of 8 stages and each of them is made of a collection plate and a
specific nozzles arrangement. Each stage is designed to trap particles of decreasing aero-
dynamic diameter [106]. A pump is connected at the bottom of the cascade impactor to
aspirate the airflow from the nebuliser and conduct it into the ACI. The inertial impaction
method is used to separate particles based on their inertia, which depends on the size and
velocity. Particles that pass through the nozzle will remain in the air stream, which is
directed through a right angle at the exit. Particles that impact on the collection plate
will remain on the surface and will not follow the airstream [105].
The particle with sufficient inertia will pass through the next stage. Ideally, each stage
is associated with a cut-off diameter, for which [104] particles larger than a certain aero-
dynamic diameter will be collected, while particles smaller than a certain aerodynamic
diameter will pass through the next stage.
The ACI used in this work was designed to operate at an air flow of 28.3 L/min, as
recommended by the manufacturer. For a flow of 28.3 L/min, the cut-off diameters for
each stage are shown in Fig. 2.12. The primary advantage of cascade impactors is the
direct measurement of the aerodynamic diameter, which represents the best approximation
of particles behaviour during inhalation [106]. Moreover, the ACI produces the required
resolution for inhalation products: 0.5 to 5 µm [106]. However, there are some limitations
to the use of the impactors. Solid particles could bounce instead of being deposited, and
under normal atmospheric conditions it is hard to collect particles smaller than 0.2 µm
[104]. Systematic errors can be produced, for instance, particle bounces favour smaller
particles in the size distribution [197]. Increase humidity in the environment, to reproduce
lungs condition, could lead to an increase of the collected particles.
2.7 Experimental Setup
2.7.1 Pre-SAW Nebulisation
Membrane Dialysis
Once the enzyme or protein has been internalised in the liposome, in order to have the
HRP solely in the internal compartment of the liposomes, the remaining non-encapsulated
drug was removed by dialysis. Dialysis refers to a technique used to separate molecules
based on their differing abilities to diffuse through a semi-permeable membrane [198].
In dialysis, a sample and a buffer solution (called the dialysate) are separated by a
semi-permeable membrane [198]. Due to the pore size of the membrane, large molecules
in the sample cannot pass through, thereby preventing their diffusion from the sample
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Figure 2.12: Andersen cascade impactor structure. A cross section of the Andersen cascade
impactor with a separation in 7 stages, where nozzles of different sizes are present.
The particles deposit onto the collection plate or continue to follow the air stream
based on their inertia. Larger particles will be cut-off at the upper stages of the
cascade. After the nebulisation ended, the collection plates were washed to analyse
the quantity deposits on each stage. Picture rearranged from [196].
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chamber [198]. By contrast, small molecules will freely diffuse across the membrane to
establish an osmotic equilibrium across the entire solution volume. The volume of the
sample is 1 ml and it is immersed in the dialysate solution, which is usually 10 times
larger [199]. An important property of the membrane is the Molecular Weight Cut Off
(MWCO), which needs to be chosen depending on the size of the molecules within the
sample. It is an indirect measure of retention, and more precisely is the lowest molecular
weight of solute (in daltons) at which 90% of the solute is prevented from passing across
the membrane [199]. Since a solute's permeability is also dependent on molecular shape,
degree of hydration, ionic charge and polarity, it is usually recommended to select an
MWCO that is half of the molecular weight (MW) of the species to be retained, and at
least 20 times the molecular weight of the species that should pass through [199]. A dialysis
Ultra-pure Biotech Cellulose Ester (CE) Membrane (Spectra/Por Float-A-Lyzer G2) with
an MWCO of 300 kDa was used; its pores were 35 nm in size [200]. The membrane was
soaked in 10% ethanol for 10 min, and then rinsed and soaked for 5 min in DI water. The
sample was then loaded into the device, which was floating in a beaker containing the
same buffer as the loaded sample, and a stir bar. The sample was dialysed under rotation
at room temperature overnight (12-20 hours), to remove the HRP (MW=44 kDa) from
solution, with 3 complete buffer changes after 2, 6 and 10 hours.[201].
SAW Nebulisation of HRP-Encapsulated Liposomes
The dialysed solution was then nebulised and collected in a TMB solution. Triton X-100
was added to release the encapsulated HRP and allow the HRP-TMB reaction. Ab-
sorbance was measured both before and after nebulisation. Only intact liposomes protect
TMB from HRP. If there are enough intact vesicles, then an increase in signal (O.D.)
following the addition of Triton X-100 is observed. Without the addition of the detergent,
the O.D. will come solely from any HRP remaining in the outer solution (after dialysis)
and should be low.
Temperature Effects in SAW Nebulisation
Enzymes and proteins are temperatures sensitive [202]; they maintain their functional
properties only if kept below a certain temperature. One of the main concerns in delivering
an active compound is the possibility of protein denaturation during nebulisation, due
to increases in temperature. This could be prevented using a cooling system, but such
has been shown to reduce ultrasonic nebuliser output [203]. Under SAW nebulisation, a
temperature test was carried out, exploiting the HRP-TMB reaction to assess the retention
of enzyme activity. A solution of 200 nM HRP was nebulised using an IDT with a resonance
frequency of 9.5 MHz, which was supplied with -6 dBm input power, and a syringe pump
(World Instruments, Aladdin) to dispense the solution at 60 µl/min. A Peltier module
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(I=1.3 A, 20 x 20 mm) was used to fix the temperature at 20◦C, 65◦C or 100◦C. Once
the IDT reached a uniform temperature, SAW nebulisation was initiated, and nebulised
liposomes were collected. The HRP assay was carried out on the collected samples, and
the optical depths were measured.
2.7.2 SAW Nebulisation Setup
The IDT was connected through a conductive silver paint, Electrodag 1415, to the high
power amplifier ZHL-5W-1 (Gain=40 dB, 50W, 5 to 500 MHz), which was obtained from
Mini Circuit (USA) and used throughout the thesis for every SAW nebulisation setup.
The signal generator N5181A MXG Analog was used in conjunction with the amplifier, as
showed in Fig. 2.13, (b). The same configuration without the application of the silicon chip
was used in Chapter 3, where only the feasibility of SAW to nebulise pre-formed liposomes
was tested. In order to remove the heat from the hot side of the Peltier, a thermal paste
was used between the Peltier and the heat sink. A thin layer of the ultrasound transmission
gel(Aquasonic 100, Parker Laboratories, USA) was used to fix the silicon chip on top of
the IDT.
SAW Nebulisation of MLVs
In order to transfer energy to the system and obtain smaller, unilamellar vesicles, IDTs
with silicon chip was used to nebulise the MLV dispersion. The IDT resonance frequency
was 9.6 MHz and an input power of -6 dBm was employed and amplified by 40 dB,
obtaining a total power of 2.5 W. The IDT was placed on top of a Peltier module (I=1.3
A, 20 x 20 mm), to keep the temperature constant and avoid thermal stresses within
the lithium niobate. As shown in Fig. 2.14, the Peltier module was located on top of
a fan-integrated heat sink (dimension 100 x 50 x 50 mm, Fischer Elektronik) to remove
the heat from a hot side of the module. The nebulisation flow was collected using 25 µl
of the same solution which MLVs were made in and the droplet was placed in front of
the nebulisation flow to collect the vesicles produced during the SAW nebulisation. The
process was repeated 6 times in order to retrieve at least 100 µl of volume, which is the
minimum volume of the sample to be measured by dynamic light scattering.
The same sample was simultaneously measured with laser diffraction to determine the
aerosol size and then collected to be analysed with dynamic light scattering to check the
vesicle size distribution.
SAW Nebulisation from Lipid-Coated IDT
A uniform layer of 10.00 mg/ml DOPC in chloroform was spun on the IDT (400 rpm, 10
s). The IDT parameters used were: 9.552 MHz with an input power of -6 dBm. IDTs
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Figure 2.13: (a) Side view of the SAW nebulisation setup. From the bottom, the heat sink is
in contact with the Peltier to remove the heat from the hot side. The cold side
of the Peltier is in contact with the IDT to keep the temperature constant and
avoid thermal stresses within the lithium niobate. On top of the IDT, a thin layer
of ultrasound transmission gel was added to fix the silicon chip on top of it. (b)
Schematic of the SAW nebulisation setup, where the different layers are shown.
From the bottom, the heat sink is connected with a power supply to activate the
fan, which removes the heat from the Peltier. A thermal paste, which is thermally
conductive, is applied between the heat sink and the hot side of the Peltier. The
cold side of the Peltier is in contact with the IDT, which is connected through a
metal conductive paste (ELectrodag) and two wires to an amplifier. The latter is
amplifying a sinusoidal signal at a resonant frequency.
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Figure 2.14: SAW Nebulisation equipment. The SAW nebuliser, placed on top of a Peltier
module and a heat sink, to keep a uniform temperature. 100 µl of MLV mixture
was nebulised and 100 µl of collection buffer was placed on top of the nebulised
flow to allow collection of sufficient volume for particle sizing.
were left in vacuum for 90 minutes in order to let the chloroform to fully evaporate. Once
the chloroform evaporated, a silicon chip with a pore size of 300 µm was placed above
the IDT. Deionised water was added on top of the silicon chip and left to incubate for 5
minutes to allow water absorption by phospholipid head. After incubation, SAWs travelled
on the surface of the lithium niobate and then on top of the silicon chip (coupled with
IDT), causing the droplets to be pulled out from the surface of the volume confined into
the cavity of the silicon chip. Nebulised vesicles were collected on an upside-down glass
slide into a droplet of water. Finally, 100 µl of the collected solution was measured on the
Zetasizer Nano ZS90 to evaluate the size distribution of the nebulised vesicles.
2.7.3 Post-SAW Nebulisation
Lipid Bilayer Solubilisation by Surfactant
To evaluate the integrity of liposomes and the activity of their encapsulated enzymes after
SAW nebulisation, liposomes were intentionally broken down by lipid bilayer solubilisation.
For this purpose, different groups have previously used surfactants [204]. Surfactants are
amphiphilic molecules that lower the surface tension of the liquid into which they are
added [205]. In this work, Triton X-100 was chosen for its property of lysing cells. It
is frequently used to extract proteins from cells [206]. Surfactants are molecules that
interact with phospholipid bilayers. They are used to solubilise liposomes and release
their encapsulated compounds. As stated by Helenius and Simons [207], a three-stage
model explains how solubilisation occurs (Fig. 2.15). Firstly, the surfactant molecule
inserts itself into the outer layer of the phospholipid bilayer (stage I), resulting in the
solubilisation of the bilayer and the consequent formation of lipid-detergent mixed micelles
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Figure 2.15: Three stage model of lipid bilayer solubilisation by Helenius and Simons. (I)
Detergent monomers (blue) insert into the outer bilayer (red), (II)Formation of
lipid-detergent mixed micelles and (III) mixed micelles become further enriched in
detergent. Picture taken from [208].
(stage II). Thereby, the encapsulated compound is released. Finally, the mixed micelles
become smaller and further enriched in detergent (stage III) [208], [209].
Collection of SAW Nebulised Particles
With the purpose of measuring the nebulised nanoparticles in the solution, the following
setup was used. A glass slide was placed in front of the nebulised flow. 25 µl of DI water or
same buffer used to prepare the solution to nebulise, was placed on the glass slide upside-
down. The nebulised particles were collected in the droplet and in the case of liposomes
a decrease in surface tension was noticed during the collection. As the liposomes were
entering the collection droplet, the droplet spread. This was repeated 5 times in order
to retrieve 100 µl volume, which is the minimum amount required from the DLS device.
For each collection droplet of 25 µl, 100 µl of the sample was nebulised. This procedure
was used for the collection of the HRP encapsulated liposomes in Chapter 3 and the
SAW-formed liposomes in Chapter 4.
Recovery of Liposomes from Andersen Cascade Impactor
Liposomes were nebulised in order to test the size stability on the collection plate of each
stage. Each stage was covered with 1 mL of the same buffer used to extrude the liposomes
to avoid the breakage of nebulised liposome on the collection plate. A volume of 1 mL of
the LUVs dispersion was nebulised. From Fig. 2.16, a syringe pump (World Instrument,
Aladin) was employed to load the mixture at 300 µl/min. An IDT with a resonance
frequency of 9.58 MHz and a silicon chip with 100 µm cavities were employed.
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Figure 2.16: Andersen cascade impactor instrumentation. (a) A silicon chip with cavities size
of 100 µm was placed on top of the IDT. A syringe pump was loading the LUVs
dispersion at 200 µl/min flow. (b) At the bottom of the cascade impactor, a pump
was connected in order to create an air flow of 28.3 L/min. The air flow was
measured using a flow meter (Platon NGX, Roxspur, UK).
CHAPTER 2. MATERIALS AND METHODS 66
Figure 2.17: Mouthpiece design. SolidWorks draft of the mouthpiece, which collects the
aerosolised particles from the SAW nebuliser into the cascade impactor. The simple
geometry has an internal diameter, set by the size of the impactor and the length
was chosen in order to have enough space to form a 90◦angle.
Mouthpiece Design
In order to collect the aerosolised particles from the SAW nebuliser and guide them through
the cascade impactor, an L-shape mouthpiece was designed using SolidWorks (Dassault
Systemes, France) and then 3D-printed. The internal diameter of 35 mm was dictated by
the cascade impactor geometry, Fig. 2.17. It represents a simplified model of the mouth-
pharynx-trachea system. The geometry of the mouthpiece could be optimised to increased
the volume fraction (%) in the impactor.
2.8 Biochemical Assays
2.8.1 HRP Assay
Horseradish Peroxidase
Horseradish Peroxidase (HRP) is an enzyme found in horseradish roots. It is commonly
used in biochemistry for its ability to improve the detection of target molecules by am-
plifying weak signals. Using Tetramethylbenzidine (TMB) as a substrate, a colourimetric
HRP assay was carried out, utilising hydrogen peroxide H2O2, to yield a colour change
that can be detected by a spectrophotometer. HRP catalyses the conversion of the chro-
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Figure 2.18: HRP-TMB reaction. (a) TMB acts as an electron donor for the reduction of H2O2
to H2O, and the reaction is catalysed by HRP. After H2O2 and TMB react with
HRP, (b) the Tetramethylbenzidine (TMB) is oxidised to form Tetramethylbenzi-
dine diimine, resulting in a blue colour
mogenic substrate TMB into coloured products. TMB acts as an electron donor for the
reduction of H2O2 to H2O by HRP. Fig. 2.18(a) shows the reaction
When the H2O2 and TMB react with HRP, the Tetramethylbenzidine (TMB) is oxi-
dised to form Tetramethylbenzidine diimine Fig. 2.18(b), resulting in a blue colour that
can be measured with a spectrophotometer at λ = 650 nm, Fig. 2.18 shows TMB oxida-
tion. In this work, the HRP assay was used as an indirect method to test liposome stability
during SAW nebulisation. The reaction of HRP with hydrogen peroxide and TMB was
exploited to assess the integrity of LUVs. HRP and TMB were purchased from Sigma
Aldrich Company Ltd. (Dorset, U.K.). The HRP assay was carried out according to the
following procedure. Firstly, HRP was encapsulated in LUVs using the thin film hydration
method, using this method HRP is present both in the inner core of the liposomes and in
the outer solution. Therefore, the removal of the HRP from the outer solution was carried
out by using a dialysis membrane (described in detail in the next Section). Then, SAW
nebulisation of HRP encapsulated in LUVs was performed and the nebulised solution was
collected. Triton X-100 was added in the collected solution in order to solubilise the lipid
bilayer and release the encapsulated HRP. TMB containing was then added into the col-
lected solution to react with HRP and the reaction was stopped by using 1M sulfuric acid
solution. The solution acquired a yellow colour that was detected by a micro-well plate
reader at λ = 450 nm.
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Absorbance Measurements
The absorbance of a solution is its capacity to absorb light at a specified wavelength. It is
measured by optical depth (O.D.), which indicates the opacity of a medium and is defined
by:
O.D. = ln(φi/φt) (2.2)
where φi is the radiant flux received by the material and φt is the radiant flux trans-
mitted by the material. From Eq. (3.1) the absorbance is represented by:
A = O.D./ln(10) (2.3)
After adding sulfuric acid to samples to stop the reaction, a microplate reader (Synergy
HTX, Biotek) was used for measuring the optical depth at the wavelength of λ = 450 nm.
2.8.2 Luciferase Assay
To test the transfection method and the efficiency with which the cationic liposomes were
transfected, a luciferase assay was performed. If the DNA luciferase plasmid success-
fully enters the nucleus of the cell, then its luciferase enzyme is expressed, which acts on
luciferin to produce luminescence. DNA plasmid luciferase was chosen for its high sen-
sitivity and low background. [210]. Luciferases are a class of oxidative enzymes found
in different species, that allow the organism to emit light. A typical example is firefly
luciferase. Fireflies emit light in a reaction in which luciferin is converted to oxyluciferin
by the luciferase enzyme. Energy is released from the reaction in the form of light [211].
This phenomenon is called bioluminescence and differs from fluorescence by the fact that
the excitation energy is supplied by the luciferase enzyme. Eukaryotes do not otherwise
produce light, and the background light from the sample is very low. Therefore, it is
not necessary to filter out light from the sample, and the luminometer collects light from
the entire visible spectrum [212]. The luciferase assay is usually used as a reporter assay,
where the gene of interest can be cloned and fused to form a vector containing both it
and the luciferase gene [210]. The vector and luciferin need to first be introduced into the
cells, and their endosome lysed so that their contents are released. Once the luciferin is
added, the luminescent signal is measured using a luminometer, which can quantitatively
measure the emitted light. Since the gene of interest is fused with the luciferase reporter,
its expression can be inferred from the intensity of the emitted light.
Complexes of DOTAP/cholesterol vesicles (at a 4:1 ratio) and DNA were formed by
mixing at different ratios, with each well containing 1 µg of luciferase plasmid.
DOTAP/cholesterol liposomes were made by extrusion. In order to determine the
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optimal amount of DNA to be bound with liposomes for cellular uptake, complexes were
prepared using 6:1, 10:1, 20:1, 30:1 and 40:1 lipid-DNA ratios in Opti-MEM, with two
different ratios of DOTAP to cholesterol: 2:1 and 4:1. After 30 min of incubation, the
complexes were added to the cells. After 4 h, the Opti-MEM was substituted with serum-
supplemented cell culture medium. At 24 h post-transfection, the cells were rinsed with
PBS and lysed in 100 µl of reporter lysis buffer. 20 µl of each sample was transferred to a
white opaque 96 well-plate and analysed using a Luminometer (Spectramax L, Molecular
Devices). The results were expressed as RLU/mg (relative light unit per mg of protein).
Protein concentrations were determined using the Bradford assay.
Luciferase Assay Calibration - DNA Quantification
In order to quantify the DNA delivered using the SAW platform, an indirect method was
employed. A calibration curve of relative light units (RLU)/mg of protein against the
concentration of DNA transfected to the A549 cells was generated. Standard transfection
with extruded liposomes (d = 100 nm) was compared with SAW transfection. A lipid
solution as made using the hydration method with 4:1 DOTAP:chol at a concentration
of 2.4 mg/m. Cells were seeded at a concentration of 0.8 × (10)5 cells/mL in single well
plates (d = 35 mm), each well containing 2 mL (1.6 × (10)5 cells per well). In order to
check if there was a linear relationship between the concentration of the transfected DNA
and the amount of light emitted, different concentrations of DNA were added to the wells:
0, 0.25, 0.50, 0.75, 1.00, 1.50, 2.00 and 2.50 µg/mL. Samples were made in triplicate.
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Figure 2.19: A calibration curve for the Bradford assay was obtained using bovine serum al-
bumin, starting from a stock solution of 1 mg/mL. Absorbance measurements at
λ = 595nm were made for BSA concentrations of: 1, 0.8, 0.6, 0.4, 0.2, 0.1 and 0
mg/mL.
2.8.3 Bradford Protein Assay
The Bradford protein assay is a method to determine the total concentration of proteins
in a solution [213]. It is based on the binding between the Coomassie Brilliant Blue G
dye and the proteins in the solution. The binding of the dye to proteins causes a shift
in the maximum absorbance of the dye from 465 nm to 595 nm, which is measurable by
a spectrophotometer or plate reader. The amount of absorption is proportional to the
amount of protein [214]. In order to evaluate the protein concentration in each DNA
luciferase plasmid transfection reaction, a calibration curve was generated. The following
equation was acquired by linear fitting, with a coefficient of determination R2=0.99
y = 0.323x+ 0.271 (2.4)
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By reversing the equation and substituting the absorbance of the samples, the protein con-
centration in each sample was calculated. Then the luminescence readings were normalised
to the protein concentrations in each sample.
2.8.4 Gel Retardation Assay
In all cases, representative gels were chosen. In some figures, gels have been cropped,
although the raw images are shown in the Appendix, Fig. E1 and E3.
The gel is typically made of polyacrylamide for proteins and small nucleic acids, or
agarose for larger nucleic acid fragments (>200 bp). A fluorescent dye, ethidium bromide,
is often employed to visualise nucleic acids in the gel. It inserts itself between the bases
of the DNA helix with a binding ratio of 1:1 (one molecule of dye to one base) [215]
and fluoresces when exposed to UV light. It was commonly used in the past, but for
safety reasons has been replaced with an alternative called GelRed, which unlike ethidium
bromide cannot pass through the cell membrane [216].
A gel retardation assay was performed to check the integrity of the nucleic acid after
SAW nebulisation. Samples were prepared by adding 2 µl of loading gel to the sample
and then adding 10 µl of the sample into an agarose gel (2% w/v) stained with GelRed.
Gel electrophoresis was run in TAE buffer at 120 V for 25 min and the gel was visualised
under UV light. In order to establish the binding affinity of lipids/siRNA complexes,
several measurements using the gel retardation assay were carried out. Different ratios of
DOTAP and cholesterol were mixed at ratios of 1:2, 1:4, 1:6, 1:10, with equal amounts
of DNA. Each solution was extruded and then analysed by the dynamic light scattering
approach to measuring the sizes of the complexes.
2.8.5 Western Blot
Western blots are a laboratory technique used to identify a specific protein in a mixture of
proteins from a cell extract. It is essentially composed of three steps: gel electrophoresis
(separation by size and charge), transfer of the proteins from the gel to a membrane
by blotting, and marking the target protein [217]. A western blot was carried out after
freezing and thawing the cells three times and performing a Bradford assay to determine
the concentration of protein in each sample. Cell extracts containing 20 µg of protein
were loaded into a 10% SDS polyacrylamide gel, and electrophoresis was run at 120 V
for 120 min. After the proteins were resolved, they were transferred onto a nitrocellulose
membrane, which was then blocked in 5% nonfat dry milk for 2 h with shaking, to reduce
background from non-specific binding. The membrane was washed twice with TBST
(Tris-buffered saline with Tween 20) and once with TBS, for 10 min each time, and then
incubated overnight with primary antibodies specific to the protein of interest, at 4◦C
CHAPTER 2. MATERIALS AND METHODS 72
with shaking. After rinsing, the membrane was incubated with anti β-actin antibody,
which binds the β-actin used as the internal control. After repeating the washing steps,
the membrane was incubated with a horseradish peroxide-conjugated secondary antibody
for 2 h at room temperature. The bound secondary antibody was detected using the
ECL western blotting detection reagents [218]. GAPDH expression was evaluated by
densitometry using the ImageJ software (Version 1.45S), and the results are reported as the
mean of three independent repeats. The remaining GAPDH expression was represented
as the density of the GAPDH band in the positive control divided by that of the GAPDH
band in the negative control, both of which were first normalised to that of the β-actin
band in their respective lanes [152].
β-Actin
β-actin is a major constituent of the contractile apparatus and one of the two non-muscular
cytoskeletal actins. Actins are proteins involved in cell motility, and the maintenance of
structure and integrity [219]. It is used as an internal control in western blots to minimise
the effects that come from experimental loading errors - to assess if protein loading is
similar across each sample and to adjust for any differences in such. β-actin's molecular
weight is around 40 kDa. As a control for good western blot execution, a clean band at
40 kDa should be visible [218].
2.8.6 MTT Cytotoxicity Assay
The MTT assay is a colourimetric assay that is used to measure the cytotoxicity of po-
tentially dangerous agents [220]. It is a reaction based on the reduction of a tetrazolium
dye - in this case of MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,
to an insoluble formazan (purple colour). The reduction of tetrazolium depends on cellu-
lar activity, particularly on the presence of NAD(P)H-dependent oxidoreductase, which is
an enzyme abundantly produced in the cytoplasm [221]. Rapidly diving cells (with high
metabolism) thus exhibit high rates of MTT reduction [220]. A549 cells were seeded in a
96 well plate at a concentration of (10)5 cells/mL, and 200 µl was added per well. Com-
plexes of DOTAP-cholesterol vesicles (4:1) and siRNA were mixed at different ratios. In
each well, 10 pmoles of GAPDH siRNA was prepared in Opti-MEM reduced serum. Com-
plexes were added to cells after 30 min of incubation. After 4 h of incubation at 37◦C, the
transfection medium was carefully replaced with MTT solution (0.8 mg/mL tetrazolium
dye). After 2 h, the MTT solution was removed and 200 µl of isopropanol was added,
in order to solubilise the formazan crystals formed by the reduction of the tetrazolium.
After solubilisation of the formazan, the 96 well-plate was shaken for 15 min, and then
the absorbance at λ = 525 nm was measured. As a control, three wells were subjected to
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Figure 2.20: Cell division over 3 days. (a) after 2 hours, (b) after 1 day and 5 hours, (c) after
2 days and (d) after 3 days, reaching 70-80% confluence. Images taken using the
CytoSMART System, Lonza
the changing of medium without transfection, to account for any loss of cells during the
suction of medium. Cell viability was expressed as the absorbance from the cells trans-
fected with the complex relative to that from those subjected to medium changes without
transfection [218].
2.9 Cell Culture
Cell coverage was evaluated using the CytoSMART system (Lonza, Switzerland), and a
confluence of 70-80% was reached after 3 days (Fig. 2.20 and 2.21). Cells were kept under
5% CO2 at 37◦C, and subcultured according to the ATCC protocol [222].
2.9.1 Cell Transfection
GAPDH siRNA Transfection
GAPDH, glyceraldehyde 3-phosphate dehydrogenase, is an enzyme that catalyses part of
the process of glycolysis that breaks down glucose to release energy and carbon. GAPDH
siRNA can be used as a control in siRNA experiments to test the transfection proce-
dure [218], due to its stability and the high expression of GAPDH in most cells. The
GAPDH siRNA sequence targets the 5’ medial region of the GAPDH mRNA. It has been
successfully transfected into multiple human cell lines, including A459 cells, in vitro, by
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Figure 2.21: Trend of cell coverage over 3 days. (a) after 2 hours, (b) after 1 day and 5 hours,
(c) after 2 days and (d) after 3 days, reaching 70-80% confluence
standard transfection methods [223]. A549 cells were seeded in a 6 well-plate at a con-
centration of 0.8× (10)5 cells/mL, with 2 mL per well. Complexes of DOTAP-cholesterol
(4:1) vesicles and siRNA were formed by mixing at different ratios. DOTAP-cholesterol
liposomes were made through extrusion. In each well, 50 pmoles (in 1 mL of Opti-MEM)
of GAPDH siRNA and negative control siRNA were prepared. 4 h following the addition
of complexes, the Opti-MEM was removed from each well and replaced with cell culture
medium. At 72 h post-transfection, cells were washed with PBS and lysed with cell lysis
buffer.
2.9.2 DNA and siRNA SAW Transfection
Upright Nebulisation Setup
Standard transfection procedures were performed with materials identical to those used
for SAW transfection of DNA and siRNA. In order to deliver the lipoplex to A549 cells,
transfection was carried out using the SAW nebuliser. With SAW transfection, the con-
centration of the DNA solution subjected to nebulisation (3.33 µg/mL) was three times
higher than that used in standard transfection (1 µg/mL), in order to account for losses
during nebulisation. The ratio of 6:1 lipid-nucleic acid was maintained.
Cells were seeded in single sterile wells of a plate that were placed upside-down on top
of the IDT, in order that only the solution inside the desired well was nebulised (Fig. ??).
Cell culture medium (DMEM) was gently removed from the well and two washing steps
with PBS were performed. Then a layer of Opti-MEM was added to prevent the cells from
drying out. A multilamellar vesicle solution of concentration 2.00 mg/mL with a DNA
concentration of 20 µg/mL was released from a syringe pump (World Instrument, Aladin)
at a flow rate of 100 µl/min for a total of 2 min. The total amount of DNA/lipid solution
nebulised was 200 µl (20 µg/mL of DNA), in a total volume of 1.2 mL of Opti-MEM.
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The nebulisation process was carried out for 2 min inside the Microflow Advanced Bio
Safety Cabinet (Astec Microflow, Hampshire, UK). After 2 min, 1 mL of Opti-MEM was
added and the cells were incubated at 37◦C for 72 h for siRNA transfection, and 24 h for
DNA plasmid luciferase transfection.
4 h following transfection, the Opti-MEM was removed from the wells, then after incuba-
tion, cells were rinsed with PBS. Then 100 µl of cell lysis buffer was added followed and
three freeze-thaw cycles were performed.
Figure 2.22: SAW transfection upright nebulisation setup. (A.) A549 cells were seeded in a
single well and after 24 h the medium was removed. Scale bar 50 µm. Two sets
of experiments were carried out: one nebulising a solution of DOTAP: cholesterol
with DNA plasmid luciferase and the other with GAPDH siRNA. The solution was
nebulised for 2 min, placing the well containing the cells upside-down on top of the
nebulised flow. (B.) Image of a lipoplex complex; picture adapted from [34].
Upside-Down Nebulisation Setup
In order to reduce loss during SAW nebulisation whilst keeping the cells in their medium,
the setup was optimised. The IDT was placed upside-down, leaving the well containing
the cells unchanged. A box was designed using Solidworks and created from laser-cut
Polymethylmethacrylate (PMMA) sheets 2.5 mm thick, as shown in Fig. 2.23. The
upside-down IDT and petri-dish were fixed inside the box. This increased the transfection
efficiency 10-fold. The medium was carefully removed and the wells were rinsed with
PBS. 1 mL of Opti-MEM was added and the well was placed below the IDT (Fig. 2.24).
Regarding SAW nebulisation, the conditions from the upright nebulisation setup were
maintained.
2.9.3 Confocal Live Cell Imaging
A549 cells were seeded in a 35 mmMattek glass-bottomed culture dish at a concentration of
1.5×(10)5 cells/mL, with 1 mL medium. MISSION siRNA Fluorescent Universal Negative
Control (Sigma Aldrich) conjugated to 6 FAM (λabs = 495 nm, λexc = 520 nm) was used
for visualisation using a fluorescent microscope and assessment of transfection efficiency.
A quantity of 150 pmoles of siRNA was used per well (2 µg/well) and the optimised
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Figure 2.23: Design of the collection box for transfection of A549 cells, using the SAW nebu-
lisation. PMMA sheets were laser-cut and glued together with a solution made
of acetone and PMMA. The nebuliser was placed upside-down to leave the cells
culture in their medium.
Figure 2.24: Upside-down nebulisation setup for SAW transfection. A549 cells were seeded
in a single well. Two sets of experiments were conducted. Solutions of
DOTAP:cholesterol with DNA luciferase plasmid and with GAPDH siRNA were
nebulised. In order to be able to leave the cells in the medium, the setup was placed
upside-down, with the nebulised flow beginning at the top of the well. Nebulised
droplets were collected in the well containing the cells.
ratio of lipids to siRNA as determined by the results of standard transfection was used
(DOTAP:Chol 4:1, lipids:siRNA 6:1). Nebulisation of the complex by SAW was carried
out for 2 minutes as described previously. After 3 h of incubation at 37◦C, the transfection
medium was replaced with fresh culture medium. Hoechst stain at a concentration of 5
µg/mL was added to each well to stain the nuclei, then cells were incubated for a further 30
min. Prior to visualisation, the wells were washed 10 times with PBS to remove any non-
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transfected siRNA. The cells were visualised under a confocal laser scanning microscope
(Zeiss LSM 780 inverted microscope, Jena).
2.9.4 Image Analysis
A densitometry assay was performed to analyse the integrity of HS-DNA and the band
density in the western blot using ImageJ software (Version 1.45S) and the results were
reported as an average of three independent repeats.
2.9.5 Statistical Analysis
The results in this thesis are presented as means ± standard deviation (SD) in triplicate
unless otherwise stated. For comparisons between different groups, an ANOVA test fol-
lowed by a Tukey test was executed. For comparisons between two groups, a t-test has
been performed. p < 0.05 was considered to be statistically significant. Statistical analyses
were performed with the GraphPad Prism 5 (GraphPad Software Inc., La Jolla, USA).
Chapter 3
The Stability of Pre-Formed
Liposomes during SAW Nebulisation
3.1 Context and Aim of Result Chapter
Liposomes nebulisation using jet and ultrasonic nebulisers have been studied previously
[69]. In 1998 Taylor and Bridges showed that using those nebulisers, a damage to lipo-
somes structures occurred, with a reduction in the measured vesicles sizes [68], [70]. The
strong shear forces, exerted on the nebulised particles, resulting in a liposomes damage
[69]. In addition, the liquid in the nebuliser was constantly recirculated, leading to the
accumulation of stresses during the prolonged nebulisation [224]. The delivery of thermo-
sensitive enzymes such as HRP is also critical in terms of denaturation of the protein.
Studies showed that the melting of the HRP’s tertiary structure takes place at 45 ◦C and
its functionality is not retained any longer [225].
This chapter focuses on the SAW nebulisation of pre-formed liposomes of a specific
size for pulmonary drug delivery. The size stability of liposomes before and after SAW
nebulisation was assessed by indirect measurements to test as unlike to jet and ultrasonic,
the SAW nebulisation preserved the size of liposomes and the enzyme functionality. Two
different techniques were used to characterise liposome stability after SAW nebulisation.
The first method was the dynamic light scattering. The second method involved was the
horseradish peroxidase (HRP) assay to test the retention of enzyme activity after the SAW
nebulisation. An indirect method, such as an enzyme assay technique, was employed to
determine LUV stability, as the size of the individual vesicles (d = 100− 200 nm) renders
their direct visualisation by conventional fluorescence microscopy unfeasible. Moreover,
the assay was chosen due to its capacity to give a high signal to noise ratio (SNR), from
small concentrations of both the enzyme and the substrate, and to be quantitative over a
wide range.
The SAW nebulisation was proved to be a suitable means of pulmonary drug delivery,
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sparing the functionality of enzymes and stability of the liposomes.
3.2 Results
3.2.1 Triton X-100 Calibration
Three different concentrations of Triton X-100 were tested, in order to determine which
was the best one for solubilising the liposomes and releasing their contents, as described
in Section 2.7.3. Triton X-100 at concentrations of 0.01% v/v, 0.50% v/v and 1% v/v
were added into a solution of extruded LUVs (Section 2.4.3), of 100− 200 nm diameter
(Fig. 3.1 and 3.2). For the lowest concentration (0.01 %v/v) the surfactant was incubated
for 20 min, without showing any change in size, thus the concentration was increased to
0.50% v/v and after 1 min a decrease in size appeared. Size measurements before and
after adding Triton X-100 showed that 1% v/v is the optimal concentration for bursting
liposomes, demonstrating a decrease in peak size from 100− 200 nm to 10 nm, indicating
solubilisation of the liposomes by the surfactant, and the formation of lipid-detergent
mixed micelles. Micelles are usually in the range of 2− 20 nm in diameter [191].
Above the critical micelle concentration (CMC), micelles are spontaneously formed, the
incubation time required for lipid bilayer solubilisation is inversely proportional to micelle
concentration. Triton X-100 was tested to see how it affected the HRP-TMB reaction. A
solution of 10 nM HRP was used as described in Section 2.4.1 and different concentrations
of Triton X-100 were added: 0.01%, 0.1%, 0.5% and 1.0% v/v. Samples with the detergent,
compared to those with water, resulted in a change of O.D. The greatest change in signal
was apparent at 1.0% v/v of Triton X-100 (see Section 3.5).
3.2.2 Lipid Bilayer Solubilisation by Triton X-100
In order to prove that the size intensity peak obtained from DLS measurements was due to
lipid bilayer vesicles, solubilisation of the bilayer was induced using 1%v/v Triton X-100,
as described in Section 2.7.3. Figure 3.3 shows that in the sample collected after SAW
nebulisation, adding Triton X-100 reduces vesicle size from 100-200 nm to 10 nm. The
change in peak size from 200 nm (red, black line) to 10 nm (blue line) can be explained by
the solubilisation of the lipid bilayer and consequent formation of mixed lipid-detergent
micelles which are usually 3-50 nm [226] in diameter. The 10 nm peak in Fig. 3.3 results
from the range of micelle sizes.
Triton X-100 Negative Control
Triton X-100 was used to solubilise the lipid bilayer of the liposomes and induce the
release of the encapsulated compound. In order to check that the increase in optical depth
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Figure 3.1: Size distribution of extruded liposomes after different incubation times.(a) Solution
of 0.01 %v/v of Triton X-100, incubation time of: 1 min (black), 5 min (red), 10 min
(blue) and 20 min (green).(b) Solution of 0.50 %v/v of Triton X-100, incubation time
of: 1 min (black), 5 min (red) and 10 min (blue). Higher concentrations of Triton
X-100 reduced the time taken for the complete solubilisation of the phospholipid
bilayer.
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Figure 3.2: Size distribution of extruded liposomes after an incubation time of 1 min with a
1.00 %v/v Triton X-100 solution. With a concentration of 1.00 %v/v of detergent,
solubilisation of the membrane was achieved by 1 min.
Figure 3.3: Size distribution of extruded liposomes with HRP encapsulated (in black). The same
sample was then subjected to SAW nebulisation (in red) and finally, the blue graph
shows the size distribution after adding Triton X-100. The results show that Triton
X-100 solubilised the liposome bilayer.
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Figure 3.4: A negative control was run to prove that the optical depth signal was due to the sole
interaction between the HRP and TMB. (a) Two samples of liposomes (a) without
HRP (10 nM) encapsulated and (b) with HRP encapsulated in the liposomes were
solubilised to test the optical depth of both samples. As expected, OD from the
sample (a) was null.
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Figure 3.5: Negative control with Triton X-100. 10 nM HRP was used for each sample and
different concentrations of Triton X-100 were tested, in order to assess if the de-
tergent was affecting the HRP-TMB reaction. Triton X-100 concentrations of 0.00
%, 0.01%, 0.10%, 0.50% and 1.00% v/v were compared. The P value obtained was
higher than 0.05, meaning that no statistically significant differences were found be-
tween the samples. Thus, Triton X-100 is suitable for solubilising HRP-containing
liposomes, since it does not seem to interfere with the HRP-TMB reaction.
was actually due to increased HRP activity, a negative control was run. Five different
concentrations of Triton X-100 were made up in DI water: 0.00 %, 0.01 %, 0.10 %, 0.50 %
and 1.00 %v/v and optical depth was measured to test if Triton X-100 alone was increasing
the optical depth. Negative control samples were made of: (1) HRP 10 nM, H2O, TMB,
and sulfuric acid to stop the reaction after 60 s and instead of H2O, (2) 0.01% v/v Triton
X-100, (3) 0.10% v/v Triton X-100, (4) 0.50% v/v Triton X-100 and (5) 1.00% v/v Triton
X-100. From Fig. 3.5, it is apparent that the O.D. was not significantly different at the
various Triton X-100 concentrations compared to in the blank sample (0 % v/v of Triton
X-100), with small variations OD = 1.83±0.13. This proved that increased optical depth
following the nebulisation of HRP-encapsulated liposomes is due to the release of HRP,
rather than from the Triton X-100 itself.
3.2.3 Horseradish Peroxidase Calibration
Before starting the nebulisation experiment, a calibration curve was generated in order to
determine the appropriate concentration of HRP to be encapsulated within the liposomes.
On a 96 well-plate, 100 µl aliquots of HRP at different concentrations were prepared: 0.002,
0.4, 0.8, 2, 5, 10, 15, 20 and 30 nM were used (Fig. 3.6 (a)), with three different incubation
times of 90 s (black line), 60 s (red) and 30 s (blue) . The following concentrations were
also tested: 5, 7.5, 10. 12.5, 15, 17.5 and 20 nM, at the same incubation time (Fig. 3.6
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Figure 3.6: A HRP-TMB reaction calibration curve was obtained in a 96-well plate. 100 µl
volumes of HRP at different concentrations were prepared (n=5). (a) Concentrations
of 0.002, 0.4, 0.8, 2, 5, 10, 15, 20 and 30 nM were used, as were three different
incubation times of 90 s (black), 60 s (red) and 30 s (blue). (b) The following
concentrations were also tested: 5, 7.5, 10. 12.5, 15, 17.5 and 20 nM, at the same
incubation time. PBS was used as a negative control.
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Figure 3.7: Size distribution of liposomes after extrusion through polycarbonate pores of 200
nm diameter. The peak width indicates a narrow, monodisperse distribution.
(b)).
100 µl of TMB was added to the HRP solution in each well. Then 100 µl of 1 M sulfuric
acid solution was added in each well at 30, 60 or 90 s to stop the reactions. PBS was used
as a negative control. Considering the obtained calibration curve, an HRP concentration
of 20 nM was chosen for encapsulation in the liposomes, which would result in O.D. values
detectable by the plate reader. HRP-encapsulated liposomes were made following the
procedure described in Section 2.4.1.
3.2.4 Particle Size
Comparison of Vesicle Size During Dialysis and SAW Nebulisation
The dynamic light scattering method (see Section 2.5.1) was used to measure the size of
the extruded liposomes and to determine changes in size after dialysis and SAW nebu-
lisation. Fig. 3.7 shows the size distribution after extrusion of lipid solution through a
membrane with 200 nm pores; the sharpness of the Gaussian distribution indicates low
polydispersity of the sample with PDI = 0.1. A sharp Gaussian distribution represents
a monodisperse sample, whose PDI lies within 0.01-0.4. According to the one size distri-
bution peak hypothesis, the PDI is the square of the standard deviation divided by the
square of the mean [227].
Size measurements were also carried out after dialysis and after SAW nebulisation in
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Figure 3.8: Size distribution of extruded liposomes containing HRP (in black). The same sam-
ple was then dialysed (results in red) and finally, the blue graph shows the size
distribution after SAW nebulisation. The results show that SAW nebulisation is a
suitable method for delivering liposomes that are 200 nm in diameter.
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order to see if the size of the liposomes was maintained during these procedures. Fig. 3.8
shows that liposome structure was stable during dialysis and SAW nebulisation, or that
most of the liposome population was the same size (200 nm in diameter). The same size
distribution was obtained for samples collected after extrusion, after membrane dialysis
and after SAW nebulisation. These results confirmed the suitability of SAW for nebulising
liposomes that are d = 100 − 200 nm in diameter, without fragmenting the phospholipid
bilayer.
3.2.5 Rhodamine B Calibration Curve and Capture Efficiency
In order to evaluate the particle loss during collection after SAW nebulisation, a solution of
Rhodamine B (RhB) at a concentration of 100µm was nebulised using SAW. A calibration
curve was made using different concentrations: 1, 2.5, 5, 10,15, 20, 25, 50 µM (Fig. 3.9,
(a)). The calibration curve was fitted with an exponential curve and the following equation
was obtained:
y = 8208− 8440e−0.08x (3.1)
with a coefficient of determination R2=0.99. 100 µl of 100 µM RhB solution was
nebulised and collected in 25 µl of DI water, and 75 µl of DI water was added after
collection to obtain a total volume of 100 µl, which was then subjected to fluorescence
intensity measurements. The fluorescence intensity of the nebulised sample was compared
with that of an equal volume of non-nebulised 100µM RhB solution (Fig. 3.9, (b)). Using
the calibration curve, it was apparent that a concentration of 12.3 µM±0.9 was obtained
following nebulisation. However, the solution had been diluted by a factor of 4 by the
addition of DI water. Considering the dilution factor and that the 12.3 µM±0.9 was
in the linear region, the effective post-nebulisation concentration was calculated to be
49.1 µM±3.6. This result indicates that around 51% of the solution was lost during
nebulisation.
3.2.6 Nebulisation of Liposomes Loaded with HRP
Further experiments were carried out to test the feasibility of using SAW nebulisation to
deliver a compound such as HRP without inducing enzymatic degradation, the setup was
described in Section 2.7.1. HRP was encapsulated in the liposome and the remaining in
the outer solution was removed by dialysis. The stability of liposomes during dialysis was
tested collecting the nebulised solution as previously mentioned in Section 2.7.1. Moreover,
TMB was added in the dialysed solution and measuring the O.D. resulting from the
colourimetric reaction between HRP and TMB (Section 2.8.1). From the results, shown
in Fig. 3.10, the optical depth signal before dialysis is high, due to the fact that not all of
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Figure 3.9: (a) A calibration curve was made using different concentrations: 1, 2.5, 5, 10, 15, 20,
25, 50 µM of RhB. (b) Comparison between Pre-SAW, which is made of 100 µM of
RhB without nebulisation, and Post-SAW, which represent the same solution after
SAW nebulisation. The reduction in signal indicates loss during nebulisation, which
was calculated to be around 51%. The graphs show the mean of three measurements
and the error bars represent the SD. ***p<0.001
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Figure 3.10: Optical depth measurements of HRP and TMB reaction products pre-dialysis,
post-dialysis, post-dialysis with the addition of DI water and post-dialysis with
the addition of Triton X-100 in the solution. The mean of three measurements
is represented and error bars show standard deviation. For comparison between
different groups, an ANOVA followed by a Tukey test was carried out with *p<0.05,
**p<0.01, ***p<0.001.
the HRP was encapsulated in the liposomes. The signal after dialysis, decreased because
the remaining HRP outside of the liposomes was cleared out, and the total quantity of
liposomes is lower due to loss during dialysis. Finally, the OD after adding Triton X-100
in the solution is higher, showing that the HRP-containing liposomes were solubilised by
the detergent and the encapsulated HRP release in the outer solution.
As shown in Fig. 3.10, dialysis was able to remove HRP from the outer solution and
decrease the O.D. by more than 50%. Once dialysis had been tested, SAW nebulisation
was commenced and the nebulised solution was collected in TMB buffer (results shown in
Fig. 3.13). After collection, Triton X-100 was added to release the encapsulated HRP.
An increase in O.D. was noticed between pre- and post-nebulisation samples after the
addition of the Triton X-100, indicating the release of encapsulated HRP. From the data
shown in Fig. 3.11 and 3.13, statistically significant differences between the pre- and
post-SAW nebulised groups are not always observed.
In Fig. 3.11, the particle loss during the nebulisation process is considered (Fig. 3.9.
The O.D of the sample post-nebulisation after the addition of Triton X-100 was multiplied
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Figure 3.11: Optical depth measurements of HRP and TMB reaction pre-dialysis, post-dialysis,
post-SAW nebulisation with the addition of DI water, post-SAW nebulisation with
the addition of Triton X-100 in the solution and the Post-SAW with the addition of
Triton X-100 normalised, taking into account the 51% loss of the original solution
during nebulisation. The mean of three measurements is represented and error bars
show standard deviation. For comparison between different groups, an ANOVA
followed by a Tukey test was carried out with ***p<0.001. A higher signal was
obtained for the nebulised sample following the addition of the detergent, showing
the release of HRP from the liposome cores. In the drawing showing the level
of OD, the blue circle represents an LUVs, the H is for HRP and the red cross
indicates the action of the Triton X-100 during the bilayer solubilisation to release
the encapsulated HRP.
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Figure 3.12: Schematic of Fig. 3.11. In the pre-dialysis sample, the HRP is both inside and
outside the liposomes, after dialysis the concentration of the HRP in the outer so-
lution decreased, but also the number of liposomes, due to the loss during pipetting
and dialysis. After the SAW nebulisation, the number of liposomes decreased more
due to the sub-optimal collection of the nebulised sample, the last sample shows
the addition of Triton X-100 to the solution which causes the solubilisation of the
liposomes and an increase of optical depth.
by the loss factor, but the difference in O.D value was still not statistically significant.
In Fig. 3.13, the difference in O.D between the pre- and post-nebulisation samples were
considered statistically significant based on an unpaired t-test. This variability in the mea-
surements pre- and post-nebulisation is explicable by the suboptimal collection equipment
and the variation of the loss occurring during SAW nebulisation. Optimising the design
of the collection equipment should reduce the variability of the obtained measurements.
Overall, the increase in O.D before and after SAW nebulisation (Fig. 3.15) provides pre-
liminary evidence of the feasibility of SAW nebulisation to deliver an enzyme encapsulated
in liposomes, without breaking the phospholipid bilayer. Further studies will be detailed in
the following chapters, with the objective of proving the efficiency of the SAW nebulisation
platform.
3.2.7 Enzyme Activity During SAW Nebulisation
As described in Section 2.7.1, a temperature test was carried out to check the suitability
of SAW nebulisation in terms of not destroying the activity of the delivered HRP enzyme
(Fig. 3.14). The solution was dispensed using a syringe pump and the Peltier was heated
to 20◦C, 65◦C or 95◦C. According to the results, enzyme activity was retained at each
of the different temperatures used. Different powers were also employed to test their
effects on the activity of HRP. Upon increasing the temperature, enzyme activity did
not decrease. The fact that the optical depth was the same for the HRP nebulised at
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Figure 3.13: Optical depth measurements of HRP and TMB reaction, after SAW nebulisation
with the addition of DI water and after SAW nebulisation with the addition of
Triton X-100 in the solution. The mean of three measurements is represented and
error bars show standard deviation. T-tests have been performed with **p<0.01
The higher optical depth after adding Triton X-100 shows the release of HRP
encapsulated in the liposomes and the suitability of SAW to nebulise active com-
pounds encapsulated in the liposomes without breaking them. An unpaired t-test
was run, showing a statistically significant difference between the two samples with
p ≤ 0.05
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Figure 3.14: Optical depth measurements of HRP and TMB reactions after heating the nebuli-
sation platform (IDT) at 20◦C, 65◦C and 95◦C. The same OD value was observed
following exposure to higher temperatures, showing that enzyme activity was not
destroyed.
95◦C (Fig. 3.14) demonstrates the feasibility of using SAW to nebulise active compounds
without denaturing their structure. The configuration of the SAW nebulisation platform,
using the syringe pump to gradually dispense the solution, minimised exposure of the
enzyme to the high temperatures reached, helping to spare its activity.
3.2.8 Discussion and Conclusion
In this Chapter, the integrity of liposomes has been monitored in terms of the size distri-
bution i.e. comparison of size distribution before and after nebulisation was performed.
In previous studies, a decrease in the size indicated liposome damage during nebulisation
[68]. Here, the integrity of liposomes after SAW nebulisation is measured, using different
methods. Size stability was first tested using dynamic light scattering. Results showed
that liposome size was unmodified by dialysis or by SAW nebulisation, as suggested by the
maintenance of the same intensity peak (100-200 nm). After dialysis, the same liposome
size was observed as before dialysis. That confirmed that dialysis left the majority of the
vesicles intact. The size of liposomes after SAW nebulisation was checked, to determine if
liposomes can be used as a carrier for drugs to be delivered by nebulisation. The results
showed that the size of the liposomes was retained, indicating that SAW nebulisation did
not fragment the liposome bilayers of 100 nm size. It represents the first step to test the
feasibility of SAW to nebulised 100 nm of diameter vesicles to use as a drug carrier.
A shift in the intensity peak from 100-200 nm to 10-20 nm - the size of micelles - upon
the addition of Triton X-100 to solubilise the liposome bilayer confirmed the presence of
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Figure 3.15: Optical depth measurements of HRP and TMB reaction, post-dialysis, post-SAW
nebulisation with the addition of water and post-SAW nebulisation with the ad-
dition of Triton X-100. The graph shows that during the nebulisation process
around 49% of the solution is lost. Then, after the addition of Triton X-100, the
O.D increased again by 50%. Each point represents the mean values of three mea-
surements. Error bars represent the standard deviation of three measurements.
the vesicles [228].
In order to prove that SAW nebulisation is suitable for delivering temperature-sensitive
enzymes [225], an indirect method was used to test the integrity of liposomes after SAW
nebulisation, using the HRP assay. The HRP was encapsulated in the liposomes through
the thin film hydration method and then nebulised using SAWs. After the collection of
the nebulised particles and the addition of Triton X-100 to release the HRP from the
vesicles, TMB was added into the solution. According to the data shown in Fig. 3.15,
the increase in signal from the HRP-TMB reaction showed that SAW nebulisation did not
destroy the enzyme activity or the liposome structure. Comparison of the O.D. before
and after nebulisation and the addition of Triton X-100 showed an increase (Fig. 3.13) of
the signal, but the difference between the two measurements was not always statistically
significant (Fig. 3.11). This is mainly due to particles loss during SAW nebulisation and
the suboptimal collection equipment, so the total amount of vesicles in the solution is
lower after nebulisation (Fig. 3.15). Improvements to the equipment configuration were
made as detailed later on in this work, in order to reduce particle loss. A nebulisation box
was designed (See Chapter 6) to confine the nebulised flow.
Elevated temperatures within the reservoirs of ultrasonic nebulisers can damage the
active molecules being delivered, reducing their functionality [203]. A temperature test was
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performed during SAW nebulisation, to see if the active compound (HRP) was denatured
at high temperatures. The measured O.D. did not change as the temperature was increased
(Fig. 3.14). The experimental equipment used the syringe pump to dispense the right
amount of liquid and allow it to be nebulised instantly. This dispensing method minimised
the exposure of the enzyme (HRP) to high temperatures, thus helping to protect its
activity.
In conclusion, it was proven that SAW nebulisation is a suitable method for the delivery
of temperature-sensitive proteins and enzymes and to nebulise pre-formed liposomes of 100
nm diameter, which can be used as drug carriers to encapsulate compound and deliver
them via inhalation. The work carried out in this Chapter represents a preliminary test to
show that SAW is a suitable method to nebulise and deliver liposomes. once the feasibility
of using SAW to nebulise liposomes was tested, the next step was to try to combine the
formation of liposomes and aerosols in one single step, without the requirement of pre-
formulation.
Chapter 4
Liposome Formation In-Situ on a
SAW Nebulisation Platform
4.1 Context and Aim of Result Chapter
A major problem with current drug delivery system is their inefficiency at delivering ex-
pensive drugs to their targets, leading to high overall treatment costs. In order to protect
and deliver the high-value compound and control the release of the drug inside the cell,
drugs are often encapsulated into protective liposomes [36]. However, a multistep process
is required for their formation, often performed during the formulation step, therefore,
limiting indirectly (e.g. freeze-drying step, or addiction of cryo-protectants) the range of
drugs available or their shelf-life [229], [40], [230]. For instance, the preparation of liposo-
mal Ciprofloxacin requires several different steps [231]: preparation of an MLV dispersion,
extrusion of the unilamellar vesicles, which is time consuming (see Section 2.4.3), active
loading of the drug and finally the nebulisation process. The work carried out in this
Chapter hopes to address the issue of liposomes stability during the nebulisation, avoiding
the need of liposomes prior-formulation and prolonging their shelf-life. Studies about the
formation of liposomes using SAWs and to use cavities to confine the nebulised volume and
thus, eliminating the production of large aerosols and indirectly of the large liposomes,
were not made previously.
A new method based on Surface Acoustic Waves (SAWs), coupled with a microfabri-
cated silicon chip, to produce aerosols within the desired range and together form liposomes
in-situ within the delivery device, is presented. The size of produced aerosols and the for-
mation of drug carriers for a successful delivery of pulmonary drug were evaluated and
analysed.
The objective of this part of the work is to create liposome drug carriers within a
SAW nebulisation platform and to control the aerosol’s size within the respirable range.
Unilamellar liposomes of 100 nm diameter were formed and encapsulated in aerosols of 1
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to 5 µm. The results obtained are proving the potential of the SAW nebulisation platform
as an efficient pulmonary drug delivery system.
4.2 Results
4.2.1 Aerosol Size Control with SAW Nebulisation in a Confined
Space
As introduced in Chapter 1, one of the key parameters for an efficient pulmonary drug
delivery system is the control of the aerosolised droplet size [232]. The complex nature of
the SAW nebulisation process makes it hard to understand and despite various studies on
the topic, the effect of specific parameters on the aerosol droplet size is not explicitly clear
[117], [233], [137]. As discussed earlier, the high shear stresses of nebulisation techniques
damage biological compound and fail to deliver them. However, SAW nebulisation is
proved to be a promising method for delivering cells, polymers, nanoparticles, proteins
and DNA [11], [234], [137], showing the presence of the undamaged compound after the
SAW nebulisation.
Figure 4.1: SAW Confined Nebulisation. (a) The graph shows volume intensity plotted against
aerosol size distribution. From laser diffraction measurements a size distribution in
the optimal size range for pulmonary drug delivery (1 µm < d < 5 µm)was obtained
using a silicon chip with pore size of 100 µm. (b) The relationship between the char-
acteristic length scale of the pores and the aerosol median droplet size. The graph
shows that with the decrease of the pore sizes, from which the SAW nebulisation
occurs, a decrease of the aerosol droplet size was obtained [235]. The mean of three
measurements is represented and error bars show the standard deviation.
A specific study regarding the size of SAW-nebulised particles was made [235] with a
completely new approach using a physical confinement made from a silicon wafer, as de-
scribed in Section 2.3, to decrease indirectly the size of the nebulised droplets, by reducing
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Figure 4.2: SAW nebulisation from silicon chip. (a) Nebulisation from 800 µm cavities in di-
ameter. (b) Close-up of the SAW nebulisation within 800 µm cavities. (c) SAW
nebulisation from 200 µm cavities.
the surface wave wavelength. Experimental evidence highlighted the relation between liq-
uid length scale and capillary wavelength; the capillary wavelength decreases as the liquid
length scale reduces [235]. The physical confinement can be consider as a low-pass filter,
which filters out capillary wave’s wavelength that results in the formation of large droplets.
This theory is implemented by using a silicon chip with an array of wells (cavities), coupled
with the IDT, as previously described in Section 2.7.2.
Using cavities of increasing diameters, the median droplet size of the aerosol produced
increases. Cavities of diameter: 100, 200, 400, 600, 800 and 1200 µm were employed. For
100-200 µm cavity, a median droplet size distribution within 1 µm and 5 µm was acquired.
Increasing the cavity size to 400, 600 and 800 µm, a size distribution of 20 µm and a
multimodal size distribution with peaks around 80 µm and over 100 µm was obtained (Fig
4.1). The smaller the cavity from which the nebulisation occurs, the smaller the aerosol
size, this is due to the physical restriction of the liquid, which decreases the wavelength of
the SAW responsible for the production of the aerosol (Fig. 4.2). The aerosol’s size was
determined using the Spraytec, which is based on the laser diffraction principle, described
in Section 2.6.1.
4.2.2 Size of SAW-Formed Liposomes
In order to form LUVs on SAW platform, two different methods were tested: (1) SAW
nebulisation of MLV solution, previously made through a silicon chip made of cylindrical
cavities and (2) spinning phospholipids on IDT, application of the silicon chip, incubation
with DI water (consequent swelling of phospholipid, with the production of MLVs) and the
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SAW nebulisation. The two methods were described in Section 2.7.2. After measuring the
vesicle output from the two approaches and determining that the two methods produced
the same size of vesicles (Fig. 4.4), the first method was chosen, because easier and faster
to carry out.
Nebulisation of Lipid Solution
An MLV solution was prepared and nebulised with and without the silicon chip, coupled
on the IDT, as described in Section 2.7.2. Size measurements of liposomes using dynamic
light scattering have shown significant differences in size (Fig. 4.3) between: (1) the
MLVs mixture, which presents a high-intensity peak at 4 µm diameter, (2) the MLVs
subjected to SAW nebulisation without silicon structure, resulting in liposomes around
200 nm and 2 µm of diameter, and (3) SAW nebulisation with the silicon structure,
exhibiting a pronounced peak around 200 nm. The nebulisation occurred for an input
power of -4 dBm (Fig. 4.3, (a)). Same measurements were done for an input power of
-2 dBm, and comparison between liposome populations produced using the two power
settings are displayed in Fig.4.3, (b)). The results present a decrease in liposome size after
nebulisation and a further decrease after the use of the silicon chip. The hypothesis is
that SAWs are supplying the energy necessary to break down the multilamellar vesicles in
smaller liposomes. Moreover, even smaller particle size distribution was measured when
the SAW nebulisation occurred through the silicon chip, obtaining a monomodal-like size
distribution around 200 nm. Higher input power (-2 dBm, 7.5 W) does not seem to
decrease the size of the vesicles, but in the next few Sections, further measurements will
be carried out in order to evaluate the effect of different parameters such as the cavities
size, the lipid concentration and the input power on the size of the liposomes produced by
SAW.
Compared to SAW nebulisation of the free sessile droplet, using a physical confinement
to contain the liquid resulted in a smaller size distribution of nebulised particles. Further
experiments were carried out, in order to test if the physical confinement could be also
responsible for the liposomes formation as well as the aerosol production in the optimal
size range (Fig. 4.1). For a better understading of the liposomes generation process,
the formation during nebulisation was monitored. A sample of the nebulised solution
was collected at different stages and checked using the confocal microscopy, as shown in
Section 4.2.6. Observations confirmed that MLVs were initially broken down, due to the
energy of SAWs, forming BPFs, which were then closing up due to the hydrophobic effect
of the phospholipid’s tail. Liposomes of sizes in the range of 100-200 nm were formed.
Once the size was measured, Cryo-TEM was used to check the structure of the liposomes,
particular the lamellarity (Section 4.2.7). SAW nebulisation is a fast process and although
a fast speed camera was also employed, a real understanding of the process was difficult.
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Figure 4.3: Size distribution from DLS of MLV mixture. (a) Measurements at an input power
of -4 dBm. The black line shows the size distribution of MLV mixture, the red line
represents the size of vesicles after SAW nebulisation without silicon structure and
the blue line represents vesicle size after SAW nebulisation with silicon structure of
300 µm pores. A reduction in vesicle size occurred when the nebulisation was carried
out through the silicon chip. (b) Measurements were repeated at -2 dBm input
power. The black line shows the size distribution of MLV mixture, red (-4 dBm) and
pink (-2 dBm) lines represent the size of liposomes after SAW nebulisation without
silicon structure. Blue (-4 dBm) and green (-2 dBm) lines represent liposomes
size after SAW nebulisation with silicon structure of 300 µm pores. When the
nebulisation occurs through the chip, the power increase does not seem to change
the size of the liposomes.
The presented results suggest that a combined effect of the SAW and the use of the silicon
chip can be considered responsible for the production of liposomes around 100-200 nm
in diameter. The silicon chip influenced indirectly the size of the vesicles, Fig. 4.3. By
controlling the liquid length scale, a manipulation of the SAW’s wavelength was obtained,
which consequently modified the size of the nebulised droplets. This indirectly affected
the size of the liposomes contained in the aerosols. The size of the aerosols is reduced,
by the use of the silicon chip, and not enough liquid can surround the larger liposomes.
Unsupported bilayers cannot exist outside of an aqueous environment, causing the collapse
of the larger liposome structure as described in Table 4.1.
Spinning Lipids on IDT
From the phospholipid spinning approach, liposomes in the same size range obtained for
the first method (described in Section 2.7.2) were formed. The same silicon chip with a
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pore size of 300 µm and the same power were used, as described in Section 2.7.2.
Figure 4.4: SAW-formed liposome size distribution from DLS. In red, spinning lipid approach,
in black nebulisation of MLV solution, a small bump is present around 30-40 nm,
which indicates that probably during the nebulisation some of the lipids collapsed
into aggregates. Sample preparation: spin uniform layer on IDT, add silicon chip,
incubate with DI water, application of SAWs.
Figure 4.4 shows the result from the second approach (red line) compared to the first
approach (black line). MLVs and giant unilamellar vesicles (GUV) started to form from
the chip pores, during the lipid hydration. Once SAWs were applied, the energy released
was breaking down MLVs into BPFs as in the first approach. The size distributions from
the two approaches are showing the same trend (Fig. 4.4), but the spinning method was
not used, due to the time consuming procedure to spin down the lipids on the chip.
4.2.3 SAW Nebulisation Through Cylindrical Cavities of Differ-
ent Pore Size
The combination of SAW nebulisation and the use of the silicon structure was considered
responsible for the size decrease in the liposome population. In order to test the influence
of the pore size of the silicon chip on the size of the liposomes formed after nebulisation,
different measurements were made, nebulising the same concentration of MLV mixture
through different cavity size: 800, 600, 400, 300 and 100 µm.
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Figure 4.5: Size distribution of the liposomes obtained by SAW nebulising an MLV mixture
through cavities of different size (100, 300, 400, 600 and 800 µm), as measured by
DLS. The solution was made of 2.00 mg/ml DOPC in DI water. Three replicas were
made for each cavity size. IDT parameters: 9.552 MHz with an input power of -4
dBm.
Liposomes Size
The results show that SAW nebulisation through dry etched cylindrical cavities breaks
down MLVs into smaller vesicles (Fig. 4.5). However, changing the diameter of the
cylindrical cavities did not lead to a significative change in the liposomes size.
The two students T-test was run to demonstrate that the difference between the set of
measurements were not statistically significant. Thus, modifying the cavity size did not
change the size of the SAW-formed liposomes.
The fact that the cavity length scale was 2 orders of magnitude larger than the size of
the MLVs and 3 orders of magnitude larger than the liposome’s size could be the reason
for not having a specific relationship between the silicon chip pore size and liposome size.
Evidence of the silicon structure effect, on the size of the aerosol and of the vesicles, was
reported (Fig. 4.3). The use of physical confinement compared to the SAW nebulisation
of the free sessile droplet is changing the size of the aerosol produced depending on the
cavities size. Regarding the size of the liposomes encapsulated in the aerosols, a difference
in size was occurred between the presence or not of the silicon chip (Fig. 4.3, (a)), but a
specific relationship with the cavity size was not found (Fig. 4.6).
CHAPTER 4. SAW NEBULISATION PLATFORM: LIPOSOME FORMATION 103
Figure 4.6: Two students T-test of liposome’s size against cavity size. SAW nebulisation of a
solution of 2.00 mg/ml DOPC in DI water was evaluated for cavity sizes of 100, 300,
400, 600 and 800 µm. This graph is showing that a clear relationship between the
cavity size and the size of the liposomes produced cannot be made.
The use of the silicon structure with cavities in the range of 100 µm to 800 µm lead
to a size distribution of vesicles around 100-200 nm, optimal for pulmonary drug delivery,
as shown in Table 4.1. Due to the fact that a layer of water surrounding the liposomes is
needed to avoid their rupture, a hypothesis regarding the unchanged size of vesicles against
the cavity size was made. The use of cavity sizes below 800 µm resulted in the formation
of smaller aerosols (between 1-20 µm) and liposomes with 100-200 nm diameter. The use
of a silicon chip with cavity sizes above 800 µm or also in the case of the nebulisation of
a sessile droplet, generated a bimodal size distribution of aerosol droplets (with the two
peaks at 1-20 µm and around 100 µm) and two populations of liposomes, with sizes of
100-200 nm and 1-2 µm. The results are presented in Fig. 4.3. A minimum amount of
water required to encapsulate the liposomes was considered as a factor in determining the
size of the liposomes, and in the indirect elimination of larger liposomes.
Aerosol Size
Laser diffraction measurements were made using Spraytec (Malvern) to evaluate the size
distribution of nebulised droplets (Fig. 4.7, (a)). Spraytec is a volume-sensitive technique
as describe in Section 2.6.1. It is unable to differentiate between particle types. Thus, the
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Figure 4.7: (a) Size distribution of nebulised droplets by laser diffraction. SAW nebulisation of
DI water through cavities of black line 180 µm, red line 200 µm, blue line 400 µm
and green line 600 µm. IDT parameters: 9.675 MHz with an amplitude of -6 dBm.
(b) Vesicles size against cavity size, measured by laser diffraction. SAW nebulisation
of a solution of 2.00 mg/ml DOPC in DI water was evaluated through cavities of
180 µm, 200 µm, 400 µm, and 600 µm. The graph shows a positive correlation
between the cavities size and the size of the aerolised droplets. The mean value of
three measurements is reported. Error bars show the standard deviation of three
measurements.
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Cavity diameter (D) Aerosol size peak (µm) Vesicle size peak (µm)
D >800 µm 100; 1-20 2.5; 0.1-0.2
D <800 µm 1-20 0.1-0.2
Table 4.1: Peak values of size distribution of aerosol droplets and vesicles generated by SAW.
For cavities with D>800 µm, the SAW nebulisation generated two peaks of aerosol
size distribution: (1) at 100 µm and (2) at 1-20 µm and two peaks of vesicle size
distribution: (1) at 2.5 µm and (2) at 100-200 nm. For cavities with D<800 µm, the
SAW nebulisation generated one peak of aerosol size distribution at 1-20 µm and a
peak of vesicle size distribution at 100-200 nm.
size distribution obtained is representative of both aerosols and aerosols containing the
SAW-formed liposomes. From the measurements, the size of the aerosols produce by SAW
depends on the pore size of the silicon chip (Fig. 4.7, (b)), but not the size of the SAW-
formed liposomes (Fig. 4.1 and 4.5). This was confirmed by nebulising both DI water
and MLV dispersion, with the same pore size chip. The size distribution obtained was
5-10 µm larger when nebulising the MLV dispersion compared to DI water, which could
be dependent on the viscosity of the nebulised sample. For cavities with the diameter of
180 µm and 200 µm, a size distribution between 1 µm and 10 µm was obtained. For 400
µm and for 600 µm cavities, aerosol droplets around 20 µm and 40 µm were produced.
4.2.4 SAW Nebulisation of Different Concentrations of MLVs
Solution
The concentration of the phospholipid solution to be nebulised was analysed as a parameter
that could possibly modify the size of the SAW-formed liposomes. MLV mixtures of
1.00 mg/ml, 5.00 mg/ml and 10.00 mg/ml were nebulised. Increasing the number of
phospholipids in the solution was expected to lead to an increase in vesicles size.
Results did not show appreciable changes in the liposome size distributions from DLS
measurements between the three concentrations (Fig. 4.8). Laser diffraction’s measure-
ments were also carried out, showing a small change in size from 1.00 mg/ml concentration
to 5.00 mg/ml and a lower volume intensity of almost 10% less for the lowest concentration
(1.00 mg/ml).
By increasing the concentration, we are increasing the number of vesicles produced,
but not changing the size range of the vesicle population, which depends on the size of
the aerosol encapsulating the vesicle.
4.2.5 SAW Nebulisation with Different Input Power
The power applied through SAW was tested, using the setup described in Section 2.7.2.
For different input powers applied, the liposome size was measured using dynamic light
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Figure 4.8: SAW nebulisation of different concentrations of MLV mixtures. Size distribution
from (a) DLS and (b) laser diffraction of different concentrations of phospholipid
dispersions, nebulised through 300 µm cavities. Black line is the size distribution of
SAW nebulisation of a solution of 1.00 mg/ml DOPC in DI water, red line is the
one of a solution of 5.00 mg/ml and blue line of a solution of 10.00 mg/ml.
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Figure 4.9: Size distribution of (a) SAW-formed vesicles and (b) Aerosol droplets at different
input power. (a) Size distribution from DLS of different input power applied through
SAW. Using input power range from -6 dBm to -1 dBm and amplified by 40 dB,
the total power used is changing from 1 W to 5 W, not showing a significant change
in size. The same result was obtained by laser diffraction measurements (b), a bi-
modal distribution was established for the nebulisation using power from -6 dBm to
-1 dBm.
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Figure 4.10: Probe sonication of MLV mixture. Sonication with 200 W power was conducted
in 1 ml of MLV mixture (represented by pink line), for 10 s (blue line), 20 s (red
line) and 30 s (black line). From the result, 30 s of sonication are necessary to be
able to obtain a monomodal-like size distribution.
scattering, while aerosol size distribution was evaluated using laser diffraction (Fig. 4.9).
Three measurements for each sample were made and the mean values of the three
measurements were shown. The SAW nebulisation was carried out with the silicon chip
coupled with the IDT and for each measurement with DLS, the same amount of volume was
collected, as described in Section 2.7.2. For laser diffraction 5 µl of volume were nebulised.
Power from -6 dBm to -1 dBm was used. The power supplied to the system was limited,
due to the high temperature reached during the nebulisation. For each measurement, the
power was increased by 1 dBm (0.1 mW amplified with a gain of 40 dB, equal to an increase
of 1 W for each measurement, Fig. 4.9). Based on the formula introduced in Chapter 1,
Section 1.10.2 from [134], the energy required to disperse a volume of liquid into smaller
droplets is approximately calculated to be around 3 mW, but a higher energy is used due
to power losses during the nebulisation process. A comparison with the probe sonication
method was made, as described in Section 2.4.4, as shown in Fig. 4.10. With the increase
of the sonication time, the size of the liposomes decreased. After 30 s, a mono-modal size
distribution was obtained, but the temperature, which was checked using an IR camera,
reached over 80◦C. The power used in probe sonication method was 100 times higher than
the power employed with SAW nebulisation, which also produced LUVs in a faster and
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more convenient way.
Figure 4.11: Confocal microscope image, 100x. (a) Picture of the MLV dispersion before the
SAW nebulisation. (c) Sample during the SAW nebulisation, which was stopped
to be able to retrieve the sample. The picture shows a decrease in vesicle size and
higher monodispersity compared to picture (a). (b), (d) represent pictures (a) and
(c) with enhanced edges to help to visualise the vesicle population.
4.2.6 Confocal Microscopy
Comparison between extruded and SAW-formed vesicles
Confocal microscopy was used to check the vesicle population at different times during
SAW nebulisation. Samples were taken before nebulisation, during nebulisation (stopping
the SAW) and after nebulisation. Due to the low resolution of the microscope, only an
estimation of the vesicle population can be done. Fig. 4.11 shows that vesicle population
before nebulisation is highly polydisperse with larger vesicles, while after stopping the SAW
nebulisation, a clear decrease in vesicle population can be noticed with a lower degree of
polydispersity. After showing the vesicles size changes during the SAW nebulisation, a
comparison between SAW-formed vesicles and those obtained through extrusion showed
a more uniform vesicles size from the latter method (Fig. 4.13). This is mainly due
to the limited resolution of the microscope, which cannot determine further information
regarding size, lamellarity and structure of the vesicles. Thus, samples were checked with
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Figure 4.12: Size distribution of liposomes during SAW nebulisation of confocal images in Fig.
4.11. The black line is the size distribution of Fig. (4.11,(b)), which represents the
pre-nebulisation sample. The red line is the size distribution of Fig. (4.11,(d)),
which represents the size distribution after interrupting the nebulisation. A de-
crease in liposome’s population size is showed.
cryo-TEM to establish the lamellarity of SAW formed liposomes. Additionally, the size
of vesicles formed through the SAW and the extrusion method were compared using DLS
measurements (Fig. 4.13). Results show a similar size distribution for both methods,
indicating the suitability of SAW nebulisation for the in-situ formation of vesicles.
4.2.7 TEM Negative Staining and Cryo-TEM
TEM negative staining was used to test if sample concentrations were sufficient to be
detectable using TEM and, to cross-examine the size distribution from DLS results. Com-
paring the images of SAW-formed liposomes and the extruded liposomes (control sample),
shown in Fig. 4.14, some similarities were noticed. The concentration of SAW-formed
liposomes was lower, but the structure appeared similar, (Fig. 4.14) shows a peculiar
structure of the vesicles indicating that the liposomes collapsed (see Appendix D, Fig.
D1). There are many potential factors that could be responsible. First of all, during
sample preparation, the sample was blotted dry, thus the solution could have been evap-
orated. It could also be due to the differences in osmotic pressure between the external
and internal core of the liposomes. In order to examine the vesicle lamellarity, further
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Figure 4.13: (a), (b) Confocal microscope image, 100x. (a) Vesicles extruded through 100 nm
membrane (b) Liposomes formed using SAW and 300 µm cavities. In both cases,
the vesicles were produced from a solution of 2.00 mg/ml DOPC in DI water. The
graphs are showing the DLS size distribution of extruded liposomes through 100
nm membrane (black) and SAW-formed liposomes, nebulisation of MLVs through
300 µm cavities size (red). The results from the two methods are comparable in
terms of size and volume intensity. Presence of a small peak around 3 µm indicates
the presence of impurities or bigger vesicles.
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Figure 4.14: TEM negative staining. Liposomes made by extrusion through a membrane of 100
nm (left), and SAW-formed liposomes from the nebulisation of MLVs through 300
µm cavities.
measurements with Cryo-TEM were needed. As shown in Fig. 4.15 and 4.16, the number
of vesicles was higher in the control sample, but the monodispersity was higher in SAW-
formed liposomes sample. In the control sample, multiple vesicle populations of different
size (50-250 nm) and various lamellarity could be seen, as highlighted in Fig. 4.15 by
the red arrows. SAW-formed liposomes were in a smaller size range, namely 50 nm-100
nm and more monodisperse, but lower in terms of the number of vesicles. The vesicles
from SAW nebulisation have optimal liposome characteristics of a monodisperse sample
with a single lamellarity (see red arrows), even though the number of vesicles is lower (see
Appendix, Fig. D2). The single lamellarity of the SAW-formed liposomes is key for a drug
carrier, in terms of higher stability and control of the release compared to multilamellar
ones.
4.2.8 Discussion
Liposomes have been an established drug delivery carriers since Bangham first described
them in 1961 [38]. Multiple ways to produce them were introduced in the last decade
[229], [36], but none of those methods was integrated into a platform to create an efficient
drug delivery system. This chapter highlights the advantage of a new method capable of
producing liposomes and delivering them directly into the lungs. The SAW platform has
the combined advantage of producing aerosol within the optimal size range for deep lung
absorption between 1 µm and 5 µm [4] and forming liposomes of a specific size (100 nm)
during the nebulisation process. Other groups have previously reported the advantage of
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Figure 4.15: Cryo-TEM. Liposomes extruded through 100 nm membrane. Images are showing
different size of vesicles with a range from 50 nm to 250 nm. Most of the vesicles
have more than one bilayer, highlighted by the red arrows.
Figure 4.16: SAW-formed liposomes, produced via nebulisation of MLVmixture through cavities
of 300 µm pore size. The size distribution is lower, with a lower concentration of
vesicles. The sample is highly monodisperse (PDI < 0.1). As indicated by the red
arrows, the vesicles produced are mainly unilamellar.
the SAW nebuliser [19], [117], [236] for the production of aerosols within the optimal range,
but none of them showed a specific method of controlling the size of the aerosols. Fig. 4.1
showed a clear relationship between the cavity size, from where the nebulisation occurred,
and the size of the aerosol droplets produced. The SAW nebulisation through a silicon
chip with 100-200 µm cavities produced vesicles in the optimal lung absorption range.
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Once the size of the aerosol droplets were tested, a phospholipid suspension was nebulised
by SAW, in order to test if SAW was transferring enough energy to the suspension to
break the MLVs into SUVs or LUVs. To explain the formation of unilamellar vesicles from
a mixture of multilamellar vesicles, two different hypotheses were proposed. The first one
is the 'filtering hypothesis ', which postulates that small unilamellar vesicles were already
contained in the MLV mixture and subsequently, during the SAW nebulisation, larger
vesicles are filtered out. This hypothesis was abandoned based on the DLS measurements
presented in Fig. 4.3, the smallest peak corresponding to the size distribution of the MLVs
in the mixture before the nebulisation, does not match with the size of the vesicles after
the SAW nebulisation. A second hypothesis was formulated, which had been previously
proposed by Lasic [47] in his studies. It is based on the formation of BPFs, as described in
Chapter 1 (Fig. 1.7), where the energy given by SAW was breaking up the MLVs into lipids
fragments. The BPFs, due to the hydrophobic nature of the phospholipid hydrocarbon
chains, were closing themselves in unilamellar vesicles [54]. Fig. 4.3 showed the effect
of the SAW only and the combined effect of the SAW and the use of the silicon chip.
The use of the physical confinement not only decreased the size of the produced aerosols,
by constraining the surface wave’s wavelength, but also allowed the formation of small
liposomes, creating a highly monodisperse sample. Different cavity sizes were employed
to track changes in the produced liposomes. The changes in the size of the aerosols,
obtained using different cavity sizes, were not noticed for the SAW-formed liposomes, a
relationship between them was not found. Different concentrations and different values
of input power were also tested to check whether those parameters were affecting the
size of the liposomes produced within the SAW platform. The only notable change in
the liposome size distribution was observed between the SAW nebulisation of the free
sessile droplet and the SAW nebulisation coupled with a silicon chip with cavities between
100 µm and 800 µm. This was also confirmed by confocal microscopy, which showed
changes in the vesicle population before, during and after the SAW nebulisation. A high
degree of monodispersity and unilamellarity of the SAW-formed liposomes was obtained,
as confirmed by TEM negative staining and Cryo-TEM. Size of the SAW-formed liposomes
was confirmed by DLS. The formation of liposomes with the desired characteristics can be
attributed, in terms of size and lamellarity, to both the use of silicon chip and high power.
Using the SAW nebulisation with input power around 5 W (free sessile droplet without
silicon chip) resulted in multimodal size distribution with a population of mainly larger
vesicles. The employment of the silicon chip reduced the size of aerosols, but also indirectly
eliminated larger vesicles from the collected sample. Larger vesicles did not survive the
nebulisation without the existence of large enough aerosols to contain them. Therefore,
larger vesicles collapsed in contact with air, creating an aggregate of phospholipids around
40 nm, as shown in Fig. 4.3. The formation of liposomes using the SAW and the silicon
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chip is the result of a combined effect of different parameters, such as the amphipathic
properties of the phospholipids, the energy transferred with the SAW and the use of the
physical confinement to reduce the size of the aerosols, which contain the liposomes.
4.2.9 Conclusion
A new method to form liposomes was presented within the same SAW nebulisation plat-
form, which will allow the delivery of different compounds using a single unique platform.
The main advantage of this technique is the combination of two effects: the production
of aerosol within the lung absorption optimal range and the production of the drug car-
rier, e.g., liposomes, to transport the compound into the cells. Different parameters were
analysed in order to propose a theory behind the formation of liposomes during the SAW
nebulisation. The effect of three parameters, such as the cavity size of the silicon chip, the
concentration of the MLV’s suspension and the power employed, on the size of both the
aerosols and the liposomes was closely examined. The cavity size of the silicon chip was
demonstrated to influence the size of the produced aerosols but did not directly affect the
size of the liposomes. The liposomes’ size changed only as a consequence of the reduction
in the size of aerosols (Fig.4.3 and 4.7). Both the phospholipid concentration and the
power supplied by the amplifier had no significant influence on the size of the vesicles.
Once the platform was made, in Chapter 5 the size distribution of the aerosols produced
by SAW will be measured using a standard device (cascade impactor) recommended in
both the US and European Pharmacopeia and in Chapter 6 the platform will be tested
in-vitro in lung cancer cells.
Chapter 5
Analytical Characterisation of
Droplet Size From SAW Nebulisation
5.1 Context and Aim of Result Chapter
One of the most important parameters for aerosol characterisation is the particle size
distribution, since the clinically validated size range is between 1-5 µm [102]. Particle size
distribution can be determined using a direct method, such as microscopy or indirect ones
such as inertial, diffusional and optical methods. In this Chapter, a cascade impactor,
which is the standard recommended by both the US and European Pharmacopeia in
determining aerosols’ size, was employed to measure the size distribution of the SAW
generated aerosols [237].
It is a method based on the inertial impaction and the aerodynamic diameter is eval-
uated, as described in Section 2.6.2.
The aim of the work carried out in this Chapter is to show the ability of the SAW nebu-
liser to generate aerosols in the optimal range and compare the newly developed nebuliser
with a commercially available one, such as OMRON NE-U22. The size distribution of the
aerosols generated from the SAW nebuliser with/without the use of the silicon cavity chip,
previously described in Section 2.3, was measured and compared with OMRON NE-U22
nebuliser. The Andersen Cascade Impactor (ACI) was used to measure the particles depo-
sition collected in each stage of the cascade and reconstruct the particle size distribution.
Moreover, the stability of liposomes was tested in each stage of the cascade. Liposomes
were delivered into the last stages of the impactor, indicating that the SAW nebuliser is
able to efficiently nebulise drugs encapsulated in liposomes.
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Figure 5.1: OMRON NE-U22 nebuliser. (a) Front view, (b1) Top view with the cap containing
the mesh opened and the view of the piezoelectric material. (b2) Top view with the
cap closed, the top view of the mesh and the reservoir at the back. (c) Drawing of
the mesh nebuliser: the solution in the reservoir goes on top of the piezoelectric ma-
terial, which pushes the solution through the mesh and creates the aerosol. Viscous
solutions can clog the mesh pores.
5.1.1 OMRON NE-U22 Mesh Nebuliser
The OMRON NE-U22 Mesh Nebuliser (OMRON, Japan) was used as a control to test the
efficiency of the SAW nebuliser. The commercially available nebuliser uses a piezoelectric
crystal which vibrates at 180 KHz and pushes the liquid through the mesh (Fig. 5.1). Main
disadvantages of the mesh nebuliser are the high cost (around GBP 100), the difficulty
in nebulising viscous solutions and in cleaning the device. Furthermore, the employment
of lower frequency compared to the SAW nebuliser (range of MHz) produces high shear
stress that can damage the molecule, as described in Section 1.10.
5.2 Results
5.2.1 Calibration Curve of Rhodamine B and Fluorescence Mea-
surements
The optimal concentration of Rhodamine B (RhB) to be nebulised in order to give a read-
able fluorescence intensity on the plate reader was obtained by constructing a calibration
curve. Different concentrations were used: 1, 5, 10, 20, 37.5, 40, 50, 75, 100 µM (Fig.
5.2, (a)). A plateau value was reached at a concentration of 100 µM, which represented
a higher limit. 1 mL of 100 µM solution of RhB was nebulised using three different neb-
ulisers: (1) SAW nebuliser without the cavities, (2) SAW nebuliser with the cavities and
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Figure 5.2: (a) Rhodamine B calibration curve was made, using the fluorescence intensity, mea-
sured at wavelength λ = 590 nm, of different concentrations of RhB: 1, 5, 10, 20,
37.5, 40, 50, 75, 100 µM. The curve shows a plateau value at 100 µM. (b) Starting
from a solution of 100 µM different concentrations were obtained using a differ-
ent fraction of volume of the starting solution. A volume/concentration curve was
obtained, from which the particle size distribution was evaluated. Error bars are
smaller than the size of the point and measurements were done in triplicate.
CHAPTER 5. CASCADE IMPACTOR: PARTICLE SIZE DISTRIBUTION 119
Figure 5.3: Aerosols deposition from the nebulisation of a 100 µM solution of rhodamine B. From
the fluorescence measurements after SAW nebulisation without cavities (blue), with
cavities (red) and OMRON NE-U22 (black), higher deposition in the optimum size
range (stages 3-7) was observed for the SAW nebuliser with cavities.
(3) OMRON NE-U22. To retrieve the volume fractions for each stage of the cascade, each
collection plate was washed using 1 mL of DI water, the solution was then collected and
analysed. The fluorescence intensity was then measured at λ = 590 nm. The calibration
curve (Fig.5.2, (a)) was fitted using an exponential curve and the following equation was
obtained:
y = 9101− 9124e−0.04x (5.1)
with a coefficient of determination R2=0.99 To retrieve the particle size distribution
for each stage, after building a calibration curve, a volume/concentration curve (Fig. 5.2,
(b)) was made.
5.2.2 Fluorescence Measurements - Particle Deposition
A 100 µM Rhodamine B solution was nebulised using the SAW nebuliser with and without
cavities, and using OMRON NE-U22. After the nebulisation of 1 mL of the initial solu-
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Stage
Number
SAW
no
cavities
(%)
SAW
with
cavities
(%)
OMRON
NE-U22
(%)
Diameters
(µm)
0 15.1 4.8 26.2 9.0+
1 6.5 0.48 3.8 5.8-9.0
2 0.8 0.98 2 4.7-5.8
3 2.1 2.5 2.5 3.3-4.7
4 4.2 4.8 6.6 2.1-3.3
5 10.8 24.5 13.1 1.1-2.1
6 21.5 37.44 19.6 0.7-1.1
7 39 24.5 26.2 0.4-0.7
Table 5.1: Percentage of the delivered volume by three different nebulisers, data from Fig. 5.3
showed that higher volume fraction in the clinical validated range were produced by
the SAW nebuliser with cavities.
tion, each stage was washed with 1 mL of DI water. Fluorescence measurements for the
SAW nebulisation with cavities indicate a higher intensity of the signal and thus, a higher
volume fraction, in stages number 5 and 6, which represent the optimum range for lungs
absorption. The SAW nebuliser with cavities produced a higher percentage of aerosols
in the useful range compared to the commercial nebuliser OMRON NE-U22 (Fig. 5.3).
Regarding upper stages (Fig. 5.3), such as stage 0 and 1 (larger cut-off diameter), the
SAW nebuliser without cavities (in black) and OMRON NE-U22 (in blue) have the highest
volume fraction, producing 3 and 5 times more the volume fraction from the SAW nebu-
liser with cavities (Fig. 5.1). The SAW nebuliser without cavities, as measured also with
the laser diffraction method in Chapter 4, has a bi-modal particles size distribution, with
the highest volume fraction for aerosols larger than 9 µm. OMRON NE-U22 is composed
by a static mesh with pores around 5 µm and the size distribution from the Omron spec-
ifications of the nebuliser [238] indicates a mass median aerodynamic diameter (MMAD)
approximately of 5 µm, which is the upper limit of the respirable range. Particles with
a similar diameter to the size of the mesh aperture diameter were expected [113], but
from the impactor measurements, a bi-modal size distribution was obtained with higher
volume fractions for stages 6, 7 and stage 0. Therefore, particles with a diameter below 1
µm and above 9 µm were produced from the mesh nebuliser. Fluorescence measurements
were substituted by conductivity measurements due to the photobleaching process, which
could cause inaccurate size measurements of the aerosols and the toxicity of Rhodamine
B, which forced the entire equipment to be enclosed in a fume hood.
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Figure 5.4: A sodium chloride calibration curve was made in order to check particles size dis-
tribution from the SAW nebulisation of a 1% w/v solution. Calibration was made
with concentrations of 1%, 0.75%, 0.5%, 0.25%, 0.1% and 0.0% w/v of sodium chlo-
ride (black line). A volume/concentration curve of NaCl was also made in order to
retrieve the particles size distribution after the SAW nebulisation with the silicon
chip (blue line). Error bars are smaller than the size of the point and measurements
were done in triplicate.
5.2.3 Calibration Curve of Sodium Chloride and Conductivity
Measurements
Electrical conductivity represents the ability of a solution to transfer (conduct) electrical
current. It is used to measure the concentration of dissolved salts, which have been ionised
in a polar solvent such as water. Conductivity measurements of a sodium chloride solution
at concentrations of 1%, 0.75%, 0.5%, 0.25% and 0.1% w/v were carried out.
A volume of 1 mL of 1% w/v solution of NaCl was nebulised using SAW nebuliser with
cavities chip. An IDT with a resonance frequency of 9.68 MHz was used, with an input
power of -2/-3 dBm and the cavities on the silicon chip were ranging from 100 to 200 µm.
To retrieve the volume fractions from the different stages of the cascade, each collection
plate was washed using 1 mL of DI water and then the solutions were analysed. The
conductivity of the collected solution was normalised subtracting the value of DI water.
All the measurements were taken using a conductivity meter (Jenway, Cole-Parmer, UK),
which was first calibrated. The calibration curve was fitted linearly using the following
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equation:
y = 19x (5.2)
with a coefficient of determination R2=1. After measuring the conductivity of each
stage of the impactor, the calibration curve (Fig. 5.4, black line) equation was re-
versed and the NaCl (% w/v) associated to each stage was evaluated by means of a
volume/concentration curve (Fig. 5.4, blue line). The total volume delivered by the SAW
nebuliser was 74% of the total volume.
Figure 5.5: Aerosols deposition of a 1% w/v solution of NaCl from the SAW nebulisation with
cavities (100-200 µm). Each collection plate of the cascade was washed with 1 mL
and the conductivity associated with each plate was measured.
5.2.4 Conductivity Measurements - Particle Deposition
Conductivity measurements of the SAW nebulisation with cavities of 1 ml of NaCl, 1%
w/v solution were carried out. From the conductivity/volume curve a percentage of the
volume deposited on each stage was evaluated with: 3% of the particles being larger than
9 µm, 1% between 2.1-3.3 µm, 10% between 1.1-2.1 µm, 21% between 0.7-1.1 µm and 26%
between 0.4-0.7 µm (Fig. 5.5). The measurement taken after the SAW nebulisation with
cavities showed a particle size distribution with a prevalence of particles between 0.5-2.1
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Figure 5.6: Percentage of the delivered volume by three different nebulisers, the data showed
that higher volume fraction in the clinical validated range (stage 5) were produced
by the SAW nebuliser with cavities.
µm, which means that the higher volume fraction of the produced aerosols were within
the optimum respirable range of aerosols [239].
A comparison of aerosols’ size produced by the three nebulisers: (1) SAW nebuliser
without silicon chip, (2) SAW nebuliser with the silicon chip and (3) OMRON NE-U22
was also made. The silicon chip used was with 400 µm cavities. A shift towards larger
droplet is represented compare to Fig. 5.5, for which the nebulisation occurred through a
100-200 µm cavities. Regarding the comparison between the three nebulisers, as shown in
Table 5.2, the higher particles fraction, correspondent to stage 3 to 7, was obtained by the
SAW nebulisation with cavities, with a percentage of 81.16%. For SAW with no cavities
the volume fraction in the optimal range was of 39.78% with the majority of aerosols larger
than 9 µm and for the OMRON NE-U22 the volume fraction in the useful range was of
57.59%. The SAW nebuliser with cavities demonstrated to produce 89.16% of the total
volume in the form of aerosols with a diameter between 1 µm and 5 µm.
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Stage
Number
SAW
no
cavities
(%)
SAW
with
cavities
(%)
OMRON
NE-U22
(%)
Diameters
(µm)
0 7.11 3.08 8.84 9.0+
1 1.91 1.38 6.78 5.8-9.0
2 1.43 1.33 4.22 4.7-5.8
3 2.06 1.80 14.49 3.3-4.7
4 2.48 8.75 23.02 2.1-3.3
5 10.62 40.47 16.34 1.1-2.1
6 15.32 23.90 2.86 0.7-1.1
7 9.30 6.24 0.88 0.4-0.7
Table 5.2: Percentage of the delivered volume by three different nebulisers, data from Fig. 5.6
showed that higher volume fraction in the clinical validated range were produced by
the SAW nebuliser with cavities.
5.2.5 Liposome Size
Pre-formed liposomes were made through extrusion and nebulised using SAW. Dynamic
light scattering was utilised to measure the size of the liposomes before and after the
nebulisation. Size stability of extruded liposomes was also measured on each stage of the
cascade impactor. A sample of 100 µl was collected from each stage. Same size liposomes
of the pre-nebulised sample were found in each stage. The result represented a proof of
concept that the SAW nebuliser was able to deliver intact liposomes in the lower stages
of the cascade and that the aerosol size was in the respirable range. Figure 5.7 shows the
presence of liposomes in each stage of the cascade, maintaining the same size 100-200 nm
in diameter of the initially extruded liposomes.
5.3 Discussion and Conclusion
The work carried out in this Chapter was aimed to measure the particle size distribu-
tion and compare the output from the SAW nebuliser with and without cavities to the
commercial nebuliser OMRON NE-U22, but also to have a proof of concept of the SAW
nebuliser's capability to deliver liposomes to different stages of the impactor.
The cascade impactor represents one of the standard characterisation methods that is
widely accepted by regulatory bodies to measure the size of the aerosol distribution [240],
but there are three major drawbacks about this method, such as it is time-consuming,
the particles can bounce and end up in a stage that does not depends on the aerody-
namic diameter and finally particles can be subjected to evaporation. Therefore, the size
distributions can be skewed towards smaller sizes [197]. An improvement could be ob-
tained increasing the humidity of the environment, and in order to reduce the losses of
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Figure 5.7: Dynamic light scattering measurements of the extruded liposomes after collection
with the cascade impactor. The graph shows the SAW nebuliser ability to deliver
100-200 nm in different stages of the impactor, displaying the same liposomes size
distribution over all stages.
the aerosols and increase the delivered volumes a box around the mouthpiece on top of
the cascade and the SAW device can be made. This could avoid the flow from the fume
hood to interfere. Also, more suitable mouthpiece can be designed. Generally, the data
collected from cascade impactors are used to validate the performance of pharmaceutical
inhalation products. Different groups [194], [136] employed cascade impactors to test the
droplet size produced by SAW nebulisation or jet and ultrasonic nebulisers [241]. Regard-
ing the SAW nebulisation, the delivery of peptides and antibodies was carried out, using
afterwards high-performance liquid chromatography (HPLC) to test the concentration of
the peptides in each stage and using Bradford assay for antibodies'concentration [139].
Previously in Chapter 4, the particle size distribution of the SAW nebuliser with cavities
was measured by a laser diffraction method. In this Chapter, the in-vitro performance of
the SAW nebuliser with cavities was compared to the OMRON NE-U22 and alternative
assays to HPLC were found to retrieve the volume fraction of the nebulised particles in
each stage. Conductivity measurements were carried out to obtain the particle size distri-
bution of the aerosols produced by the SAW. For the conductivity measurements, the SAW
nebuliser with cavities of 100-200 µm pores was employed and a particle size distribution
with the majority of the aerosols produced (more than 90%) in the respirable range. A
shift towards larger particles was found when a silicon chip with cavities of 400 µm was
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used, with 81.16% of aerosols produced in the respirable range. Fluorescence measure-
ments were also made to test the efficiency in producing aerosols in the optimum range of
three different nebulisers: SAW nebuliser with and without cavities and the commercial
nebuliser OMRON NE-U22. The SAW nebuliser with cavities presented higher deposition
in stages 3, 4, 5 and 6 with the larger number of aerosols within the optimum aerosols
range 0.5-5 µm. The particle size distribution was obtained through a calibration curve
and a volume/concentration curve, which was then converted to the percentage of the
volume in each stage. The fluorescence measurements were replaced by the conductivity
measurements due to the photobleaching process which was affecting the recovery of the
particles size distribution. The use of conductivity has not been previously used to assess
the particle size distribution from the Andersen cascade impactor. It resulted in a fast
way to obtain the volume fraction of each stage after the nebulisation.
The results from the SAW nebulisation with cavities showed in Tables 4.1 and 5.2,
confirmed the same particle size distribution obtained previously (Chapter 4) using the
laser diffraction method. Using the impactor, cavities of 100 µm) and 400 µm were tested,
which have been proven to produce a monodisperse particle size distribution [132].
Extruded liposomes were nebulised through SAW nebuliser with cavities and their
presence was found in each stage, as shown in Fig. 5.7. DLS measurements showed the
presence of vesicles of 100 nm in diameter after washing the stages with the buffer. Nega-
tive control was run, nebulising the buffer without extruded liposomes in the solution, and
from the DLS measurement, the analysed sample was indicated as blank. Liposomes were
efficiently delivered on different stages of the cascade. The in-vitro analytical characteri-
sation of droplet size from SAW nebulisation was performed, indicating a high potential of
the SAW platform to deliver successfully liposomes and produced aerosols in the clinically
validated range.
Chapter 6
SAW Nebulisation of siRNA and
DNA for Gene Therapy
6.1 Context and Aim of Result Chapter
The increasing interest in gene therapy and the difficulties to deliver naked nucleic acids
into cells, mainly due to the negative charge of their phosphate component, is the main
motivation of the work carried out in this Chapter. Therefore, the work accomplished in
this Chapter hopes to address this issue with the following aims:
• show that the SAW nebulisation did not alter the nucleic acid’s structure
• demonstrate the feasibility of using a SAW-based device for cell transfection, through
the delivery of a DNA luciferase plasmid and GAPDH siRNA to A549 epithelial lung
cancer cells
• test the formation of liposomes during the nebulisation process
• compare the effect of extruded liposomes and SAW-formed liposomes in delivering
nucleic acids.
A gel retardation assay was employed to assess if the SAW nebulisation was suitable
to nebulise nucleic acid without modifying their structure, as described in Section 2.8.4.
Then the platform was used to test the efficiency in delivering DNA plasmid and GAPDH
siRNA, with the production in-situ of the lipid/nucleic acid complex during the nebulisa-
tion process, as reported in Section 1.11.1.
The use of a SAW device allows the integration of the manufacture of nucleic acid-
liposome complexes with the delivery of the nebulised particles to target cells.
127
CHAPTER 6. SAW NEBULISATION FOR GENE THERAPY 128
6.2 Results
6.2.1 Gel Retardation Assay
Figure 6.1: Gel retardation assay of HS-DNA before and after SAW nebulisation. The similar
intensities of the two bands (A. HS-DNA solution before SAW and B. Solution
with DI water and C. same solution of A. but after SAW nebulisation) indicate the
suitability of SAW for the nebulisation of nucleic acids.
Figure 6.2: Gel retardation assay of DOTAP:cholesterol (4:1) and lipid-siRNA complexes pre-
pared at 2:1, 10:1, 20:1 and 30:1 ratios (w/w). Lipid vesicle and siRNA complexes
were incubated for 30 min.
Results from a gel retardation assay were analysed, for which samples were collected
before and after nebulisation, the assay was performed as described in Section 2.8.4. Im-
ageJ was used to compare the intensities of the bands (Fig. 6.1). Band A., which was a
sample containing HS-DNA and not subjected to SAW, was used as a control. Band B.
was a sample containing DI water, and used as a negative control, and Band C. repre-
sented the same sample as band A. but after SAW nebulisation. The results show that
SAW nebulisation did not harm the structural integrity of the nucleic acids. Thus, it is
a suitable means of nebulisation for the delivery of nucleic acids. A gel retardation assay
was then performed to test the binding affinity of lipids and siRNA complexes. Cationic
liposomes were formed by the extrusion method, described in Section 2.4.3 following the
method described in Section 2.4.1. Results from the gel show a decrease in the band
intensity as the lipid to siRNA ratio was increased, up to 20:1, past which the intensity
increased again up to 30:1. Naked siRNA was saturated by lipid vesicles before the 30:1
ratio. The complete disappearance of the band when the ratio was 10:1 indicated full
binding of the nucleic acids to the lipid vesicles. The optimal lipid to siRNA ratio was
found to be between 2:1 and 10:1 (Fig. 6.2). Further measurements determined the best
ratios for DOTAP:Chol and lipid:siRNA to be 4:1 and 6:1 respectively.
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Figure 6.3: A549 cells were seeded in a 96-well plate. 24 h post-transfection, lipid vesicles
complex bound with GAPDH siRNA were added to cells in order to test their
toxicity. After 4 h, MTT solution (0.8 mg/ml) was added to the cells. After 2 h, the
formazan precipitate was dissolved in 100 µl isopropanol and the absorbance was
measured at λ = 595 nm. The graph shows the mean of three measurements and
the error bars represent the SD.
6.2.2 MTT Cytotoxicity Assay
In order to test the cytotoxicity of the complexes towards A549 cells, the MTT assay was
performed at 24 h post-transfection, as described in Section 2.8.6. As a control, samples
that were subjected to the same changing of the medium as other samples, but not actually
transfected, were included, so as to account for cells being removed or damaged during
the changes of medium. For all the complexes prepared with lipid to siRNA ratios of up
to 20:1, cell viability was over 80%. The lipid concentration was kept below 20 µg/mL.
As shown in Fig. 6.3, the MTT assay showed that there were no significant differences in
cell viability between the samples with the siRNA-lipid complexes and the control with
Lipofectamine 2000. Compared to the untreated sample, the sample with phospholipids
showed a decrease in cell viability of around 30%. An MTT assay of the sole lipid vesicles
was also carried out. The result shows higher viability of the cells in the case of the
delivery of the sole liposomes compare to the lipid:siRNA complexes (see Appendix E,
Fig. E2), which was expected to due to the fact that the lipid:siRNA complex entered
into the cells.
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Figure 6.4: DNA luciferase luminescence measurements. Naked DNA and DNA bound with
Lipofectamine 2000 were used as controls. Two different DOTAP:cholesterol lipid
ratios - 4:1 and 2:1 - were tested. For each of them, different ratios of lipid to DNA
were made in order to check the efficiency of the carrier. The graph shows the mean
of three measurements and the error bars represent the SD.
6.2.3 DNA Transfection - Luciferase Assay
DNA transfection efficiency was tested using the Luciferase assay (see Section 2.8.2).
The DNA luciferase plasmid was tested in different ratios in order to determine the best
lipid carrier. Lipofectamine 2000 was used as a carrier control. For all of the samples,
the luciferase signal was at least as high as for Lipofectamine (Fig. 6.4). The results are
reported in terms of relative unit lights (RLU)/mg of protein. After obtaining RLU values
from the luminometer, the Bradford assay, described in Section 2.8.3, was performed to
evaluate the protein concentration in each sample. The results showed that lipid carriers
made of DOTAP and cholesterol successfully delivered the DNA plasmid into cell nuclei,
slightly better so at lower lipid to siRNA ratios. DOTAP:cholesterol vesicles are therefore
a suitable carrier for DNA luciferase plasmid transfection.
6.2.4 Luciferase Assay Calibration - DNA quantification
In order to evaluate and compare the effectiveness with which different concentrations of
DNA were delivered by the SAW platform, with that delivered by standard transfection,
a calibration curve for standard transfection was generated. Different concentrations of
DNA were delivered: 0, 0.25, 0.5, 0.75, 1.00, 1.50, 2.00, 2.50 µg/mL, in triplicate.
The curve was fitted with a third-degree polynomial equation, although between 0.75
µg/mL and 1.5 µg/mL the RLU signal increases linearly (Fig. 6.5).
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Figure 6.5: Luminescence measurements were made following the standard transfection of differ-
ent concentrations of DNA luciferase plasmid. 0, 0.25, 0.5, 0.75, 1.00, 1.50, 2.00, 2.50
µg/mL of DNA were delivered in triplicate. A dose-response curve was obtained.
6.2.5 SiRNA Transfection: GAPDH siRNA
The efficiency with which GAPDH siRNA was transfected was tested in A549 cells us-
ing DOTAP-cholesterol vesicles as the siRNA carrier and verifying the gene knock-down
through western blot, described in Section 2.8.5. Lipofectamine 2000 was used as a carrier
control. The various ratios of lipid carriers used to deliver GAPDH siRNA all resulted in
the knock-down of GAPDH expression. Over 50% knockdown resulted after using DOTAP
-cholesterol at a 4:1 ratio and a lipid - siRNA ratio of 6:1; there was no significant difference
between these results and those obtained from the use of Lipofectamine 2000.
Two samples with the same ratio of lipid-nucleic acid in complexes were transfected
into A549 cells, with a positive control GAPDH siRNA and a negative control GAPDH
siRNA. From the western blot (Fig. 6.6), samples transfected with the positive control
GAPDH siRNA show a lower intensity of the GAPDH band compared to the same sam-
ples transfected with the negative control siRNA. This confirms that the GADPH siRNA
entered the cytoplasm and blocked the expression of the protein. β-actin was used as
an internal control, and showed a similar intensity of band across all the samples. The
densities of the GADPH bands were normalised to those of β-actin.
6.2.6 SAW DNA Transfection
After testing the transfection efficiency of DOTAP-cholesterol extruded vesicles using stan-
dard cell culture transfection, SAW nebulisation-based transfection was tested for the de-
livery of the nucleic acid directly into cells, the equipment used is described in Section 2.9.2
and 2.9.2. In both methods, extruded cationic liposomes (d = 200 nm) and multilamellar
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Figure 6.6: Western blot of lipid - siRNA complexes prepared with: A. DOTAP-Cholesterol ratio
of 4:1, 2.4 mg/mL and a lipid-siRNA ratio of 6:1 or 10:1. B. DOTAP-Cholesterol
ratio of 2:1, 2.4 mg/mL and ratio of lipid-siRNA of 6:1, 10:1, or 20:1. RE samples
were prepared by the hydration of the lipids. (+) indicates transfection with the
positive GAPDH siRNA, and (-) with negative control siRNA. In each sample,
the density of the band for (+) samples is lower than in those transfected with
negative control siRNA (-). This demonstrates the successful knockdown of GAPDH
expression in A549 cells.
vesicle mixture (MLVs 2.4 mg/mL, 4:1 DOTAP:chol), and a lipid:DNA ratio of 6:1 were
used for transfection (see Section 2.4.1).
The amount of DNA delivered by upright SAW nebulisation-based transfection was
lower than that delivered by standard transfection (Fig. 6.7). This could be due to loss of
DNA during nebulisation. The experiments were carried out in a cell culture fume hood,
the air flow inside which could have reduced the capture efficiency. Using the upside-down
nebulisation setup, comparable results were obtained from the standard and SAW-based
transfection methods for MLV dispersion (Fig. 6.8), indicating that the upside-down setup
reduced the loss induced by the nebulisation process. LUV STD is the sample made of ex-
truded liposomes bound with DNA, and MLV STD is made of multilamellar vesicles bound
with DNA. Both solutions were also delivered using the standard transfection method. To
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Figure 6.7: Comparison between the untreated sample, standard transfection of extruded lipo-
somes and SAW transfection with the upright nebulisation setup (Section 2.9.2 of
MLV mixture. The luminescence value of the SAW-transfected sample is very low
compared to that of the standard transfected one, although higher than that of the
untreated sample. The main reason for this is loss during SAW nebulisation. The
graph shows the mean of three measurements and the error bars represent the SD.
**p<0.01
test the efficacy of the lipid carriers formed during SAW nebulisation, an MLV mixture
(the same solution that was used for transfection by the standard method) was transfected
using SAW. The unilamellar vesicles formed during SAW nebulisation were similar to those
produced by extrusion and transfected by the standard method (Fig. 6.8). Therefore, it
is proved that: (1) SAW nebulisation of MLVs mixture obtained the same transfection
efficiency than the standard transfection with pre-formed liposomes; as a consequence,
during the SAW nebulisation, unilamellar vesicles are formed, (2) MLV mixtures were
delivered both using the standard and SAW nebulisation, showing a higher transfection
efficiency with SAW.
This demonstrates that the SAW nebuliser is an optimal platform for pulmonary drug
delivery that eliminates the lipoplex production step and delivers DNA to cell nuclei
quickly and efficiently.
Multilamellar vesicles with DNA at concentrations of 3.33 µg/mL and 6.66 µg/mL
(Fig. 6.9), were transfected using both standard method and SAW nebulisation. During
the nebulisation, the formation of LUVs showed an improved transfection of DNA into the
cell. The standard transfection of MLVs resulted in a lower signal of the luciferase, due
to the fact that the MLV mixture is made of a heterogeneous population of the vesicle.
It is also demonstrated that increasing the DNA concentration and amount of lipids (so
that the lipid:DNA ratio of 6:1 is maintained), the amount of DNA delivered increases.
This study demonstrates the suitability of using a SAW-based nebuliser to deliver a DNA
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Figure 6.8: DNA luciferase transfection was carried out using both STD, the standard transfec-
tion method, and the SAW nebulisation-based method with the optimised upside-
down setup. Both extruded cationic liposomes and multilamellar lipid solution were
used as carriers. SAW-based and standard transfection were compared in order to
test the feasibility of using the SAW platform to nebulise nucleic acids for drug
delivery in the lungs. For the standard transfection of naked DNA and the SAW
transfection of naked DNA, the delivered DNA resulted almost null. The standard
transfection of extruded liposomes and the SAW transfection of MLV mixture ob-
tained comparable signals, indicating the formation during the SAW nebulisation of
the nucleic acid carriers. When using the same lipid solution MLVs but through the
standard transfection method, a lower transfection efficiency, 30% reduction of the
signal, was reported, which can be explained by the fact that unilamellar vesicles
were forming during the SAW nebulisation. The graph shows the mean of three
measurements and the error bars represent the SD. *p<0.05, **p<0.01
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Figure 6.9: SAW transfection was employed to transfect the same MLV mixtures, bound with
DNA at a concentration of 3.33 µg/mL and 6.66 µg/mL, but using standard trans-
fection method and SAW nebulisation. SAW transfection of MLVs resulted in 50%
higher signal compared to the standard transfection method of MLVs. It is shown
that: (1) increasing the DNA concentration and amount of lipids (so as to maintain
the 6:1 lipid:DNA ratio), increased the amount of DNA delivered, (2) during SAW
nebulisation compared to standard transfection the formation of LUVs occurred,
which increased the quantity of DNA that entered into the cell. *p<0.05, **p<0.01,
***p<0.001
plasmid, whilst simultaneously forming the nucleic acid carriers that assist its entry into
the cell nuclei.
6.2.7 SAW GAPDH siRNA Transfection
The efficiency of transfecting GAPDH or negative control siRNA by SAW nebulisation was
tested, with DOTAP-cholesterol vesicles as the siRNA carrier. Nebulisation was performed
for 2 min inside the well containing the A549 cells, as described in Section 2.9.2. The stan-
dard cell culture transfection method was also used for comparison. With both methods,
decreases in GADPH expression compared to the untreated sample (UT) were observed,
confirming the cellular uptake of the GAPDH siRNA. No significant differences in remain-
ing GAPDH expression were noticed following transfection by the two different methods,
demonstrating that the SAW nebuliser is a similarly efficient method of delivering siRNA
into the cells. GADPH was knocked down by over 50% when the DOTAP:cholesterol ratio
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Figure 6.10: siRNA GAPDH transfection was carried out using extruded cationic liposomes as
a carrier. SAW-based and standard transfection methods were compared. (A) Un-
treated sample, (B) Standard transfection of extruded LUVs and (C) SAW trans-
fection of MLVs. Results show the comparable performance of the SAW-based and
standard transfection methods.
was 4:1 and the lipid:siRNA ratio was 6:1. Similar samples (containing 1.6 × (10)5 cells)
were transfected with DNA at 2.00 µg/mL for standard transfection, and 3.33 µg/mL for
SAW transfection, along with a (-) negative control siRNA and a (+) GAPDH siRNA.
From the western blot (Fig. 6.10), it is clear that the density of the band for the GAPDH
siRNA sample is lower than that for the negative control siRNA sample, indicating knock-
down of GAPDH expression, and thus the successful entry of the siRNA into the cyto-
plasm. In order to quantify the knockdown, the densities of the bands were normalised to
those of β-actin.
6.2.8 Confocal Microscopy
Live confocal imaging was used to check the efficiency of transfection by the SAW neb-
ulisation platform compared to that of the standard cell culture transfection method,
as reported in Section 2.9.3. A solution of DOTAP-cholesterol (4:1) at 2.4 mg/mL was
prepared - without pre-forming - liposomes, in order to check if the SAW nebulisation
process was able to form the siRNA carriers and then deliver the complexes into the cells.
MISSION siRNA Fluorescent Universal Negative Control conjugated to 6FAM was added
in the solution, and incubated with the cells for 30 min. Cell nuclei were stained using
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Hoechst (blue stain). As showed in Fig. 6.11, standard transfection was not successful
in delivering siRNA into the cell cytoplasm, because unilamellar lipid vesicles were not
forming that would facilitate cell entry. As shown in Fig. 6.12, SAW transfection resulted
in the efficient delivery of siRNA due to the formation of liposomes during the nebuli-
sation process, creating small lipid carriers that facilitated entry of the siRNA into the
cells (see Appendix B Fig. E4). In order to be sure that siRNA entered the cells, and to
remove any unbound siRNA, the wells containing the cells were rinsed 10 times in PBS
and then visualised under a confocal microscope. The concentration of siRNA around the
nuclei is clear in the SAW-transfected samples compared with those subject to standard
transfection of the MLV solution.
6.2.9 Discussion and Conclusion
The work carried out in this Chapter demonstrates the feasibility of using a SAW nebuliser
as a method of transfecting nucleic acids into cells. It represents a step towards the in-
vivo testing of the platform. The SAW nebuliser successfully delivered nucleic acids such
as DNA luciferase plasmid and GAPDH siRNA to A549 lung epithelial carcinoma cells,
showing that the SAW nebuliser constitutes a versatile new tool for gene therapy. A gel
retardation assay showed that SAW did not destroy the functionality of either the DNA
luciferase plasmid or the GAPDH siRNA.
Different compounds can be carried in different parts of the lipid carrier for delivery
via the SAW platform; a polar compound can be encapsulated in the inner hydrophilic
core or bound with the polar headgroups in the outer layer, while hydrophobic material
can be carried within the membrane.
The in-vitro experiments confirmed that once the nucleic acids reached the deep lung,
by means of SAW nebulisation coupled with a mesh structure, the DNA or siRNA can be
absorbed effectively by the cells. Only the SAW nebulisation platform has the capabilities
of delivering an aerosol within a specific size range, whilst simultaneously forming the
vectors for the delivery of nucleic acids in gene therapy. It also overcomes stability issues
with respect to the drugs or other compounds bound to the liposomes. The platform could
have different compartments, separately containing the active compound and the lipid
solution, preventing them from being mixed until patient treatment is to be commenced.
One of the main innovative aspects of the SAW platform is the formation of the carriers for
the nucleic acids or drugs during the nebulisation process itself. It achieves greater delivery
efficiency compared methods proposed by other groups work [137]; the SAW platform
transfected DNA of concentration 100 times lower with even greater efficiency. Advantages
of forming the lipoplexes dynamically during the aerosol formation process are not only
that it assists the entry of the nucleic acids into the cells, but that it is also less time-
consuming compared to the production of liposomes by the standard method (extrusion).
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Figure 6.11: Confocal Images of A549 cells at 4 h post-transfection. The cell was transfected
by standard transfection. A lipid-siRNA mixture was used, made of DOTAP-
cholesterol (4:1) in 5% glucose, with a lipid-siRNA ratio of 6:1. Cell nuclei (blue)
were stained with Hoechst. No cellular uptake resulted from the standard trans-
fection of the lipid-siRNA mixture. The wells containing the cells were rinsed 10
times using PBS and then visualised under the confocal microscope. Scale bar 40
µm.
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Figure 6.12: Confocal Images of A549 cells at 4 h post-transfection. Cell were transfected by
SAW transfection. A lipid-siRNA mixture identical to that used for standard
transfection was used, made of DOTAP-cholesterol (4:1) in 5% glucose, with a
lipid-siRNA ratio of 6:1. Regarding SAW transfection, a total volume of 200 µl
solution was nebulised for 2 min. siRNA (green) was labelled; the nuclei (blue)
were stained with Hoechst. High cellular uptake resulted from SAW transfection,
showing that lipid vesicles were formed during SAW nebulisation that were able to
act as siRNA carriers. Scale bar 40 µm.
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Using the SAW platform, three different steps can be integrated into one, increasing the
efficiency of delivery, reducing the operation time, and improving the stability of the
active compound. Despite the numerous advantages of the SAW nebuliser platform thus
far demonstrated, there are still some improvements to be made, such as optimising the
setup to even further minimise DNA loss. The last Chapter will describe future work to be
done in order to test the SAW platform in-vivo in a small animal model and will illustrate
the designs of both an integrated platform and a mouse inhalation chamber.
Chapter 7
Conclusion and Future Works
7.1 Summary of Findings and Conclusion
Lungs diseases affect millions of people lives. Engineering and biology tools could help in
solving this problem, creating an efficient pulmonary drug delivery system. The respiratory
tract is one of the oldest routes employed to deliver drugs. Although the term 'aerosol 'was
coined only around 1920, the inhalation therapy for asthma was born at least 4,000 years
ago in India with cigarettes made of herbal mixture. Since then, a lot of improvements were
made in the aerosol therapy field, but there is still a lack of control in current nebulisers
on the market. As mentioned in the introduction (see Chapter 1), an effective nebuliser
delivers the drug in a targeted way with minimum wastage and at a low-cost [6]. That
means tight control over the produced droplet size and the formation of a drug carrier
to help the entry of compounds across cell membranes. Plus, to reduce the cost of the
nebuliser production, the employment of disposable superstrates on top of the nebuliser
and the versatility of the platform to be used with a different type of compounds can be
of help. It is the first SAW nebuliser which is able to have precise control over the size of
the droplets and that is capable to produce liposomes/nucleic acid complexes during the
nebulisation.
The aim of this thesis was to develop a pulmonary drug delivery platform, which has
all the features previously mentioned and that can deliver complex compounds, such as
nucleic acids into lung cancer cells. The main findings in this study will be divided per
chapter.
In Chapter 3, differently from the ultrasonic nebuliser, which caused damage to lipo-
somes during the nebulisation process, SAW nebulisation was proven to be suitable to
nebulise pre-formed liposomes of 100 nm in diameter. The stability of the liposomes was
measured using DLS to check the size before and after nebulisation and also using an
indirect method as the HRP assay. The liposomes encapsulating HRP were voluntarily
solubilised in order for the HRP to react with the substrate, showing an increased in op-
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tical depth, after the nebulisation. In Chapter 4, a study about the control of the size
of the aerosols was made. Previous reports have shown a correlation between wavelength
on the surface of liquid and median droplet size of the resulting aerosol. By manipulat-
ing the liquid length scale, using a microfabricated silicon chip, the waves on the surface
of a vibrating liquid were controlled and consequently the size of the nebulised droplets.
Changing the liquid length scale and confining the volume in small wells of 100 µm in
diameter, the shorter wavelength of the surface waves (capillary wavelengths) were cre-
ated and thus, smaller aerosols. Another finding in this chapter is regarding the formation
of unilamellar vesicles in-situ in the SAW platform. The SAW nebulisation with power
around 5 W, gives the energy to break down multilamellar vesicles in phospholipid frag-
ments, which in contact with water closed immediately themselves, due to the hydrophobic
effect of the hydrocarbon chains. It has to be mentioned that a relationship between the
cavities size and the size of the vesicles encapsulated in the aerosol, was not found. For
cavities size below 800 µm, in diameter, vesicles of 100 nm encapsulated in aerosols of
around 2 µm were found. For cavities size above 800 µm, same size of vesicles (100 nm
in 2 µm aerosols) were found and also vesicles of 2.5 µm in diameter encapsulated in 100
µm aerosols. The polar heads of the phospholipids are exposed to the inner core and the
outer solution, forcing the liposomes to have a layer of water, which are surrounding them.
There is a minimum amount of water that has to be around the liposomes. Changing the
cavities size and consequently the size of the aerosols, we are indirectly filtering different
size of liposomes. The big advantage of this new method to form liposomes is that in one
single step, we produced the drug carrier encapsulated in aerosols of the optimum size
range for lungs absorption.
In Chapter 5, the Andersen cascade impactor, a standard characterisation method to
evaluate the aerosol size, was employed to measure the particle size distribution from the
SAW nebulisation. Two methods (conductivity and fluorescence measurements) were used
to test the collected aerosols in each stage of the impactor and the results confirmed the
same size distributions obtained previously (see Chapter 4) with laser diffraction measure-
ments. Also, a comparison with the mesh nebuliser OMRON NE U-22 was made, showing
a larger production of particles in the optimum range from the SAW nebuliser.
Finally, in Chapter 6, an in-vitro study of the platform was made. We demonstrated
that the SAW nebuliser is capable of delivering nucleic acids of different size (in base
pairs), such as DNA luciferase plasmid and GAPDH siRNA. Firstly, it was showed that
the SAW nebulisation did not alter the structure of DNA and siRNA. Then, the production
of a carrier, during the nebulisation was confirmed, comparing the nebulisation of naked
nucleic acid with the MLVs dispersion with nucleic acids. The results highlighted the
role of the positively charged phospholipids in helping the nucleic acid to cross the cell
membrane and enter the nucleus or cytoplasm, in siRNA case.
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Figure 7.1: Prototype of the SAW nebuliser. The back side will contain AAA type batteries,
while the front part will be composed by the Peltier and heat sink, with 2 reservoirs,
one for the MLVs mixture and the other for the compound to deliver. On top of it,
there will be the IDT and the silicon chip.
In conclusion, the work carried out in this thesis showed a new device for pulmonary
drug delivery, which is capable of delivering biologics, thanks to the formation in-situ of
liposomes that can guide the nucleic acids into the cells. It is also shown the control of
the aerosols’ size during the nebulisation, through the use of silicon chip, which is one of
the main critical parameter for a targeted delivery of the compound into the lungs.
7.2 Future Works
As future works, in-vivo testing of the SAW nebulisation platform will be carried out. The
aim is to prove that using the platform we can deliver different compounds in deep lungs
in small animal models.
In order to have less variability in the measurements, an optimised design is needed.
Fixed position of the IDT, silicon chip and a feeding tube can increase the reproducibility
of the experiments and the portability of the setup. A prototype of the nebuliser will be
built. As shown in Fig. 7.1, the SAW neb platform will have two chambers, one for the
power supply and the first part will be dedicated to the nebuliser. The first chamber will
contain two reservoirs one for the drug carrier mixture and the other for the compound to
deliver. The IDT and the silicon chip will be placed on top of it. Both laser cutting and 3D
printing will be employed to build the prototype. Moreover, a mice inhalation chamber will
be designed. Figure 7.2 shows a nose-only exposure chamber (CH technologies, USA) used
by Mainelis et al, [82]. The containment tubes are connected to the distribution chamber,
the nebuliser was placed outside and connected to the distribution chamber. The SAW
nebuliser could be placed inside the distribution chamber to reduce the loss during the
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Figure 7.2: A 5 port nose-only inhalation exposure chamber from CH Technologies. A distri-
bution chamber is represented with 5 mice containers. Figure adapted from [82],
where the SAW nebuliser was placed in the center of the distribution chamber.
nebulisation, as shown in Fig. 7.2, [82]. The advantage of using a nose-only inhalation
exposure system is the elimination of alternative exposure routes, like dermal absorption.
A drawback of the system is the animal discomfort, created by the limited space, which
raises ethical concerns, causing also animal's hyperventilation (Fig. 7.4, (B)). Da Silva et
al. [242], adapted an Erlenmeyer flask as a nose-only inhalation chamber. Other methods
to deliver compounds in-vivo are the intratracheal delivery (Fig. 7.4, (C)) or using a whole
body inhalation exposure chamber (Fig. 7.4, (A)), which will reduce the animal stress but
will increase the wastage and includes other delivery routes.
7.2.1 In Vivo Experimentation
In animal studies and clinical trials, one of the most important components of the design
of an experiment is the calculation of sample size, which is needed to answer a research
question [243]. If a lower number of animals is selected, the study could be not representa-
tive of the population and the real effect in the experiments can be missed. On the other
side, if the sample is too large, it leads to a wastage of resources and ethical issues. To
calculate the sample size, two different calculations can be made, one is the power analysis
and the second is called the resource equation We want to prove the SAW Nebulisation
platform efficiency in delivering compounds in lungs. Thus, in the power analysis, two
hypotheses are considered [244]:
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Figure 7.3: A 4 port nose-only inhalation exposure chamber from Silva et al., [242], where
an Erlenmeyer flask was adapted and used as a distribution chamber. Inhalation
chamber coupled with nebuliser. From [242], (1) animal holder; (2) lid; (3) later
hooks; (4) central part; (5) head; (6)silicon hose; (7) glass joint; (8) nebuliser cup;
(9) nebuliser; (10) sampling port; (11) plastic screw cap; (12) air output.
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Figure 7.4: Different in-vivo delivery method. (A) Total body exposure chamber. (B) Nose-only
inhalation exposure chamber. (C) Intratracheal instillation. Fig. adapted from [245]
• the null hypothesis implies no difference or effect of the study
• the alternative hypothesis states a statistical significance between two measured
phenomena
In this future study, a proof of concept that shows the efficiency of SAW nebuliser to
deliver nucleic acids in mice lungs will be carried out.
Power analysis will be employed later in this study, but here, an estimation of the
sample size using the resource equation will be shown. This method is used in exploratory
studies, where the testing of the hypothesis is not the primary objective, but only the
understanding of differences between the groups [244]. A value 'E' is measured as followed:
E = TotalNumberOfAnimals− TotalNumberOfGroups (7.1)
where experiments with 10 < E < 20 are considered appropriate. If E is less than 10,
more animals should be added to the study to increase the significance of the result. If
E is more than 20, adding more animals will not increase the significance. In our study,
three groups will be tested: (1) positive control group (intratracheal delivery), (2) negative
control group (healthy mice) and (3) SAW group. If we consider 5 mice per each group (3
in total), E = 12 is within the range of the adequate experiments.
Bibliography
[1] “WHO | Chronic respiratory diseases (CRDs)”. In: WHO (2018). url: https:
//www.who.int/respiratory/en/.
[2] William Berger. “Aerosol Devices and Asthma Therapy”. In: Current Drug Delivery
6.1 (Jan. 2009), pp. 38–49. issn: 15672018. doi: 10.2174/156720109787048203.
url: http://www.eurekaselect.com/openurl/content.php?genre=article%
7B%5C&%7Dissn=1567-2018%7B%5C&%7Dvolume=6%7B%5C&%7Dissue=1%7B%5C&
%7Dspage=38.
[3] Byron P R Patton J S. “Inhaling medicines:delivering drugs to the body through
the lungs”. In: (2007). doi: 10.1038/nrd2153. url: https://www.nature.com/
articles/nrd2153.pdf.
[4] Mariam Ibrahim, Rahul Verma, and Lucila Garcia-Contreras. “Inhalation drug de-
livery devices: technology update.” In: Medical devices (Auckland, N.Z.) 8 (2015),
pp. 131–9. issn: 1179-1470. doi: 10.2147/MDER.S48888. url: http://www.ncbi.
nlm.nih.gov/pubmed/25709510%20http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=PMC4334339.
[5] Arzu Ari. “Jet, Ultrasonic, and Mesh Nebulizers: An Evaluation of Nebulizers
for Better Clinical Outcomes”. In: Eurasian J Pulmonol 16.1 (2014), p. 7. issn:
21483620. doi: 10.5152/ejp.2014.00087.
[6] C O’Callaghan and P W Barry. “The science of nebulised drug delivery.” In: Thorax
52 Suppl 2.Suppl 2 (1997), S31–S44. issn: 0040-6376. doi: 10.1136/thx.52.2008.
S31.
[7] S P Newman and M T Newhouse. “Effect of add-on devices for aerosol drug delivery:
deposition studies and clinical aspects.” In: Journal of aerosol medicine : the official
journal of the International Society for Aerosols in Medicine 9.1 (1996), pp. 55–70.
issn: 0894-2684. doi: 10.1089/jam.1996.9.55.
[8] N. R. Labiris and M. B. Dolovich. “Pulmonary drug delivery. Part I: Physiological
factors affecting therapeutic effectiveness of aerosolized medications”. In: British
Journal of Clinical Pharmacology 56.6 (2003), pp. 588–599. issn: 03065251. doi:
10.1046/j.1365-2125.2003.01892.x.
147
BIBLIOGRAPHY 148
[9] John N Pritchard, Ross Hm Hatley, John Denyer, and Dirk Von Hollen. “Mesh neb-
ulizers have become the first choice for new nebulized pharmaceutical drug devel-
opments”. In: (). doi: 10.4155/tde-2017-0102. url: https://clinicaltrials.
gov.
[10] Julien Reboud, Rab Wilson, Yi Zhang, Mohd H Ismail, Yannyk Bourquin, and
Jonathan M Cooper. “Nebulisation on a disposable array structured with phononic
lattices.” In: Lab on a chip 12.7 (2012), pp. 1268–73. issn: 1473-0189. doi: 10.
1039/c2lc20705b. url: http://www.ncbi.nlm.nih.gov/pubmed/22327572.
[11] Leslie Y Yeo, James R Friend, Michelle P McIntosh, Els N T Meeusen, and David
a V Morton. “Ultrasonic nebulization platforms for pulmonary drug delivery.” In:
Expert opinion on drug delivery 7.6 (2010), pp. 663–679. issn: 1742-5247. doi:
10.1517/17425247.2010.485608.
[12] Yue Huang, Sung Hwan Yoon, Scott R. Heron, Christophe D. Masselon, J. Scott
Edgar, Frantisek Turecek, and David R. Goodlett. “Surface acoustic wave nebu-
lization produces ions with lower internal energy than electrospray ionization”. In:
Journal of the American Society for Mass Spectrometry 23.6 (2012), pp. 1062–1070.
issn: 10440305. doi: 10.1007/s13361-012-0352-8.
[13] Liqiang Ren, Yuchao Chen, Peng Li, Zhangming Mao, Po-Hsun Huang, Joseph
Rufo, Feng Guo, Lin Wang, J Philip Mccoy, Stewart J Levine, and Tony Jun Huang.
“A high-throughput standing surface acoustic wave (SSAW)-based cell sorter”. In:
(). doi: 10.1039/c5lc00706b. url: https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC4641751/pdf/nihms-717385.pdf.
[14] J. Reboud, Y. Bourquin, R. Wilson, G. S. Pall, M. Jiwaji, A. R. Pitt, A. Graham,
A. P. Waters, and J. M. Cooper. “Shaping acoustic fields as a toolset for microfluidic
manipulations in diagnostic technologies”. In: Proceedings of the National Academy
of Sciences 109.38 (2012), pp. 15162–15167. issn: 0027-8424. doi: 10.1073/pnas.
1206055109. url: http://www.pnas.org/cgi/doi/10.1073/pnas.1206055109.
[15] Tao Wang, Ryan Green, Rajesh Ramakrishnan Nair, Mark Howell, Subhra Mo-
hapatra, Rasim Guldiken, Shyam Sundar Mohapatra, Zhiping Wang, and Charles
Chun Yang. “Surface Acoustic Waves (SAW)-Based Biosensing for Quantification
of Cell Growth in 2D and 3D Cultures”. In: Sensors 15 (2015), pp. 32045–32055.
doi: 10.3390/s151229909. url: www.mdpi.com/journal/sensors.
[16] Minoru Kurosawa, Takayuki Watanabe, Akira Futami, and Toshiro Higuchi. Sur-
face acoustic wave atomizer. 1995. doi: 10.1016/0924-4247(96)80086-0. url:
http://linkinghub.elsevier.com/retrieve/pii/0924424796800860.
BIBLIOGRAPHY 149
[17] Leslie Y Yeo, James R Friend, Michelle P McIntosh, Els NT Meeusen, and David
AV Morton. “Ultrasonic nebulization platforms for pulmonary drug delivery”. In:
(1742). doi: 10.1517/17425247.2010.485608. url: https://pdfs.semanticscholar.
org/6d7f/9377c5d016c89fa90a903b6d0a47a59ffa8e.pdf.
[18] James R Friend, Leslie Y Yeo, Dian R Arifin, and Adam Mechler. “Evaporative
self-assembly assisted synthesis of polymeric nanoparticles by surface acoustic wave
atomization Recent citations This content was downloaded from IP address Evapo-
rative self-assembly assisted synthesis of polymeric nanoparticles by surface ac”. In:
NANOTECHNOLOGY 19 (2008), p. 6. doi: 10.1088/0957-4484/19/14/145301.
url: http://iopscience.iop.org/article/10.1088/0957- 4484/19/14/
145301/pdf.
[19] Leslie Y. Yeo and James R. Friend. “Surface Acoustic Wave Microfluidics”. In:
Annual Review of Fluid Mechanics 46.1 (2014), pp. 379–406. issn: 0066-4189. doi:
10.1146/annurev-fluid-010313-141418. url: http://www.annualreviews.
org/doi/abs/10.1146/annurev-fluid-010313-141418.
[20] Katsumi Chono, Norifumi Shimizu, Yoshikazu Matsui, Jun Kondoh, and Showko
Shiokawa. “Development of novel atomization system based on SAW streaming”.
In: Japanese Journal of Applied Physics, Part 1: Regular Papers and Short Notes
and Review Papers 43.5 B (2004), pp. 2987–2991. issn: 00214922. doi: 10.1109/
ULTSYM.2003.1293259.
[21] Yannyk Bourquin, Julien Reboud, Rab Wilson, and Jonathan M. Cooper. “Tune-
able surface acoustic waves for fluid and particle manipulations on disposable
chips”. In: Lab on a Chip 10.15 (2010), p. 1898. issn: 1473-0197. doi: 10.1039/
c004506c. url: http://xlink.rsc.org/?DOI=c004506c.
[22] Rab Wilson, Julien Reboud, Yannyk Bourquin, Steven L. Neale, Yi Zhang, and
Jonathan M. Cooper. “Phononic crystal structures for acoustically driven microflu-
idic manipulations”. In: Lab Chip 11.2 (2011), pp. 323–328. issn: 1473-0197. doi:
10.1039/C0LC00234H. url: http://xlink.rsc.org/?DOI=C0LC00234H.
[23] H. Rasool and a. Bassam. “Overview on Drug Delivery System”. In: Pharmaceutica
Analytica Acta 03.10 (2012), p. 4172. issn: 21532435. doi: 10.4172/2153-2435.
1000e137. url: http://www.omicsonline.org/overview-on-drug-delivery-
system-2153-2435.1000e137.php?aid=10652.
[24] Drug Delivery Systems: Getting Drugs to Their Targets in a Controlled Manner
| National Institute of Biomedical Imaging and Bioengineering. url: https://
www.nibib.nih.gov/science-education/science-topics/drug-delivery-
systems - getting - drugs - their - targets - controlled - manner (visited on
10/15/2018).
BIBLIOGRAPHY 150
[25] Routes of administration - an overview | ScienceDirect Topics. url: https://www.
sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-
science/routes-of-administration (visited on 10/15/2018).
[26] Shuguang Hou, Jiangyue Wu, Xu Li, and Hong Shu. “Practical, regulatory and clin-
ical considerations for development of inhalation drug products”. In: Asian Journal
of Pharmaceutical Sciences 10.6 (Dec. 2015), pp. 490–500. issn: 1818-0876. doi:
10.1016/J.AJPS.2015.08.008. url: https://www.sciencedirect.com/
science/article/pii/S1818087615000690.
[27] C. Darquenne. “Particle deposition in the lung”. In: Encyclopedia of Respiratory
Medicine (2006), pp. 300–304.
[28] Chen Hou, Stefan Gheorghiu, Virginia H. Huxley, and Peter Pfeifer. “Reverse engi-
neering of oxygen transport in the lung: Adaptation to changing demands and re-
sources through space-filling networks”. In: PLoS Computational Biology 6.8 (2010).
issn: 1553734X. doi: 10.1371/journal.pcbi.1000902.
[29] J S Patil and S Sarasija. “Pulmonary drug delivery strategies: A concise, systematic
review.” In: Lung India : official organ of Indian Chest Society 29.1 (Jan. 2012),
pp. 44–9. issn: 0974-598X. doi: 10.4103/0970-2113.92361. url: http://www.
ncbi.nlm.nih.gov/pubmed/22345913%20http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=PMC3276033.
[30] Rajesh Singh, Shailesh Singh, and James W Lillard. “Past, present, and future
technologies for oral delivery of therapeutic proteins.” In: Journal of pharmaceutical
sciences 97.7 (July 2008), pp. 2497–523. issn: 1520-6017. doi: 10.1002/jps.21183.
url: http://www.ncbi.nlm.nih.gov/pubmed/17918721%20http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4627499.
[31] T V Thulasiramaraju, B Tejeswar Kumar, and M Nikilesh Babu. PULMONARY
DRUG DELIVERY SYSTEM: AN OVERVIEW. Tech. rep. 1. 2013, pp. 16–34.
url: www.uptodateresearchpublication.com.
[32] A H Kendrick and C Newall. “Chapter 2 - Anatomy & Physiology of the Respiratory
System”. In: ARTP Ebooks Pdf and Magazines Free Download Manuals (). url:
http://www.freebookspdf.org/free/pdf/b-anatomy-and-physiology-of-
the-respiratory-system-artp.html.
[33] N. R. Labiris and M. B. Dolovich. “Pulmonary drug delivery. Part II: The role
of inhalant delivery devices and drug formulations in therapeutic effectiveness of
aerosolized medications”. In: British Journal of Clinical Pharmacology 56.6 (Aug.
2003), pp. 600–612. issn: 03065251. doi: 10.1046/j.1365-2125.2003.01893.x.
url: http://doi.wiley.com/10.1046/j.1365-2125.2003.01893.x.
BIBLIOGRAPHY 151
[34] David J Paterson, Manlio Tassieri, Julien Reboud, Rab Wilson, and Jonathan M
Cooper. “Lipid topology and electrostatic interactions underpin lytic activity of
linear cationic antimicrobial peptides in membranes”. In: (). doi: 10.1073/pnas.
1704489114. url: http://www.pnas.org/content/pnas/114/40/E8324.full.
pdf.
[35] Abolfazl Akbarzadeh, Rogaie Rezaei-Sadabady, Soodabeh Davaran, Sang Woo Joo,
Nosratollah Zarghami, Younes Hanifehpour, Mohammad Samiei, Mohammad Kouhi,
and Kazem Nejati-Koshki. “Liposome: classification, preparation, and applications.”
en. In: Nanoscale research letters 8.1 (Jan. 2013), p. 102. issn: 1931-7573. doi: 10.
1186/1556-276X-8-102. url: http://www.nanoscalereslett.com/content/8/
1/102.
[36] Dr. a. K. Bhandari J.S. Dua, Prof. A. C. Rana. “Review Article LIPOSOME :
METHODS OF PREPARATION AND APPLICATIONS”. In: International Jour-
nal of Pharmaceutical Studies and Research III.II (2012), p. 7.
[37] A D Bangham, M M Standish, and J C Watkins. Diffusion of Univalent Ions
across the Lamellae of Swollen Phospholipids. Tech. rep. 1965, 238–252, IN26–
IN27. doi: 10.1016/S0022-2836(65)80093-6. url: https://ac.els-cdn.com/
S0022283665800936/1-s2.0-S0022283665800936-main.pdf?%7B%5C_%7Dtid=
1436ab04-dbf9-46e2-b8cc-c13be53c8ccc%7B%5C&%7Dacdnat=1533821535%7B%
5C_%7D40bba01982580fb6809ef829e06c4aad.
[38] A. D. Bangham. “Liposomes: the Babraham connection”. In: Chemistry and Physics
of Lipids 64.1-3 (1993), pp. 275–285. issn: 00093084. doi: 10.1016/0009-3084(93)
90071-A.
[39] Aus Der Wissenschaft. “The Discovery of Liposomes”. In: (1994), pp. 1064–1067.
[40] F Szoka and D Papahadjopoulos. “Comparative properties and methods of prepa-
ration of lipid vesicles (liposomes).” In: Annual review of biophysics and bioengi-
neering 9 (1980), pp. 467–508. issn: 0084-6589. doi: 10.1146/annurev.bb.09.
060180.002343.
[41] F Szoka, D Papahadjopoulos, and D Papahadjopoulos. “Procedure for preparation
of liposomes with large internal aqueous space and high capture by reverse-phase
evaporation.” In: Proceedings of the National Academy of Sciences of the United
States of America 75.9 (Sept. 1978), pp. 4194–8. issn: 0027-8424. url: http :
//www.ncbi.nlm.nih.gov/pubmed/279908%20http://www.pubmedcentral.nih.
gov/articlerender.fcgi?artid=PMC336078.
[42] S. Vemuri and C. T. Rhodes. “Preparation and characterization of liposomes as
therapeutic delivery systems: A review”. In: Pharmaceutica Acta Helvetiae 70.2
(1995), pp. 95–111. issn: 00316865. doi: 10.1016/0031-6865(95)00010-7.
BIBLIOGRAPHY 152
[43] What Is The Transition Temperature Of The Lipid? | Avanti Polar Lipids. url:
https://avantilipids.com/tech-support/faqs/transition-temperature/
(visited on 07/18/2018).
[44] W. W. Sułkowski, D. Pentak, K. Nowak, and a. Sułkowska. “The influence of
temperature, cholesterol content and pH on liposome stability”. In: Journal of
Molecular Structure 744-747.SPEC. ISS. (2005), pp. 737–747. issn: 00222860. doi:
10.1016/j.molstruc.2004.11.075.
[45] “Spherical Ellipsoid Cylindrical”. In: (). url: https://onlinelibrary.wiley.
com/doi/pdf/10.1016/0307-4412(91)90103-F.
[46] J Du Plessis, C Ramachandran, N Weiner, and D G Moiler. “The influence of lipid
composition and lamellarity of liposomes on the physical stability of liposomes upon
storage”. In: International Journal of Pharmaceutics 127 (1996), pp. 273–278. url:
https://ac.els-cdn.com/0378517395042814/1-s2.0-0378517395042814-
main.pdf?%7B%5C_%7Dtid=608b94f3-5d8d-4855-b5e4-d54a9bc6d15d%7B%5C&
%7Dacdnat=1522321741%7B%5C_%7D0d2182f6cbd4c0f811c420010bc6c138.
[47] D. D. Lasic and F. J. Martin. “On the mechanism of vesicle formation”. In: Journal
of Membrane Science 50.2 (1990), pp. 215–222. issn: 03767388. doi: 10.1016/
S0376-7388(00)80317-8.
[48] R L Juliano. “Factors affecting the clearance kinetics and tissue distribution of
liposomes, microspheres and emulsions”. In: Advanced Drug Delivery Reviews 2
(1988), pp. 31–54. url: https://ac.els-cdn.com/0169409X8890004X/1-s2.0-
0169409X8890004X-main.pdf?%7B%5C_%7Dtid=8cfefdb0-7636-40b9-ae55-
3332dfbf083d%7B%5C&%7Dacdnat=1526896053%7B%5C_%7D87e5ad3fe786ee055f0b20ea268cc02f.
[49] D. D. Lasic and F. J. Martin. “On the mechanism of vesicle formation”. In: Journal
of Membrane Science 50.2 (1990), pp. 215–222. issn: 03767388. doi: 10.1016/
S0376-7388(00)80317-8.
[50] Jacob N Israelachvil1, D John Mitchell, and Barry W Ninham. “Theory of Self-
Assembly of Hydrocarbon Amphiphiles into Micelles and Bilayers FORMULATION
OF A MODEL FOR THE FREE ENERGIES”. In: (). url: http://pubs.rsc.
org/en/content/articlepdf/1976/f2/f29767201525.
[51] Taras Sych, Yves Mély, and Winfried Römer. “Lipid self-assembly and lectin-
induced reorganization of the plasma membrane”. In: (). doi: 10.1098/rstb.
2017.0117. url: http://dx.doi.org/10.1098/rstb.2017.0117.
BIBLIOGRAPHY 153
[52] V V Kumar. “Complementary molecular shapes and additivity of the packing pa-
rameter of lipids.” In: Proceedings of the National Academy of Sciences of the United
States of America 88.2 (1991), pp. 444–448. issn: 0027-8424. doi: 10.1073/pnas.
88.2.444.
[53] Danilo D. Lasic. “A General Model of Vesicle Formation”. In: Journal of Theoretical
Biology 124.June 1985 (1987), pp. 35–41. doi: 10.1016/S0022-5193(87)80250-3.
[54] DD Lasic, A Belic, and T Valentincic. “A new method for the instant preparation of
large unilamellar vesicles”. In: Journal of the American . . . 9 (1988), pp. 970–971.
issn: 00027863. url: http://pubs.acs.org/doi/abs/10.1021/ja00211a049.
[55] Herre Talsma, Mies J. Van Steenbergen, Johan C.H. Borchert, and Daan J.A. Crom-
melin. “A Novel Technique for the One-Step Preparation of Liposomes and Nonionic
Surfactant Vesicles without the Use of Organic Solvents. Liposome Formation in
a Continuous Gas Stream: The ‘Bubble’ Method”. In: Journal of Pharmaceuti-
cal Sciences 83.3 (Mar. 1994), pp. 276–280. issn: 0022-3549. doi: 10.1002/JPS.
2600830303. url: https://www.sciencedirect.com/science/article/pii/
S0022354915493803?via%7B%5C%%7D3Dihub.
[56] Jie Feng, Matthieu Roché, Daniele Vigolo, Luben N Arnaudov, Simeon D Stoyanov,
Theodor D Gurkov, Gichka G Tsutsumanova, and Howard A Stone. “Nanoemul-
sions obtained via bubble-bursting at a compound interface”. In: (2014). doi: 10.
1038/NPHYS3003. url: https://www.nature.com/articles/nphys3003.pdf.
[57] “ORGANIC LABORATORY TECHNIQUES 8”. In: (). url: http://www.chem.
ucalgary.ca/courses/351/laboratory/rotavap.pdf.
[58] Abolfazl Akbarzadeh, Rogaie Rezaei-Sadabady, Soodabeh Davaran, Sang Woo Joo,
Nosratollah Zarghami, Younes Hanifehpour, Mohammad Samiei, Mohammad Kouhi,
and Kazem Nejati-Koshki. “Liposome: classification, preparation, and applications.”
In: Nanoscale research letters 8.1 (Feb. 2013), p. 102. issn: 1931-7573. doi: 10.
1186/1556- 276X- 8- 102. url: http://www.ncbi.nlm.nih.gov/pubmed/
23432972 % 20http : / / www . pubmedcentral . nih . gov / articlerender . fcgi ?
artid=PMC3599573.
[59] Hongwei Zhang. “Thin-Film Hydration Followed by Extrusion Method for Lipo-
some Preparation”. In:Methods in molecular biology (Clifton, N.J.) Vol. 1522. 2017,
pp. 17–22. doi: 10.1007/978-1-4939-6591-5_2. url: http://www.ncbi.nlm.
nih.gov/pubmed/27837527%20http://link.springer.com/10.1007/978-1-
4939-6591-5%7B%5C_%7D2.
BIBLIOGRAPHY 154
[60] Uri Pick. “Liposomes with a large trapping capacity prepared by freezing and thaw-
ing of sonicated phospholipid mixtures”. In: Archives of Biochemistry and Bio-
physics 212.1 (Nov. 1981), pp. 186–194. issn: 0003-9861. doi: 10.1016/0003-
9861(81)90358-1. url: https://www.sciencedirect.com/science/article/
pii/0003986181903581.
[61] F Olson, C a Hunt, F C Szoka, W J Vail, and D Papahadjopoulos. “Preparation
of liposomes of defined size distribution by extrusion through polycarbonate mem-
branes.” In: Biochimica et biophysica acta 557.1 (1979), pp. 9–23. issn: 00052736.
doi: 10.1016/0005-2736(79)90085-3.
[62] F Szoka and D Papahadjopoulos. “Comparative properties and methods of prepa-
ration of lipid vesicles (liposomes).” In: Annual review of biophysics and bioengi-
neering 9 (1980), pp. 467–508. issn: 0084-6589. doi: 10.1146/annurev.bb.09.
060180.002343.
[63] Danieli Lasic Thomas Fisher. “Molecular Crystals and Liquid Crystals”. In: (). doi:
10.1080/01406568408072064. url: http://www.tandfonline.com/action/
journalInformation?journalCode=gmcl16.
[64] W Jiskoot, T Teerlink, E C Beuvery, and D J Crommelin. “Preparation of liposomes
via detergent removal from mixed micelles by dilution. The effect of bilayer com-
position and process parameters on liposome characteristics.” In: Pharmaceutisch
weekblad. Scientific edition 8.5 (Oct. 1986), pp. 259–65. issn: 0167-6555. url: http:
//www.ncbi.nlm.nih.gov/pubmed/3786108.
[65] F Olson, C a Hunt, F C Szoka, W J Vail, and D Papahadjopoulos. “Preparation
of liposomes of defined size distribution by extrusion through polycarbonate mem-
branes.” In: Biochimica et biophysica acta 557.1 (1979), pp. 9–23. issn: 00052736.
doi: 10.1016/0005-2736(79)90085-3.
[66] A.M.A. Elhissi and K.M.G. Taylor. “Delivery of liposomes generated from prolipo-
somes using air-jet, ultrasonic, and vibrating-mesh nebulisers”. In: Journal of Drug
Delivery Science and Technology 15.4 (Jan. 2005), pp. 261–265. issn: 1773-2247.
doi: 10.1016/S1773-2247(05)50047-9. url: https://www.sciencedirect.
com/science/article/pii/S1773224705500479.
[67] Stability aspects of liposomes. url: https://www.slideshare.net/Harnishapatel1/
stability-aspects-of-liposomes (visited on 07/16/2018).
[68] Paul a. Bridges and K. M G Taylor. “Nebulisers for the generation of liposomal
aerosols”. In: International Journal of Pharmaceutics 173.1-2 (1998), pp. 117–125.
issn: 03785173. doi: 10.1016/S0378-5173(98)00212-9.
BIBLIOGRAPHY 155
[69] Paul A Bridges and Kevin M G Taylor. “An investigation of some of the factors
influencing the jet nebulisation of liposomes”. In: International Journal of Phar-
maceutics 204 (2000), pp. 69–79. url: www.elsevier.com/locate/ijpharm.
[70] K M G Taylor, G Taylor, I W Kellaway, and J Stevens. “The stability of li-
posomes to nebulisation”. In: International Journal of Pharmaceutics 58 (1990),
pp. 57–61. url: https : / / ac . els - cdn . com / 037851739090287E / 1 - s2 . 0 -
037851739090287E-main.pdf?%7B%5C_%7Dtid=8e3035ff-b5b2-416e-98fa-
79c7ef538f59%7B%5C&%7Dacdnat=1531736690%7B%5C_%7D66888d795ef82ac26409a0247b3b4256.
[71] O. N M Mc Callion, K. M G Taylor, M. Thomas, and a. J. Taylor. “The influence
of surface tension on aerosols produced by medical nebulisers”. In: International
Journal of Pharmaceutics 129.1-2 (1996), pp. 123–136. issn: 03785173. doi: 10.
1016/0378-5173(95)04279-2.
[72] K M Taylor and J M Newton. “Liposomes for controlled delivery of drugs to the
lung.” In: Thorax 47.4 (1992), pp. 257–259. issn: 0040-6376. doi: 10.1136/thx.
47.4.257.
[73] Brian Wowk. HOW Cryoprotectants Work. Tech. rep. url: www.alcor.org.
[74] David Cipolla, Huiying Wu, Igor Gonda, and Hak-Kim Chan. “Aerosol Performance
and Stability of Liposomes Containing Ciprofloxacin Nanocrystals”. In: (). doi:
10 . 1089 / jamp . 2015 . 1241. url: https : / / www . ncbi . nlm . nih . gov / pmc /
articles/PMC4685509/pdf/jamp.2015.1241.pdf.
[75] F Ross Hallett, Jackie Marsh, Bernie G Nickel, and Janet M Wood. Mechani-
cal properties of vesicles. II. A model for osmotic swelling and lysis. Tech. rep.
doi: 10.1016/S0006- 3495(93)81384- 5. url: https://ac.els- cdn.com/
S0006349593813845/1-s2.0-S0006349593813845-main.pdf?%7B%5C_%7Dtid=
60acab5d-e4c2-4d06-a2d2-ce8336f3d929%7B%5C&%7Dacdnat=1538386482%7B%
5C_%7D72bd1fda1e17d8edb65d6fbdfac35dc8.
[76] Alexander Ewe and Achim Aigner. “Nebulization of liposome-polyethylenimine
complexes (lipopolyplexes) for DNA or siRNA delivery: Physicochemical proper-
ties and biological activity”. In: European Journal of Lipid Science and Technology
116.9 (Sept. 2014), pp. 1195–1204. issn: 14387697. doi: 10.1002/ejlt.201300404.
url: http://doi.wiley.com/10.1002/ejlt.201300404.
[77] A E Canonico, J D Plitman, J T Conary, B O Meyrick, and K L Brigham. “No lung
toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome
complexes.” In: Journal of applied physiology (Bethesda, Md. : 1985) 77.1 (July
1994), pp. 415–9. issn: 8750-7587. doi: 10.1152/jappl.1994.77.1.415. url:
http://www.ncbi.nlm.nih.gov/pubmed/7961263.
BIBLIOGRAPHY 156
[78] C. F. Verschraegen, Brian E Gilbert, Evelyne Loyer, Armando Huaringa, Garrett
Walsh, Robert A Newman, and Vernon Knight. “Clinical Evaluation of the Delivery
and Safety of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with
Advanced Pulmonary Malignancies”. In: Clinical Cancer Research 10.7 (Apr. 2004),
pp. 2319–2326. issn: 1078-0432. doi: 10.1158/1078-0432.CCR-0929-3. url:
http://www.ncbi.nlm.nih.gov/pubmed/15073107%20http://clincancerres.
aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-0929-3.
[79] V Knight, E S Kleinerman, J C Waldrep, B C Giovanella, B E Gilbert, and N
V Koshkina. “9-Nitrocamptothecin liposome aerosol treatment of human cancer
subcutaneous xenografts and pulmonary cancer metastases in mice.” In: Annals of
the New York Academy of Sciences 922.July (2000), pp. 151–163. issn: 0077-8923.
[80] Mindaugas Rudokas, Mohammad Najlah, Mohamed Albed Alhnan, and Abdelbary
Elhissi. “Liposome Delivery Systems for Inhalation: A Critical Review Highlight-
ing Formulation Issues and Anticancer Applications”. In: Medical Principles and
Practice 25.2 (2016), pp. 60–72. issn: 14230151. doi: 10.1159/000445116. url:
www.karger.com/OA-license.
[81] Mindaugas Rudokas, Mohammad Najlah, Mohamed Albed Alhnan, and Abdel-
bary Elhissi. “E-Mail Liposome Delivery Systems for Inhalation: A Critical Review
Highlighting Formulation Issues and Anticancer Applications”. In: (2016). doi:
10.1159/000445116. url: www.karger.com/OA-license.
[82] G Mainelis, S Seshadri, O B Garbuzenko, T Han, Z Wang, and T Minko. “Charac-
terization and application of a nose-only exposure chamber for inhalation delivery of
liposomal drugs and nucleic acids to mice.” In: Journal of aerosol medicine and pul-
monary drug delivery 26.6 (2013), pp. 345–54. issn: 1941-2703. doi: 10.1089/jamp.
2011-0966. url: http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=3889495%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract.
[83] G Mainelis, S Seshadri, O B Garbuzenko, T Han, Z Wang, and T Minko. “Charac-
terization and application of a nose-only exposure chamber for inhalation delivery of
liposomal drugs and nucleic acids to mice.” In: Journal of aerosol medicine and pul-
monary drug delivery 26.6 (2013), pp. 345–54. issn: 1941-2703. doi: 10.1089/jamp.
2011-0966. url: http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=3889495%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract.
[84] Paul B. Myrdal, Poonam Sheth, and Stephen W. Stein. “Advances in Metered
Dose Inhaler Technology: Formulation Development”. In: AAPS PharmSciTech
15.2 (Apr. 2014), p. 434. issn: 1530-9932. doi: 10.1208/S12249-013-0063-X.
url: http://www.ncbi.nlm.nih.gov/pubmed/24452499%20http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3969484.
BIBLIOGRAPHY 157
[85] Luca Lelli. “Aerosol and Clouds WS2014 - Scattering Regimes”. In: November
(2014), p. 47. url: http://www.iup.uni-bremen.de/%7B~%7Dluca/?download=
01%7B%5C_%7DLL%7B%5C_%7DVO.pdf.
[86] D. Arzenšek. “Dynamic light scattering and application to proteins in solutions”.
In: (2010), pp. 1–19.
[87] M Instruments and Malvern Instruments. “Dynamic Light Scattering: An Introduc-
tion in 30 Minutes”. In:Http://Www.Malvern.Com/En/Products/Technology/Dynamic-
Light-Scattering/ (2000), pp. 1–8. url: http://scholar.google.com/scholar?
hl = en % 7B % 5C & %7DbtnG = Search % 7B % 5C & %7Dq = intitle : Dynamic + Light +
Scattering+:+An+Introduction+in+30+Minutes%7B%5C#%7D3.
[88] W. I. Goldburg. “Dynamic light scattering”. In: American Journal of Physics 67.12
(1999), p. 1152. issn: 00029505. doi: 10.1119/1.19101. url: http://link.aip.
org/link/?AJP/67/1152/1%7B%5C&%7DAgg=doi.
[89] B. J. Berne and R. Pecora. “Dynamic light scattering. With applications to chem-
istry, biology, and physics.” In: Dynamic light scattering. With applications to chem-
istry, biology, and physics., by Berne, B. J.; Pecora, R.. New York, NY (USA):
Wiley-Interscience, 8 + 376 p. (1976). url: http://adsabs.harvard.edu/abs/
1976dlsw.book.....B.
[90] Malvern Instruments. “InformWhite Paper Dynamic Light Scattering”. In:Malvern
Guides (2011), pp. 1–6.
[91] F. R. Hallett, J. Watton, and P. Krygsman. “Vesicle sizing: Number distributions
by dynamic light scattering”. In: Biophysical Journal 59.2 (1991), pp. 357–362.
issn: 00063495. doi: 10.1016/S0006-3495(91)82229-9.
[92] Denis Semwogerere and Eric R Weeks. “Confocal Microscopy”. In: (). doi: 10.
1081/E-EBBE-120024153. url: http://www.physics.emory.edu/faculty/
weeks//lab/papers/ebbe05.pdf.
[93] Robert and Webb. “Confocal optical microscopy”. In: Rep. Prog. Phys 59 (1996).
url: http://iopscience.iop.org/article/10.1088/0034-4885/59/3/003/
pdf.
[94] T Dokland. “Back to the basics: The fundamentals of cryo-electron microscopy”.
In: Microscopy and Microanalysis 15.S2 (2009), p. 1538. issn: 1431-9276. doi:
10.1017/S1431927609099280. url: http://www.journals.cambridge.org/
abstract%7B%5C_%7DS1431927609099280.
[95] The University of Utah. Introduction to Electron Microscopy - Advanced Microscopy
- Imaging Facilities - The University of Utah. url: http://advanced-microscopy.
utah.edu/education/electron-micro/ (visited on 04/04/2018).
BIBLIOGRAPHY 158
[96] Debora Ferreira Barreto-Vieira and Ortrud Monika Barth. “Negative and Positive
Staining in Transmission Electron Microscopy for Virus Diagnosis”. In: Microbiol-
ogy in Agriculture and Human Health. InTech, July 2015. doi: 10.5772/60511.
url: http://www.intechopen.com/books/microbiology-in-agriculture-
and-human-health/negative-and-positive-staining-in-transmission-
electron-microscopy-for-virus-diagnosis.
[97] Rebecca F. Thompson, Matt Walker, C. Alistair Siebert, Stephen P. Muench, and
Neil A. Ranson. “An introduction to sample preparation and imaging by cryo-
electron microscopy for structural biology”. In: Methods 100 (2016), pp. 3–15. issn:
10959130. doi: 10.1016/j.ymeth.2016.02.017. url: http://dx.doi.org/10.
1016/j.ymeth.2016.02.017.
[98] T Dokland. “Back to the basics: The fundamentals of cryo-electron microscopy”.
In: Microscopy and Microanalysis 15.S2 (2009), p. 1538. issn: 1431-9276. doi:
10.1017/S1431927609099280. url: http://www.journals.cambridge.org/
abstract%7B%5C_%7DS1431927609099280.
[99] Mats Almgren, Katarina Edwards, and Göran Karlsson. “Cryo transmission elec-
tron microscopy of liposomes and related structures”. In: Colloids and Surfaces A:
Physicochemical and Engineering Aspects 174.1-2 (2000), pp. 3–21. issn: 09277757.
doi: 10.1016/S0927-7757(00)00516-1.
[100] Rajesh Singh and James W Lillard. “Nanoparticle-based targeted drug delivery”.
In: (). doi: 10.1016/j.yexmp.2008.12.004. url: https://www.ncbi.nlm.nih.
gov/pmc/articles/PMC3249419/pdf/nihms87089.pdf.
[101] Khalil Hafiz Luqman. Methods of particle size measrement. url: https://www.
slideshare.net/maan%7B%5C_%7Dali/methods-of-particle-size-measrement-
032 (visited on 08/27/2018).
[102] John S. Patton. “Mechanisms of macromolecule absorption by the lungs”. In: Ad-
vanced Drug Delivery Reviews 19.1 (1996), pp. 3–36. issn: 0169409X. doi: 10.
1016/0169-409X(95)00113-L.
[103] WHITEPAPER 2 A basic guide to particle characterization 2. Better understanding
of products, ingredients and processes. Tech. rep. url: https://www.cif.iastate.
edu/sites/default/files/uploads/Other%7B%5C_%7DInst/Particle%20Size/
Particle%20Characterization%20Guide.pdf.
[104] Ju-Hyeong Park. Impactors and Particle Size Distribution (1) Particle motion, par-
ticle size, and aerodynamic diameter. Tech. rep. url: http://www.industrialventilation.
net/ClassDownloads/IHS%7B%5C_%7D725/L11%20Impactor%20Data%20Reduction/
Impactor%7B%5C_%7DPark%20%7B%5C%%7D281%7B%5C%%7D29.pdf.
BIBLIOGRAPHY 159
[105] An Overview of the Different Particle Size Measurement Techniques - ATA Scien-
tific. url: https://www.atascientific.com.au/overview-particle-size-
measurement-techniques/ (visited on 08/15/2018).
[106] Mark Copley. “Understanding cascade impaction and its importance for inhaler
testing”. In: (2007), pp. 1–6.
[107] Jolyon P Mitchell, Mark W Nagel, Kimberly J Wiersema, and Cathy C Doyle. Aero-
dynamic Particle Size Analysis of Aerosols from Pressurized Metered-Dose Inhalers:
Comparison of Andersen 8-Stage Cascade Impactor, Next Generation Pharmaceu-
tical Impactor, and Model 3321 Aerodynamic Par-ticle Sizer Aerosol Spectrometer.
Tech. rep. 4. 2003, p. 54. url: http://www.aapspharmscitech.org.
[108] Malvern Instruments Ltd. “A basic guide to particle characterization”. In: Inform
White Paper (2012), pp. 1–26.
[109] Fraunhofer Diffraction Theory and Mie Scattering Theory : SHIMADZU (Shimadzu
Corporation). url: https://www.shimadzu.com/an/powder/support/practice/
p01/lesson13.html (visited on 10/08/2018).
[110] S. Pedersen. “Inhalers and nebulizers: Which to choose and why”. In: Respiratory
Medicine 90.2 (1996), pp. 69–77. issn: 09546111. doi: 10.1016/S0954-6111(96)
90201-2.
[111] Early Atomizers, Asthma Cigarettes, Hand-bulb Nebulizer, Early Electric, Com-
pressor Nebulizers, Theoretical Models, and Particle Sizing Techniques. “History of
Aerosol Therapy : Liquid Nebulization to MDIs to DPIs Ceramic Inhalers ( 19th
Century )”. In: Respiratory care 50.9 (2005), pp. 1139–1149.
[112] Myrna B. Dolovich and Rajiv Dhand. “Aerosol drug delivery: Developments in
device design and clinical use”. In: The Lancet 377.9770 (2011), pp. 1032–1045.
issn: 01406736. doi: 10.1016/S0140-6736(10)60926-9. url: http://dx.doi.
org/10.1016/S0140-6736(10)60926-9.
[113] Nebulisers review. Tech. rep. url: https://www.ers-education.org/lrmedia/
2006/pdf/40403.pdf.
[114] C J Harvey, M J O’doherty, C J Page, S H L Thomas, T O Nunan, and D F
Treacher. “Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition
during mechanical ventilation”. In: Eur Respir J 10 (1997), pp. 905–909. doi: 10.
1183/09031936.97.10040905. url: https://erj.ersjournals.com/content/
erj/10/4/905.full.pdf.
[115] C O’Callaghan and P W Barry. “The science of nebulised drug delivery.” In: Thorax
52 Suppl 2.Suppl 2 (1997), S31–S44. issn: 0040-6376. doi: 10.1136/thx.52.2008.
S31.
BIBLIOGRAPHY 160
[116] Eugene R. Arulmuthu, David J. Williams, Helen Baldascini, Henk K. Versteeg, and
Mike Hoare. “Studies on aerosol delivery of plasmid DNA using a mesh nebulizer”.
In: Biotechnology and Bioengineering 98.5 (Dec. 2007), pp. 939–955. issn: 00063592.
doi: 10.1002/bit.21493. url: http://doi.wiley.com/10.1002/bit.21493.
[117] Aisha Qi, Leslie Y. Yeo, and James R. Friend. “Interfacial destabilization and
atomization driven by surface acoustic waves”. In: Physics of Fluids 20.7 (2008).
issn: 10706631. doi: 10.1063/1.2953537.
[118] Julien Reboud, Rab Wilson, Yi Zhang, Mohd H Ismail, Yannyk Bourquin, and
Jonathan M Cooper. “Nebulisation on a disposable array structured with phononic
lattices.” In: Lab on a chip 12.7 (2012), pp. 1268–73. issn: 1473-0189. doi: 10.
1039/c2lc20705b. url: http://www.ncbi.nlm.nih.gov/pubmed/22327572.
[119] Safa Kasap. Principles of electronic materials and devices, p. 978. isbn: 0078028183.
url: http://materials.usask.ca/.
[120] Ahmad Safari and E.Koray Akdogan. Piezoelectric and Acoustic Materials for
Transducer Applications - Google Libri. url: https://books.google.co.uk/
books?hl=it%7B%5C&%7Dlr=%7B%5C&%7Did=gvDjYzHTfYkC%7B%5C&%7Doi=
fnd%7B%5C&%7Dpg=PR5%7B%5C&%7Ddq=piezoelectric+materials+structure+
properties+and+applications%7B%5C&%7Dots=-aDYbIqt4V%7B%5C&%7Dsig=
dvmNht4Z9A0gKbRu3pBqLu%7B%5C_%7DO7A8%7B%5C#%7Dv=onepage%7B%5C&%7Dq=
piezoelectric%7B%5C%%7D252520materials%7B%5C%%7D252520structure%7B%
5C%%7D252520properties%7B%5C%%7D252.
[121] Farhin Rehnuma et al. Piezoelectric Materials. url: https://www.slideshare.
net/foysalmd/piezoelectric-materials (visited on 09/20/2018).
[122] CRYSTAL SYMMETRY. Tech. rep. url: http://academic.uprm.edu/pcaceres/
Courses/Smart/SMD-5A.pdf.
[123] Earthquake Glossary. url: https://earthquake.usgs.gov/learn/glossary/
?term=Rayleigh%20wave (visited on 10/24/2018).
[124] Kazuhiko Yamanouchi. “Propagation and Amplification of Rayleigh Waves and
Piezoelectric Leaky Surface Waves in LiNbO3”. In: Journal of Applied Physics
43.3 (1972), p. 856. issn: 00218979. doi: 10.1063/1.1661294. url: http://
scitation.aip.org/content/aip/journal/jap/43/3/10.1063/1.1661294.
[125] Leslie Y Yeo and James R Friend. “Ultrafast microfluidics using surface acous-
tic waves.” In: Biomicrofluidics 3.1 (Jan. 2009), p. 12002. issn: 1932-1058. doi:
10.1063/1.3056040. url: http://www.ncbi.nlm.nih.gov/pubmed/19693383%
20http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2717600.
BIBLIOGRAPHY 161
[126] Leslie Y Yeo and James R Friend. “Surface Acoustic Wave Microfluidics Review”.
In: Annu. Rev. Fluid Mech 46 (2014), pp. 379–406. doi: 10.1146/annurev-fluid-
010313-141418. url: www.annualreviews.org.
[127] Ming K Tan, James R Friend, Omar K Matar, and Leslie Y Yeo. “Capillary
wave motion excited by high frequency surface acoustic waves Frequency effect
on streaming phenomenon induced by Rayleigh surface acoustic wave in micro-
droplets Capillary wave motion excited by high frequency surface acoustic waves”.
In: Physics of Fluids Journal of Applied Physics Acoustical Society of America Ap-
plied Physics Letters Journal of Applied Physics 221.10 (2010), pp. 112112–14910.
doi: 10.1063/1.1754276. url: https://doi.org/10.1063/1.3505044%20http:
//aip.scitation.org/toc/phf/22/11.
[128] Robert J Lang and Robert J Lano. “Mechanisms of free-surface breakup in vibration-
induced liquid atomization”. In: Ultrasonic Atomization Studies The Journal of the
Acoustical Society of America 34 (1962), p. 515. doi: 10.1121/1.1909020. url:
http://asa.scitation.org/toc/jas/34/1.
[129] Rayleigh. “The theory of sound : Rayleigh, John William Strutt, Baron, 1842-
1919 : Free Download, Borrow, and Streaming : Internet Archive”. In: (1877). url:
https://archive.org/details/theorysound06raylgoog/page/n7.
[130] L. Gaete-Garretón, D. Briceño-Gutiérrez, Y. Vargas-Hernández, and C. I. Zanelli.
“Ultrasonic atomization of distilled water”. In: The Journal of the Acoustical Society
of America 144.1 (2018), pp. 222–227. issn: 0001-4966. doi: 10.1121/1.5045558.
url: http://asa.scitation.org/doi/10.1121/1.5045558.
[131] James Friend and Leslie Y. Yeo. “Microscale acoustofluidics: Microfluidics driven
via acoustics and ultrasonics”. In: Reviews of Modern Physics 83.2 (2011), pp. 647–
704. issn: 00346861. doi: 10.1103/RevModPhys.83.647.
[132] Elijah Nazarzadeh, Rab Wilson, Xi King, Julien Reboud, Manlio Tassieri, and
Jonathan M. Coopera. “Confinement of surface waves at the air-water interface
to control aerosol size and dispersity”. In: Physics of Fluids 29.11 (2017). issn:
10897666. doi: 10.1063/1.4993793.
[133] M. Kurosawa, a. Futami, and T. Higuchi. “Characteristics of liquids atomization
using surface acoustic wave”. In: Proceedings of International Solid State Sensors
and Actuators Conference (Transducers ’97) 2.November (1997), pp. 4–7. doi: 10.
1109/SENSOR.1997.635221.
[134] “New Piezoelectrical Droplets Generator”. In: Ultrasonics 8 (1994), pp. 611–614.
BIBLIOGRAPHY 162
[135] Aisha Qi, James R Friend, Leslie Y Yeo, David a V Morton, Michelle P McIntosh,
and Leone Spiccia. “Miniature inhalation therapy platform using surface acoustic
wave microfluidic atomization.” In: Lab on a chip 9.15 (2009), pp. 2184–2193. issn:
1473-0197. doi: 10.1039/b903575c.
[136] Christina Cortez-Jugo, Aisha Qi, Anushi Rajapaksa, James R. Friend, and Leslie
Y. Yeo. “Pulmonary monoclonal antibody delivery via a portable microfluidic neb-
ulization platform”. In: Biomicrofluidics 9.5 (Sept. 2015), p. 052603. issn: 1932-
1058. doi: 10.1063/1.4917181. url: http://www.ncbi.nlm.nih.gov/pubmed/
25945147 % 20http : / / www . pubmedcentral . nih . gov / articlerender . fcgi ?
artid=PMC4393410%20http://aip.scitation.org/doi/10.1063/1.4917181.
[137] Anushi E Rajapaksa, Jenny J Ho, Aisha Qi, Rob Bischof, Tri-Hung Nguyen, Michelle
Tate, David Piedrafita, Michelle P McIntosh, Leslie Y Yeo, Els Meeusen, Ross L
Coppel, and James R Friend. “Effective pulmonary delivery of an aerosolized plas-
mid DNA vaccine via surface acoustic wave nebulization.” In: Respiratory research
15 (2014), p. 60. issn: 1465-993X. doi: 10.1186/1465-9921-15-60. url: http:
//www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4040411%7B%5C&
%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract.
[138] Layla Alhasan, Aisha Qi, Amgad R Rezk, Leslie Y Yeo, and Peggy P Y Chan.
“Integrative Biology Assessment of the potential of a high frequency acoustomi-
crofluidic nebulisation platform for inhaled stem cell therapy †”. In: This jour-
nal is Cite this: Integr. Biol 8 (2016), p. 12. doi: 10.1039/c5ib00206k. url:
www.rsc.org/ibiology.
[139] Christina Cortez-Jugo, Aisha Qi, Anushi Rajapaksa, James R Friend, and Leslie Y
Yeo. “Pulmonary monoclonal antibody delivery via a portable microfluidic nebu-
lization platform”. In: (). doi: 10.1063/1.4917181. url: https://www.ncbi.
nlm.nih.gov/pmc/articles/PMC4393410/pdf/BIOMGB-000009-052603%7B%5C_
%7D1.pdf.
[140] Nucleic acid - an overview | ScienceDirect Topics. url: https://www.sciencedirect.
com/topics/neuroscience/nucleic-acid (visited on 05/16/2018).
[141] Joanna B. Opalinska and Alan M. Gewirtz. “Nucleic-acid therapeutics: basic prin-
ciples and recent applications”. In: Nature Reviews Drug Discovery 1.7 (2002),
pp. 503–514. issn: 14741784. doi: 10.1038/nrd837. url: http://www.nature.
com/doifinder/10.1038/nrd837.
[142] Enrico Mastrobattista, Wim E. Hennink, and Raymond M. Schiffelers. “Delivery
of nucleic acids”. In: Pharmaceutical Research 24.8 (2007), pp. 1561–1563. issn:
07248741. doi: 10.1007/s11095-007-9349-6.
BIBLIOGRAPHY 163
[143] U.S National Library of Medicine. What is gene therapy? - Genetics Home Refer-
ence. url: https://ghr.nlm.nih.gov/primer/therapy/genetherapy (visited
on 03/22/2018).
[144] Luigi Naldini.Gene therapy returns to centre stage. 2015. doi: 10.1038/nature15818.
[145] Sanjukta Misra. Human gene therapy: a brief overview of the genetic revolution.
2013.
[146] Jack McCain. “The future of gene therapy.” In: Biotechnology healthcare 2.3 (June
2005), pp. 52–60. issn: 1554-169X. url: http://www.ncbi.nlm.nih.gov/pubmed/
23393464 % 20http : / / www . pubmedcentral . nih . gov / articlerender . fcgi ?
artid=PMC3564347.
[147] Timothy P. O’Connor and Ronald G. Crystal. “Genetic medicines: treatment strate-
gies for hereditary disorders”. In: Nature Reviews Genetics 7.4 (Apr. 2006), pp. 261–
276. issn: 1471-0056. doi: 10.1038/nrg1829. url: http://www.nature.com/
doifinder/10.1038/nrg1829.
[148] Rosenberg et al. “Gene Transfer Into Humans”. In: The New England Journal of
Medicine Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on
March 22 (2018). url: http://www.nejm.org/doi/pdf/10.1056/NEJM199008303230904.
[149] Eve Hanna, Cécile Rémuzat, Pascal Auquier, and Mondher Toumi. “Gene therapies
development: slow progress and promising prospect.” In: Journal of market access
& health policy 5.1 (2017), p. 1265293. issn: 2001-6689. doi: 10.1080/20016689.
2017.1265293. url: http://www.ncbi.nlm.nih.gov/pubmed/28265348%20http:
//www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5328344.
[150] B Sibbald. “Death but one unintended consequence of gene-therapy trial.” In:
CMAJ : Canadian Medical Association journal = journal de l’Association medi-
cale canadienne 164.11 (May 2001), p. 1612. issn: 0820-3946. url: http://www.
ncbi.nlm.nih.gov/pubmed/11402803%20http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=PMC81135.
[151] Jie Wang, Ze Lu, M Guillaume Wientjes, and Jessie L-S Au. “Delivery of siRNA
therapeutics: barriers and carriers.” In: The AAPS journal 12.4 (Dec. 2010), pp. 492–
503. issn: 1550-7416. doi: 10.1208/s12248-010-9210-4. url: http://www.
ncbi.nlm.nih.gov/pubmed/20544328%20http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=PMC2977003.
[152] Yingshan Qiu, Jenny K.W. Lam, Susan W.S. Leung, and Wanling Liang. “Delivery
of RNAi Therapeutics to the Airways—From Bench to Bedside”. In: Molecules 21.9
(2016), p. 1249. issn: 1420-3049. doi: 10.3390/molecules21091249. url: http:
//www.mdpi.com/1420-3049/21/9/1249.
BIBLIOGRAPHY 164
[153] Volker A. Erdmann and Jan Barciszewski. “From nucleic acids sequences to molec-
ular medicine”. In: From Nucleic Acids Sequences to Molecular Medicine (2012),
pp. 1–654. doi: 10.1007/978-3-642-27426-8.
[154] Kelly M Martinovich, Nicole C Shaw, Anthony Kicic, André Schultz, Sue Fletcher,
Steve D Wilton, and Stephen M Stick. “The potential of antisense oligonucleotide
therapies for inherited childhood lung diseases.” In: Molecular and cellular pedi-
atrics 5.1 (Feb. 2018), p. 3. issn: 2194-7791. doi: 10.1186/s40348-018-0081-6.
url: http://www.ncbi.nlm.nih.gov/pubmed/29411170%20http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5801198.
[155] Nathalie Dias and C a Stein. “Minireview Antisense Oligonucleotides : Basic Con-
cepts and Mechanisms”. In:Molecular Cancer Therapeutics 1.March (2002), pp. 347–
355. issn: 15357163. doi: 10.1016/s1357-4310(99)01638-x. url: http://www.
ncbi.nlm.nih.gov/pubmed/12489851.
[156] G B Mulamba, A Hu, R F Azad, K P Anderson, and D M Coen. “Human cy-
tomegalovirus mutant with sequence-dependent resistance to the phosphorothioate
oligonucleotide fomivirsen (ISIS 2922).” In: Antimicrobial agents and chemotherapy
42.4 (Apr. 1998), pp. 971–3. issn: 0066-4804. url: http://www.ncbi.nlm.nih.
gov/pubmed/9559825%20http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid=PMC105584.
[157] Sven Kruspe and Paloma Giangrande. “Aptamer-siRNA Chimeras: Discovery, Progress,
and Future Prospects”. In: Biomedicines 5.3 (2017), p. 45. issn: 2227-9059. doi:
10.3390/biomedicines5030045. url: http://www.mdpi.com/2227-9059/5/3/
45.
[158] Nill Bergstrand. Liposomes for Drug Delivery from Physico-chemical Studies to
Application. 2003. isbn: 9155455921.
[159] et al. Griffiths AJF, Miller JH, Suzuki DT. An Introduction to Genetic Analysis
- Transcription and RNA polymerase. 2000. doi: 10.1111/j.1365-2141.2011.
08807.x. url: http://doi.wiley.com/10.1111/j.1365-2141.2011.08807.x.
[160] et al. Alberts B, Johnson A, Lewis J. Molecular Biology of the Cell - From DNA
to RNA. 2002. doi: 10.1111/j.1365-2141.2011.08807.x. url: http://doi.
wiley.com/10.1111/j.1365-2141.2011.08807.x.
[161] Randy Schekman. “Merging cultures in the study of membrane traffic”. In: Na-
ture Cell Biology 6.6 (June 2004), pp. 483–486. issn: 1465-7392. doi: 10.1038/
ncb0604-483. url: http://www.nature.com/articles/ncb0604-483.
BIBLIOGRAPHY 165
[162] Jenny K W Lam, Michael Y T Chow, Yu Zhang, and Susan W S Leung. “siRNA
Versus miRNA as Therapeutics for Gene Silencing.” In: Molecular therapy. Nu-
cleic acids 4.9 (Sept. 2015), e252. issn: 2162-2531. doi: 10.1038/mtna.2015.23.
url: http://www.ncbi.nlm.nih.gov/pubmed/26372022%20http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4877448.
[163] Jenny K.W. Lam, Michael Y.T. Chow, Yu Zhang, and Susan W.S. Leung. “siRNA
versus miRNA as therapeutics for gene silencing”. In: Molecular Therapy - Nucleic
Acids 4.9 (2015), pp. 1–20. issn: 21622531. doi: 10.1038/mtna.2015.23.
[164] R C C Ryther, A S Flynt, J A Phillips, and J G Patton. “siRNA therapeutics: big
potential from small RNAs”. In: Gene Therapy 12.1 (2005), pp. 5–11. issn: 0969-
7128. doi: 10.1038/sj.gt.3302356. url: http://www.nature.com/doifinder/
10.1038/sj.gt.3302356.
[165] Michael Y.T. Chow, Yingshan Qiu, Fiona F.K. Lo, Hinson H.S. Lin, Hak Kim Chan,
Philip C.L. Kwok, and Jenny K.W. Lam. “Inhaled powder formulation of naked
siRNA using spray drying technology with L-leucine as dispersion enhancer”. In:
International Journal of Pharmaceutics 530.1-2 (2017), pp. 40–52. issn: 18733476.
doi: 10.1016/j.ijpharm.2017.07.013. url: http://dx.doi.org/10.1016/j.
ijpharm.2017.07.013.
[166] Neema Agrawal, P V N Dasaradhi, Asif Mohmmed, Pawan Malhotra, Raj K Bhat-
nagar, and Sunil K Mukherjee. “RNA interference: biology, mechanism, and appli-
cations.” In: Microbiology and molecular biology reviews : MMBR 67.4 (Dec. 2003),
pp. 657–85. issn: 1092-2172. doi: 10.1128/MMBR.67.4.657-685.2003. url: http:
//www.ncbi.nlm.nih.gov/pubmed/14665679%20http://www.pubmedcentral.
nih.gov/articlerender.fcgi?artid=PMC309050.
[167] P. Gonzalez-Alegre. “RNA Interference”. In: Encyclopedia of Movement Disorders.
Elsevier, 2010, pp. 47–49. isbn: 9780123741059. doi: 10 . 1016 / B978 - 0 - 12 -
374105-9.00192-1. url: http://linkinghub.elsevier.com/retrieve/pii/
B9780123741059001921.
[168] Jenny Ka-Wing Lam, Wanling Liang, and Hak-Kim Chan. “Pulmonary delivery of
therapeutic siRNA”. In: Advanced Drug Delivery Reviews 64.1 (2012), pp. 1–15.
issn: 0169409X. doi: 10.1016/j.addr.2011.02.006. url: http://dx.doi.org/
10.1016/j.addr.2011.02.006.
[169] Richard W Carthew and Erik J Sontheimer. “Origins and Mechanisms of miRNAs
and siRNAs.” In: Cell 136.4 (Feb. 2009), pp. 642–55. issn: 1097-4172. doi: 10.
1016/j.cell.2009.01.035. url: http://www.ncbi.nlm.nih.gov/pubmed/
19239886 % 20http : / / www . pubmedcentral . nih . gov / articlerender . fcgi ?
artid=PMC2675692.
BIBLIOGRAPHY 166
[170] Chuan Huang, Min Li, Changyi Chen, and Qizhi Yao. “Small interfering RNA
therapy in cancer: mechanism, potential targets, and clinical applications.” In: Ex-
pert opinion on therapeutic targets 12.5 (2008), pp. 637–645. issn: 1472-8222. doi:
10.1517/14728222.12.5.637.
[171] Olivia M Merkel, Israel Rubinstein, and Thomas Kissel. “siRNA delivery to the
lung: what’s new?” In: Advanced drug delivery reviews 75 (Aug. 2014), pp. 112–28.
issn: 1872-8294. doi: 10.1016/j.addr.2014.05.018. url: http://www.ncbi.
nlm.nih.gov/pubmed/24907426%20http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=PMC4160355.
[172] Bieong Kil Kim, Guen Bae Hwang, Young Bae Seu, Jong Soo Choi, Kyeong Sik Jin,
and Kyung Oh Doh. “DOTAP/DOPE ratio and cell type determine transfection
efficiency with DOTAP-liposomes”. In: Biochimica et Biophysica Acta - Biomem-
branes 1848.10 (2015), pp. 1996–2001. issn: 18792642. doi: 10.1016/j.bbamem.
2015.06.020. url: http://dx.doi.org/10.1016/j.bbamem.2015.06.020.
[173] Xiaoming Xu, Mansoor A. Khan, and Diane J. Burgess. “Predicting hydrophilic
drug encapsulation inside unilamellar liposomes”. In: International Journal of Phar-
maceutics 423.2 (2012), pp. 410–418. issn: 03785173. doi: 10.1016/j.ijpharm.
2011.12.019. url: http://dx.doi.org/10.1016/j.ijpharm.2011.12.019.
[174] Martin Kolb, Gail Martin, Maria Medina, Kjetil Ask, and Jack Gauldie. “Gene
Therapy for Pulmonary Diseases”. In: Chest 130.3 (Sept. 2006), pp. 879–884. issn:
0012-3692. doi: 10.1378/CHEST.130.3.879. url: https://www.sciencedirect.
com/science/article/pii/S0012369215528055?via%7B%5C%%7D3Dihub.
[175] Roberto Sessa and Akiko Hata. “Role of microRNAs in lung development and pul-
monary diseases.” In: Pulmonary circulation 3.2 (Apr. 2013), pp. 315–28. issn:
2045-8932. doi: 10.4103/2045-8932.114758. url: http://www.ncbi.nlm.nih.
gov/pubmed/24015331%20http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid=PMC3757825.
[176] Amir K. Varkouhi, Marije Scholte, Gert Storm, and Hidde J. Haisma. “Endoso-
mal escape pathways for delivery of biologicals”. In: Journal of Controlled Re-
lease 151.3 (May 2011), pp. 220–228. issn: 0168-3659. doi: 10.1016/J.JCONREL.
2010.11.004. url: https://www.sciencedirect.com/science/article/pii/
S0168365910009053?via%7B%5C%%7D3Dihub.
[177] CrispinR. Dass. “Lipoplex-mediated delivery of nucleic acids: factors affecting in
vivo transfection”. In: Journal of Molecular Medicine 82.9 (Sept. 2004), pp. 579–
591. issn: 0946-2716. doi: 10.1007/s00109-004-0558-8. url: http://link.
springer.com/10.1007/s00109-004-0558-8.
BIBLIOGRAPHY 167
[178] Xiao-Xiang Zhang, Thomas J McIntosh, and Mark W Grinstaff. “Functional lipids
and lipoplexes for improved gene delivery.” In: Biochimie 94.1 (Jan. 2012), pp. 42–
58. issn: 1638-6183. doi: 10.1016/j.biochi.2011.05.005. url: http://www.
ncbi.nlm.nih.gov/pubmed/21621581%20http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=PMC3771368.
[179] Peter Lönn, Apollo D. Kacsinta, Xian Shu Cui, Alexander S. Hamil, Manuel Kaulich,
Khirud Gogoi, and Steven F. Dowdy. “Enhancing Endosomal Escape for Intra-
cellular Delivery of Macromolecular Biologic Therapeutics”. In: Scientific Reports
6.March (2016), pp. 1–9. issn: 20452322. doi: 10.1038/srep32301. url: http:
//dx.doi.org/10.1038/srep32301.
[180] Yoshihiro Sasaki, Sayaka Toita, and Kazunari Akiyoshi. “Cycloamylose-based nanocar-
riers as a nucleic acid delivery system”. In: Colloid and Interface Science in Pharma-
ceutical Research and Development. Elsevier, 2014, pp. 369–388. isbn: 9780444626141.
doi: 10.1016/B978- 0- 444- 62614- 1.00018- 1. url: http://linkinghub.
elsevier.com/retrieve/pii/B9780444626141000181.
[181] Paul D. Robbins, Hideaki Tahara, and Steven C. Ghivizzani. “Viral vectors for gene
therapy”. In: Trends in Biotechnology 16.1 (Jan. 1998), pp. 35–40. issn: 01677799.
doi: 10.1016/S0167- 7799(97)01137- 2. url: http://www.ncbi.nlm.nih.
gov/pubmed/9470229%20http://linkinghub.elsevier.com/retrieve/pii/
S0167779997011372.
[182] Murali Ramamoorth and Aparna Narvekar. “Non viral vectors in gene therapy- an
overview.” In: Journal of clinical and diagnostic research : JCDR 9.1 (Jan. 2015),
GE01–6. issn: 2249-782X. doi: 10.7860/JCDR/2015/10443.5394. url: http:
//www.ncbi.nlm.nih.gov/pubmed/25738007%20http://www.pubmedcentral.
nih.gov/articlerender.fcgi?artid=PMC4347098.
[183] Adam J Mellott, M Laird Forrest, and Michael S Detamore. “Physical non-viral
gene delivery methods for tissue engineering.” In: Annals of biomedical engineering
41.3 (Mar. 2013), pp. 446–68. issn: 1573-9686. doi: 10.1007/s10439-012-0678-
1. url: http://www.ncbi.nlm.nih.gov/pubmed/23099792%20http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5102682.
[184] Lynn F Gottfried and David a Dean. “Extracellular and Intracellular Barriers to
Non-Viral Gene Transfer”. In: Novel Gene Therapy Approaches (2013), pp. 75–88.
doi: 10.5772/54699.
[185] Jonas Gustafsson, Gösta Arvidson, Göran Karlsson, and Mats Almgren. “Com-
plexes between cationic liposomes and DNA visualized by cryo-TEM”. In: Biochim-
ica et Biophysica Acta (BBA) - Biomembranes 1235.2 (May 1995), pp. 305–312.
BIBLIOGRAPHY 168
issn: 0005-2736. doi: 10.1016/0005-2736(95)80018-B. url: https://www.
sciencedirect.com/science/article/pii/000527369580018B.
[186] Kai K. Ewert, Alexandra Zidovska, Ayesha Ahmad, Nathan F. Bouxsein, Heather
M. Evans, Christopher S. McAllister, Charles E. Samuel, and Cyrus R. Safinya.
“Cationic liposome-nucleic acid complexes for gene delivery and silencing: Pathways
and mechanisms for plasmid DNA and siRNA”. In: Topics in Current Chemistry
296.Cl (2010), pp. 191–226. issn: 03401022. doi: 10.1007/128_2010_70.
[187] Molecular Interactions (Noncovalent Interactions). url: https://ww2.chemistry.
gatech.edu/%7B~%7Dlw26/structure/molecular%7B%5C_%7Dinteractions/
mol%7B%5C_%7Dint.html%7B%5C#%7DB (visited on 05/09/2018).
[188] A. Schroeder, C. G. Levins, C. Cortez, R. Langer, and D. G. Anderson. “Lipid-based
nanotherapeutics for siRNA delivery”. In: Journal of Internal Medicine 267.1 (Jan.
2010), pp. 9–21. issn: 09546820. doi: 10.1111/j.1365-2796.2009.02189.x. url:
http://doi.wiley.com/10.1111/j.1365-2796.2009.02189.x.
[189] Magendira Mani. Electrophoresis and factors affecting electrophoresis. url: https:
//www.slideshare.net/magendiramanivinayag/electrophoresis-and-factors-
affecting-electrophoresis (visited on 05/17/2018).
[190] “Network Analyser Manual”. In: ().
[191] File:Vna3.png - Wikimedia Commons. url: https://commons.wikimedia.org/
wiki/File:Vna3.png (visited on 10/05/2018).
[192] Dry etching - an overview | ScienceDirect Topics. url: https://www.sciencedirect.
com/topics/materials-science/dry-etching (visited on 06/01/2018).
[193] Tech Support. “Preparing Large, Unilamellar Vesicles by Extrusion (LUVET) |
Avanti Polar Lipids”. In: (2018), pp. 10–11. url: https://avantilipids.com/
tech-support/liposome-preparation/luvet.
[194] Anna Wang, Christopher Chan Miller, and Jack W Szostak. “Interpreting turbidity
measurements for vesicle studies”. In: (). doi: 10.1101/348904. url: http://dx.
doi.org/10.1101/348904.
[195] Vanessa Cabra and Montserrat Samsó. “Do’s and don’ts of cryo-electron microscopy:
a primer on sample preparation and high quality data collection for macromolec-
ular 3D reconstruction.” In: Journal of visualized experiments : JoVE 95 (2015),
p. 52311. issn: 1940-087X. doi: 10.3791/52311. url: http://www.jove.com/
video/52311/do-s-don-ts-cryo-electron-microscopy-primer-on-sample-
preparation.
BIBLIOGRAPHY 169
[196] Cardinal Arithmetic. “Sampling and Characterization of Bioaerosols”. In: NIOSH
Manual of Analytical Methods March (1998), pp. 82–112. issn: 10980121. doi: 10.
1103/PhysRevB.71.165307.
[197] Joseph G. Vasiliou, Diana Sorensen, and Peter H. McMurry. “Sampling at con-
trolled relative humidity with a cascade impactor”. In: Atmospheric Environment
33.7 (Mar. 1999), pp. 1049–1056. issn: 1352-2310. doi: 10.1016/S1352-2310(98)
00323- 9. url: https://www.sciencedirect.com/science/article/pii/
S1352231098003239.
[198] Sarah M. Andrew, Julie A. Titus, and Louis Zumstein. “Dialysis and Concen-
tration of Protein Solutions”. In: Current Protocols in Toxicology. Vol. Appendix
3. Hoboken, NJ, USA: John Wiley & Sons, Inc., Feb. 2002, A.3H.1–5. doi: 10.
1002/0471140856.txa03hs10. url: http://www.ncbi.nlm.nih.gov/pubmed/
20976673%20http://doi.wiley.com/10.1002/0471140856.txa03hs10.
[199] Selection Guide: Separation Products for Centrifugal and Tangential Flow Filtra-
tion. Tech. rep. url: www.pall.com/contact.
[200] Selection Guide: Separation Products for Centrifugal and Tangential Flow Filtra-
tion. Tech. rep. url: www.pall.com/contact.
[201] Biotech Grade Dialysis Membranes Cellulose Ester (CE) Regenerated Cellulose
(RC) Spectra/Por Biotech RC Membranes. Tech. rep. url: http://spectrumlabs.
com/lit/420x10688x000.pdf.
[202] Chemistry for Biologists: Enzymes. url: http : / / www . rsc . org / Education /
Teachers/Resources/cfb/enzymes.htm (visited on 08/11/2018).
[203] R W Niven, A Y Ip, S Mittelman, S J Prestrelski, and T Arakawa. “Some factors
associated with the ultrasonic nebulization of proteins.” In: Pharmaceutical research
12.1 (Jan. 1995), pp. 53–9. issn: 0724-8741. url: http://www.ncbi.nlm.nih.
gov/pubmed/7724488.
[204] Maria-Angeles Urbaneja, Ftlix M Gori, and Alicia Alonso. Structural changes in-
duced by Triton X-100 on sonicated phosphatidylcholine liposomes. Tech. rep. 1988,
pp. 585–588. url: https://febs.onlinelibrary.wiley.com/doi/pdf/10.1111/
j.1432-1033.1988.tb14039.x.
[205] Dov Lichtenberg, Hasna Ahyayauch, Alicia Alonso, Fé Lix, and M Goñ. “Detergent
solubilization of lipid bilayers: a balance of driving forces”. In: Trends in Biochem-
ical Sciences 38.2 (2013), pp. 85–93. doi: 10.1016/j.tibs.2012.11.005. url:
http://dx.doi.org/10.1016/.
BIBLIOGRAPHY 170
[206] Dipankar Koley and Allen J Bard. “Triton X-100 concentration effects on mem-
brane permeability of a single HeLa cell by scanning electrochemical microscopy
(SECM)”. In: (). doi: 10 . 1073 / pnas . 1011614107/ - /DCSupplemental. url:
www.pnas.org/lookup/suppl/.
[207] A R I Helenius and K A I Simons. “BY DETERGENTS membrane structure and
function it is usually necessary to dissociate the membrane into its components .
The techniques for extraction and analysis of the membrane lipids are well worked
out , and are mainly based on the use of organic solve”. In: 415 (1975), pp. 29–79.
[208] Dov Lichtenberg, Hasna Ahyayauch, Fé Lix, and M Goñ. “The Mechanism of De-
tergent Solubilization of Lipid Bilayers”. In: Biophysj 105 (2013), pp. 289–299. doi:
10.1016/j.bpj.2013.06.007. url: https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC3714928/pdf/main.pdf.
[209] Hasna Ahyayauch, Banafshe Larijani, Alicia Alonso, and Félix M Goñi. “Detergent
solubilization of phosphatidylcholine bilayers in the fluid state: Influence of the
acyl chain structure”. In: (2006). doi: 10.1016/j.bbamem.2006.01.016. url:
http://www.elsevier.com/locate/bba.
[210] “Luciferase Reporters”. In: (). url: https://www.thermofisher.com/us/en/
home/life-science/protein-biology/protein-biology-learning-center/
protein-biology-resource-library/pierce-protein-methods/luciferase-
reporters.html.
[211] The Luciferase Reporter Assay: How it works - Bitesize Bio. url: https : / /
bitesizebio.com/10774/the-luciferase-reporter-assay-how-it-works/
(visited on 05/09/2018).
[212] Why You Don’t Need to Select a Wavelength for a Luciferase Assay |. url: https:
//www.promegaconnections.com/why-you-dont-need-to-select-a-wavelength-
for-a-luciferase-assay/ (visited on 05/16/2018).
[213] “Overview of Protein Assays Methods”. In: (). url: https://www.thermofisher.
com/us/en/home/life-science/protein-biology/protein-biology-learning-
center / protein - biology - resource - library / pierce - protein - methods /
overview-protein-assays.html.
[214] “Chemistry of Protein Assays”. In: (). url: https://www.thermofisher.com/
us/en/home/life-science/protein-biology/protein-biology-learning-
center / protein - biology - resource - library / pierce - protein - methods /
chemistry-protein-assays.html.
BIBLIOGRAPHY 171
[215] Ethidium bromide - an overview | ScienceDirect Topics. url: https : / / www .
sciencedirect . com / topics / neuroscience / ethidium - bromide (visited on
05/16/2018).
[216] Ethidium Bromide | Environmental Health and Safety. url: https://ehs.research.
uiowa.edu/ethidium-bromide (visited on 05/16/2018).
[217] Tahrin Mahmood and Ping-Chang Yang. “Western blot: technique, theory, and
trouble shooting.” In: North American journal of medical sciences 4.9 (Sept. 2012),
pp. 429–34. issn: 1947-2714. doi: 10 . 4103 / 1947 - 2714 . 100998. url: http :
//www.ncbi.nlm.nih.gov/pubmed/23050259%20http://www.pubmedcentral.
nih.gov/articlerender.fcgi?artid=PMC3456489.
[218] Yingshan Qiu, Michael Y. T. Chow, Wanling Liang, Winnie W. Y. Chung, Judith
C. W. Mak, and Jenny K. W. Lam. “From Pulmonary Surfactant, Synthetic KL4
Peptide as Effective siRNA Delivery Vector for Pulmonary Delivery”. In: Molecular
Pharmaceutics 14.12 (Dec. 2017), pp. 4606–4617. issn: 1543-8384. doi: 10.1021/
acs.molpharmaceut.7b00725. url: http://pubs.acs.org/doi/10.1021/acs.
molpharmaceut.7b00725.
[219] Rufang Zhang, Deyu Yang, Chanjuan Zhou, Ke Cheng, Zhao Liu, Liang Chen,
Liang Fang, and Peng Xie. “β-Actin as a loading control for plasma-based Western
blot analysis of major depressive disorder patients”. In: Analytical Biochemistry
427.2 (Aug. 2012), pp. 116–120. issn: 00032697. doi: 10.1016/j.ab.2012.05.008.
url: http://www.ncbi.nlm.nih.gov/pubmed/22617797%20http://linkinghub.
elsevier.com/retrieve/pii/S0003269712002692.
[220] MTT assay - an overview | ScienceDirect Topics. url: https://www.sciencedirect.
com/topics/neuroscience/mtt-assay (visited on 05/09/2018).
[221] Matthew Trendowski, Guowu Yu, Victoria Wong, Christopher Acquafondata, Tim-
othy Christen, and Thomas P. Fondy. “The real deal: Using cytochalasin B in sono-
dynamic therapy to preferentially damage leukemia cells”. In: Anticancer Research
34.5 (2014), pp. 2195–2202. issn: 02507005. doi: 10.1016/S1387-2656(05)11004-
7.
[222] A549 ATCC. url: https://www.lgcstandards- atcc.org/Products/All/
CCL- 185?geo%7B%5C_%7Dcountry=gb%7B%5C#%7Dculturemethod (visited on
05/17/2018).
[223] “AM4605 Silencer GAPDH siRNA Control”. In: (2007). url: https://assets.
thermofisher.com/TFS-Assets/LSG/manuals/sp%7B%5C_%7D4605.pdf.
BIBLIOGRAPHY 172
[224] a. M a Elhissi, M. Faizi, W. F. Naji, H. S. Gill, and K. M G Taylor. “Physical
stability and aerosol properties of liposomes delivered using an air-jet nebulizer and
a novel micropump device with large mesh apertures”. In: International Journal
of Pharmaceutics 334.1-2 (2007), pp. 62–70. issn: 03785173. doi: 10.1016/j.
ijpharm.2006.10.022.
[225] Krishnananda Chattopadhyay and Shyamalava Mazumdar. “Structural and Con-
formational Stability of Horseradish Peroxidase: Effect of Temperature and pH”. In:
(2000). doi: 10.1021/bi990729o. url: https://pubs.acs.org/sharingguidelines.
[226] Arne Thomas. Micelle Formation. Tech. rep. url: https://www.mpikg.mpg.de/
886719/MicelleFormation.pdf.
[227] Can one calculate a PDI value for an individual peak in DLS? url: https://www.
materials-talks.com/blog/2015/03/31/pdi-from-an-individual-peak-in-
dls/ (visited on 10/28/2018).
[228] Structural Biochemistry/Lipids/Micelles - Wikibooks, open books for an open world.
url: https://en.wikibooks.org/wiki/Structural%7B%5C_%7DBiochemistry/
Lipids/Micelles (visited on 09/05/2018).
[229] Lisa Sercombe, Tejaswi Veerati, Fatemeh Moheimani, Sherry Y Wu, Anil K Sood,
and Susan Hua. “Advances and Challenges of Liposome Assisted Drug Delivery.” In:
Frontiers in pharmacology 6 (2015), p. 286. issn: 1663-9812. doi: 10.3389/fphar.
2015.00286. url: http://www.ncbi.nlm.nih.gov/pubmed/26648870%20http:
//www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4664963.
[230] K. Kuribayashi, G. Tresset, Ph Coquet, H. Fujita, and S. Takeuchi. “Electrofor-
mation of giant liposomes in microfluidic channels”. In: Digest of Technical Pa-
pers - International Conference on Solid State Sensors and Actuators and Mi-
crosystems, TRANSDUCERS ’05 2 (2005), pp. 1159–1162. issn: 0957-0233. doi:
10.1109/SENSOR.2005.1497283.
[231] David Cipolla, Huiying Wu, Igor Gonda, and Hak-Kim Chan. “Aerosol Performance
and Stability of Liposomes Containing Ciprofloxacin Nanocrystals”. In: Journal of
Aerosol Medicine and Pulmonary Drug Delivery 28.6 (2015), pp. 411–422. issn:
1941-2711. doi: 10.1089/jamp.2015.1241. url: http://online.liebertpub.
com/doi/10.1089/jamp.2015.1241.
[232] Gerhard Scheuch, Martin J. Kohlhaeufl, Peter Brand, and Ruediger Siekmeier.
“Clinical perspectives on pulmonary systemic and macromolecular delivery”. In:
Advanced Drug Delivery Reviews 58.9-10 (2006), pp. 996–1008. issn: 0169409X.
doi: 10.1016/j.addr.2006.07.009.
BIBLIOGRAPHY 173
[233] Mar Alvarez, James Friend, and Leslie Y Yeo. “Rapid generation of protein aerosols
and nanoparticles via surface acoustic wave atomization”. In: Nanotechnology 19.45
(2008), p. 455103. issn: 0957-4484. doi: 10.1088/0957-4484/19/45/455103. url:
http://stacks.iop.org/0957- 4484/19/i=45/a=455103?key=crossref.
12e4470f7cbfbaa87d97a2d9194e9f00.
[234] Leslie Y. Yeo, Hsueh Chia Chang, Peggy P Y Chan, and James R. Friend. “Microflu-
idic devices for bioapplications”. In: Small 7.1 (2011), pp. 12–48. issn: 16136810.
doi: 10.1002/smll.201000946.
[235] Elijah Nazarzadeh, Rab Wilson, Xi King, Julien Reboud, Manlio Tassieri, and
Jonathan M Cooper. “Confinement of surface waves at the air-water interface to
control aerosol size and dispersity”. In: Citation: Physics of Fluids 29 (2017). url:
https://doi.org/10.1063/1.4993793%20http://aip.scitation.org/toc/
phf/29/11.
[236] Aisha Qi, Peggy Chan, Jenny Ho, Anushi Rajapaksa, James Friend, and Leslie Yeo.
“Template-free synthesis and encapsulation technique for layer-by-layer polymer
nanocarrier fabrication”. In: ACS Nano 5.12 (2011), pp. 9583–9591. issn: 19360851.
doi: 10.1021/nn202833n.
[237] Based Nottingham. “Quality Solutions for Who are Copley”. In: (2012).
[238] Omron Manual Specifications. Tech. rep. url: https://omronhealthcare.com.
au/pdf/omron-NE-U22-instructions.pdf.
[239] Ana Fernández Tena and Pere Casan Clarà. “Depósito pulmonar de partículas
inhaladas”. In: Archivos de Bronconeumología 48.7 (July 2012), pp. 240–246. issn:
03002896. doi: 10.1016/j.arbres.2012.02.003. url: http://www.ncbi.nlm.
nih.gov/pubmed/22464044%20http://linkinghub.elsevier.com/retrieve/
pii/S0300289612000646.
[240] W T Jenny Kwong, Sharon L Ho, and Allan L Coates. Comparison of Nebulized
Particle Size Distribution with Malvern Laser Diffraction Analyzer Versus Ander-
sen Cascade Impactor and Low-Flow Marple Personal Cascade Impactor. Tech. rep.
4. 2000, pp. 303–314. url: www.liebertpub.com.
[241] A H Hashish. “Droplet Size and Charge Distribution Analysis of Aerosols Generated
by Jet and Ultrasonic Nebulizers”. In: Rdd2012 May 2012 (2008), pp. 751–756. doi:
10.13140/2.1.5034.5929.
[242] Eduardo R Da Silva, Humberto R Bizzo, Patrícia D Fernandes, Valdir F Da Veiga
Junior, Suzana G Leitão, and Danilo R De Oliveira. “Development and evaluation
of an inhalation chamber for in vivo tests”. In: An Acad Bras Cienc 89.3 (2017),
pp. 1643–1653. issn: 1678-2690. doi: 10.1590/0001- 3765201720160793. url:
BIBLIOGRAPHY 174
http://dx.doi.org/10.1590/0001-3765201720160793www.scielo.br/aabc%
7B%5C%%7D7Cwww.fb.com/aabcjournal.
[243] S R Jones, S Carley, and M Harrison. “An introduction to power and sample size
estimation”. In: Emerg Med J 20 (2003), pp. 453–458. doi: 10.1136/emj.20.5.
453. url: www.emjonline.com.
[244] Jaykaran Charan and N D Kantharia. “How to calculate sample size in animal
studies?” In: Journal of pharmacology & pharmacotherapeutics 4.4 (Oct. 2013),
pp. 303–6. issn: 0976-500X. doi: 10.4103/0976-500X.119726. url: http://www.
ncbi.nlm.nih.gov/pubmed/24250214%20http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=PMC3826013.
[245] Dominique N Price, Nitesh K Kunda, and Pavan Muttil. “Challenges Associated
with the Pulmonary Delivery of Therapeutic Dry Challenges Associated with the
Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing †”. In:
March (2018). doi: 10.14356/kona.2019008.
Appendices
Appendix A
DOPC Bilayer Structures
Figure A1: Images from optical microscopy, where dried DOPC was hydrated with PBS. The
pictures show toroidal and donuts shape, made of bilayers. DOPC has (S < 1) a
cylinder shape.
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Appendix B
Dry-Etched Silicon Structure With Rectangular Pattern
Figure B1: SEM SU8240 images of a dry-etched silicon structure, with rectangular pattern,
obtained using photolitography.
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Appendix C
Freeze-Thaw Cycles
Figure C1: Freeze-thaw cycles. MLVs are rapidly frozen (pink line) at -80◦C and thawed in a
water bath at 37◦C. This process is repeated at least 3 cycles (1 cycle = black line, 2
cycles = red line and 3 cycles = blue line). During freeze-thawing, rapidly-forming
ice crystal disrupts the structure of MLVs, leading to the formation of liposomes
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Displacement
Figure C2: Displacement measurements using a laser doppler vibrometer. The graph shows the
increase in displacement with the power increase. The displacement seems to reach
the saturation around 4-5 W.
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Appendix D
TEM Negative Staining of SAW-Formed Liposomes
Figure D1: TEM negative staining was used with 2% MethylCellulose/Uranyl Acetate (pH 7)
as a negative stain, in order to visualise SAW-formed liposomes.
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Cryo-TEM of SAW-Formed Liposomes
Figure D2: Cryo-TEM was carried out in order to have a better resolution of SAW-formed
liposomes. Unilamellar vesicles were obtained after the SAW nebulisation using a
silicon chip with 300 µm cavities. Using cryo-TEM it was possible to visualise the
number of lamellae of the vesicles.
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Appendix E - The University of Hong Kong
HS-DNA Purification Protocol
1. 40 mL, 3 M sodium acetate, adjusted pH 5.2
2. 24 mg HS-DNA for 48 eppendorf in 24 mL of ultrapure water.(DNA powder 4C)
3. 40 mL of ethanol are chilled at 4C for 30 min
4. Add 500 µl of HS-DNA and 50 µl of NaOAc
5. Vortex
6. Add 900 µl of ethanol
7. Vortex
8. Left tube in freezer (-20◦C for at least 30 min)
9. Centrifuge the tubes at 13000 rpm at 4◦C for 15 min
10. Remove and discard supernatant
11. Add 500 µl of 70% chilled ethanol in each tube and shake tube
12. = repeat 9, 10, 11 (at room T)
13. Centrifuge at 13,000 rpm at room T for 15 min
14. = repeat 10.
15. Air dry sample overnight (ensure tubes are fully dried)
16. Resuspend each sample in 200 µl of DIW/ or TAE buffer
17. Combine 6 tubes of sample into one. Take 1.2 mL sample in 1.5 mL centrifuge tube
18. Plate reader TAKE3 nucleic acid quantification
19. 2 µl sample and pure water
20. Run blank
21. Load sample and run
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Agarose Gel electrophoresis Raw Images
Figure E1: Agarose gel electrophoresis of : (a) Sample before and after nebulisation (See Chapter
6), (b) lipid:siRNA different ratios
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MTT Citotoxiciy Assay: Only Lipids
Figure E2: A549 cells were seeded in a 96-well plate. 24 h post-transfection, lipid vesicles made
of DOTAP:Chol were added to cells in order to test their toxicity. After 4 h, MTT
solution (0.8 mg/ml) was added to the cells. After 2 h, the formazan precipitate was
dissolved in 100 µl isopropanol and the absorbance was measured at λ = 595 nm.
The graph shows the mean of three measurements and the error bars represent the
SD.
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Western Blot Raw Images
Figure E3: (a), (c), (d) Raw images of different ratio of lipid and GAPDH siRNA complex
(values shown in Chapter 6). (b) Raw image of the samples after SAW nebulisation of
GAPDH siRNA and MLVs mixture. Comparison between SAW-based and standard
transfection method showed a 50% knockdown of the gene. Gel pictures in Chapter
6 were cropped from these raw pictures.
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Figure E4: Confocal Images of A549 cells at 4 h post-transfection. Cell were transfected by SAW
transfection. A lipid-siRNA mixture identical to that used for standard transfection
was used, made of DOTAP-cholesterol (4:1) in 5% glucose, with a lipid-siRNA ratio
of 6:1. Regarding SAW transfection, a total volume of 200 µl solution was nebulised
for 2 min. siRNA (green) was labelled; the nuclei (blue) were stained with Hoechst.
High cellular uptake resulted from SAW transfection, showing that lipid vesicles were
formed during SAW nebulisation that were able to act as siRNA carriers. Scale bar
40 µm.
